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Itch Mediation and How It Differs from Pain
Nechama Rappaport

Nechama Rappaport graduated in June 2016 with a BS in Biology and will be attending Hunter College’s Adolescent Chemistry Education program.

Abstract
Itch, to most, is a common nuisance, although when chronic it can negatively affect quality of life. It is obvious that itch is
processed differently than pain, but how it differs is not clear. Researchers have been trying to find a path that specifically
mediates itch. They have found that itch is mediated through at least two different pathways: histamine dependent and
histamine independent. However, many of the mediators involved in the transduction of itch also mediate pain. Although
some itch-specific neurons have been found, the majority of the pruritogenic neurons are also responsive to pain stimuli.
Two theories that can explain how the brain processes itch and pain as different sensations are the specificity theory
and the selectivity theory.
Introduction
Itch is defined as “a stimulation of free nerve endings, usually
at the junction of the dermis and epidermis of the skin, that
evokes a desire to scratch.” (Encyclopedia Britannica) Although
most assume itch to be harmless, chronic itch can cause much
discomfort and affect quality of life. Pain and itch are obviously
different to the one experiencing either feeling, but whether
these sensations are processed differently is not so obvious.
Since the late nineteenth century when pain was discovered
to be a real sensation, itch was thought of as just a weaker
form of pain (Von Frey cited in Handwereker, 2014). Later, scientists found certain unmyelinated C-fibres of the dorsal root
ganglion that were sensitive specifically to histamine (Schmelz,
et. al. 1997). Similar histamine sensitive neurons were found in
lamina I of the spinal cord (Andrew, Craig, 2001). This led to the
specificity theory for itch, also called the labelled line theory,
which proposes that different sets of neurons exclusively mediate itch or pain. However, many of the receptors that respond
to itchy stimuli are also involved in mediating pain and later
studies show that most of the neurons that respond to itch also
react to pain producing substances (Shmelz, et.al.2003, Simons,
2004, Davidson, et. al., 2007, Akiyama, et. al.2009, Akiyama, et.al.
2010). So although itch and pain have separate pathways, a lot
of overlap seems to exist between them.

Methods
This review was written through the critical analysis of clinical
research papers and peer reviewed journal articles. The papers
were found in searches on Google Scholar and access was obtained through the Touro College Library.

Discussion
Researchers first thought of itch as a milder form of pain, a
theory known as the intensity theory. According to this theory,
pain and itch sensations are mediated by the same neurons; if
the stimulus is strong, there is a pain sensation, and if the stimulus is weak, an itch sensation (quoted in Patel, Dong, 2010). The
basis for this theory was that cordotomy, surgical disconnection
of the spinothalamic tract, leads to loss of both itch and pain
on the contralateral side of the cut, whereas the perception of
touch is impaired on the ipsilateral side (Nathan, 1990). This led
to the theory that itch and pain are conducted along the same

ascending pathway whereas mechanosensation travels along a
separate path (quoted in Handwerker, 2014). However, many
well-known characteristics of itch and pain don’t seem to fit
with this theory. For one, itch can be quite intense and never
turn into pain, (Tuckett, 1982) and similarly, a painful stimulus
does not feel like itch when administered at a lower intensity (Ochoa, Torebjork, 1989). More, the reflexes in response to
pain and itch are quite different. The pain reflex is withdrawal,
whereas the itch reflex is scratching. These observations seem
to suggest that pain and itch have separate neural pathways.
One of the first steps in the advancement of itch research was
the discovery of histamine. Histamine is released from mast
cells and white blood cells, as a response to allergens or inflammatory mediators. A “triple response” to histamine was found.
There is a local reaction, swelling, and also erythema, a flare,
skin reddening around the affected skin (quoted in Handwerker,
2014). Histamine could be applied to specific regions and
therefore allowed for the identification of the neurons which
responded to it.
The breakthrough came in 1997, when using the new computer-assisted marking technique in microneurography, one group
was able to identify histamine-sensitive C-fibers. Previous research had shown that itch had sometimes been induced during
microstimulation in skin nerves where C-fibers were recorded.
But most C-fibers identified were insensitive or only weakly
responsive to histamine.The new technique was able to identify
even small units that could not be identified with the old methods. Researchers identified 56 fibers in the superficial peroneal
nerve of 52 healthy patients. Units were classified as mechanically and heat-responsive (CMH), heat-responsive (CH), or
unresponsive to mechanical and heat stimulation (CMiHi). All
of the fibers were tested by iontophoresis of histamine and the
subjects rated the itch feeling. After the application of histamine,
itch was usually felt 30-60 seconds after, reached a maximum
after 2-3 minutes, and lasted for about 10 minutes. Twentythree of the fifty-six units studied were not at all excited by the
histamine. Twenty were weakly activated but their discharges
did not match up with the time response of the subjects. Eight
of the units (5 CH and 3 CMiHi) showed lasting responses to
the histamine that coordinated with the time response of the
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subjects. These neurons were found to have a much slower
conduction velocity than the non- histamine responsive neurons, suggesting that these neurons are a class onto themselves.
The units with histamine responses had a mean velocity of
.52m/sec., compared to the .9m/sec. of the other units. The
slow velocity reflects small axon diameters. Additionally, the
units were found to have unusually large innervation territories.
This finding explains the flare that is found after application of
histamine (Schmelz, et. al. 1997).
The next study that supported the idea of an itch-specific pathway was done on cats and found a population of histamine-selective lamina I spinothalamic tract (STT) neurons. The researchers
obtained recordings from 190 lamina I STT neurons that had
distal hind limb fields in the lumbosacral spinal cords of 33 cats.
After categorizing these neurons into three main classes- nociceptive-specific, thermoreceptive- specific, and polymodal nociceptive- based on response to natural mechanical and thermal
stimuli, there were 17 neurons left that were mechanically and
thermally insensitive. Unlike the mechanically and thermally sensitive neurons, these neurons did not show spontaneous activity. These neurons were found to have a similar response time
after histamine application to their innervation area of skin to
the histamine selective neurons found in the previous study. The
conduction velocities of these neurons were slower than the rest
of the lamina I STT neurons, which is also consistent with the
findings of the previously mentioned study. In addition, they all
had large receptive fields, similar to the histamine selective fibers
in the previous study.These characteristics that differed from the
rest of the neurons seem to put these neurons into a class of
their own. Some of the histamine-responsive neurons were tested with mustard oil, which causes a burning sensation, and some
responded to it. Of those that responded to the mustard oil,
most had responses that were much weaker than the response
to histamine. The neuron that had a strong response to the mustard oil had been found to have a weaker response to histamine
than the rest of the histamine-responsive neurons. Some of the
histamine- responsive neurons did not respond at all to mustard
oil, indicating that they are histamine-selective. (One should note,
however, that the neurons were never tested with capsaicin, an
algogen) (Andrew, Craig, 2001).This study and the one mentioned
above both support the “specificity theory,” as it seems like units
were found that responded specifically to histamine.
Knowing that histamine is not the only pruritogen, a later study
tested different pruritogens to see if the histamine-selective
units would respond to them in accordance with pruritic potency of the pruritogen. They found that many histamine-selective units responded to the other pruritogens more than the
non-histamine-selective units. However, they also found that the
mechano- insensitive, histamine responsive units could also be
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excited by capsaicin and bradykinin, both algogens, albeit with
a different response pattern than the CMH units. The mechano-responsive units had intense, short-lasting responses to capsaicin, whereas the mechano-insensitive units had longer lasting
responses. This challenges the specificity theory as the itch
units were activated by algogens (Shmelz,et.al.2003). Another
study tested the responsiveness of STT neurons from the ventral posterior lateral nucleus of the thalamus in monkeys to
different algogens and pruritogens. Neurons were found that
responded to both histamine and capsaicin, another challenge
to specificity, this time in the STT. (Simone, 2003)
As the pathway for itch becomes clearer and more defined, the
question of how the brain processes the signals from the pathway as itch rather than pain remains uncertain.

The Histamine Dependent Pathway
Histamine binds with histamine receptors on free nerve endings. These receptors are classified into four subtypes, 1-4. In
order to determine which of the four histamine receptors are
responsible for the Ca2+ influx into the cell after the applica-

tion of histamine, agonists of the different subtypes were applied
with the histamine. The only agonist that stopped the calcium
response was the histamine type-1 receptor (H1R) agonist, mepyramine (Nicolson, et.al. 2002). In pharmaceutical attempts to
alleviate itch the H1R became the major target (Simons, 2004).
In the mediation of itch, H1R was found to activate phospholipase Cβ 3 (PLCβ3). PLCβ3 is expressed in neurons with histological markers for unmyelinated, C-fiber nociceptors. PLCβ3 is
coexpressed with H1R in 90% of H1R neurons, suggesting that
PLCβ3 may also be involved in the transduction of itch. Indeed,
PLCβ3-deficient mice showed low Ca2+ release in response to
histamine application, compared to the regular Ca2+ response
to application of ATP, capsaicin, UTP, and bradykinin. In vivo
testing showed that PLCβ3 deficient mice started scratching
later and scratched less in response to histamine injection than
wild-type mice. The PLCβ3 deficiency was most noticed when
the H1R agonist, HTMT, was applied to the PLCβ3-deficient
mice, and was compared to application of agonists of the other
histamine receptors. The scratching response to HTMT was almost as low as the response to the control, saline injection.This
indicates that PLCβ3 responds mainly to activity in the H1R
receptor. Reduced scratching was also found in the response to
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48/80, a substance that causes degranulation of mast cells and
therefore the release of histamine (Han, et.al. 2006).
Activation of PLCβ3 causes increase in intracellular Ca2+ in the
DRG neurons through the ion channel TRPV1. TRPV1, transient
receptor potential vanilloid receptor-1, an ion channel, is a receptor that is found on free nerve endings and allows the action
potential to occur by allowing Ca2+ into the neuron. Although
TRPV1 was previously only known for its role in mediating pain,
there were clues that it may also be involved in processing itch.
For one, capsaicin, a major algogen that activates TRPV1, can
cause itch when applied to the skin surface (Green, Shaffer,
1993). In addition,TRPV1 and histamine receptors are found on
the same subset of neurons )Nicolson, et. al. 2002). Lastly, when
high levels of capsaicin are applied to the skin,TPRV1 is desensitized and, interestingly, pruritus is also stopped (quoted in Shim,
et. al. 2007). Indeed, studies show that TRPV1 has a role in mediating itch. When H1R or TRPV1 alone was transfected to HEK
293T cells, these cells did not respond to histamine. However,
H1R and TRPV1 transfected together caused a large current in
response to histamine application. Further, when capsazapine,
a TRPV1 antagonist, was applied to the skin before histamine
application, it caused smaller Ca2+ responses to histamine. In
addition, TRPV1-deficient mice did not have a large increase
in intracellular Ca2+ when histamine was applied, in contrast
to wild-type mice who did. In vivo studies also proved TPRV1’s
involvement in the mediation of itch. Capsazapine given before
histamine injection in mice resulted in reduced scratching to
the histamine. Compared to wild-type mice, TRPV1-deficient
mice also showed reduced scratching in response to histamine
injection (Shim, et.al. 2007). These experiments demonstrate
that TRPV1 plays a role in the transduction of itch.

The Histamine Independent Pathway
Although histamine plays a role in allergic itch, histamine is not
the main pruritic mediator in most diseases of chronic itch
(Klein, Clark, 1999). The use of H1R antagonists, antihistamines,
are ineffective in stopping chronic itch (Twycross, et.al. 2003).

Chronic itch can be caused by the release of pruritogens from
lymphocytes, mast cells, and eosinophils (Ikoma, et,al, 2006). In
patients with atopic dermatitis, antihistamines did not suppress
itch upon degranulation of mast cells. This suggests that there
are mast cell itch mediators other than histamine (Rukweid,
et.al. 2000). In addition, one of the regular characteristics of

histamine induced itch, the flare, is missing in many types of itch
(Ikoma, et. al. 2005).These findings point to another pathway for
itch other than the mechano-insensitive C-fibres that mediate
histamine induced itch.
Cowhage, the common name for the spicules that cover the
tropical plant Mucuna pruriens, causes severe itch without a
flare response (Johanek, et. al. 2007). It has been found in biochemical studies that mucunain, a proteinase in the cowhage,
is what makes cowhage itchy (Reddy, et.al. 2008) In a study
designed to test if histamine and cowhage activate the same
C-fibres, all CMH units responded to cowhage, and none of the
CMi, histamine responsive, units did, proving that cowhage and
histamine do not activate the same fibres (Namer, et.al. 2008).
Thus, cowhage has been used in many studies to understand
histamine- independent itch.
Proteinases, such as mucunain, activate proteinase-activated
receptors (PARs). A specific proteinase-activated receptor,
PAR-2, has been identified on afferent nerve fibers (Steinhoff,
et. al. 2000). PAR-2 is also activated by trypsin and tryptase.
Tryptase is released by mast calls and trypsin is expressed in
the skin (quoted in Shimada, et. al. 2006). The first study that
found a connection between PAR-2 and itch was done on mice
and found that PAR-2 played a major role in allergic dermatitis.
PAR-2 deficiency led to reduced ear swelling. (Kawagoe, et.al.
2002) Patients with atopic dermatitis (AD) were found to have
an increase in PAR-2 signaling, which was seen through higher
levels of codeine-induced tryptase, PAR-2 expression on keratinocytes, and a greater response to PAR-2 agonist (Steinhoff,
et.al. 2003).Another study found that itch was induced by PAR-2
agonist, a peptide, SLIGRL-NH2. When mice were injected with
SLIGRL-NH2 they started vigorously scratching in levels much
higher than when injected with saline vehicle. The application
of an antihistamine, pyrilamine, did not reduce the scratching,
confirming that PAR-2 is a receptor in non-histaminergic itch
(Shimada, et.al. 2006).
One of the drugs used to treat malaria is chloroquine. Many
patients complain about intense itch while taking chloroquine.
The itch can be so intense that they stop taking the medicine.
Antihistamines were ineffective in relieving the itch (quoted in Liu, et.al. 2009). Parts of the Mrgpr family (Mas related
G-protein coupled receptors), a family of G protein-coupled
receptors (GPCR), have been detected only on small-diameter
sensory neurons in the DRG and TG. This would make them
likely to be involved in the sensation of pain or itch. Itch induced
by chloroquine was reduced in Mrpgr deficient mice, although
the response to histamine induced itch was not significantly
reduced in these mice. Further study found that the specific
Mrgpr receptor for chloroquine was MrgprA3. BAM-822 was
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found to excite MrgprC11 (Liu, et.al. 2009).
TRPA1, an ion channel, plays the same role in histamine- independent and chronic itch as TRPV1 plays in histamine dependent
itch. That is, it allows the action potential to occur by allowing
Ca2+ into the neurons. Researchers found that TRPA1 is greatly
expressed in subset of TRPV1 positive neurons. Chloroquine
and BAM-822 were found to activate the subset of TRPV1
neurons that also expressed TRPA1. Yet, neurons from TRPV1deficient mice and neurons treated with capsazapine, a TRPV1
antagonist, both showed regular Ca2+ signaling in response to
BAM and chloroquine. There was also no difference in action
potential firing in response to chloroquine and BAM between
TRPV1-deficient neurons and wild-type neurons. Thus, it is
shown that the TRPV1 ion channel is not required for the mediation of BAM and chloroquine itch. However, TRPA1-deficient
neurons had significantly decreased responses to both BAM and
chloroquine. (As would be expected, they did have normal responses to histamine.) Further testing showed that the primary
target for the MrgprA3 and MrgprC11 receptors was TRPA1.
Interestingly, BAM and chloroquine have different mechanisms
leading to activation of TRPA1. Thus, TRPA1 is downstream of
different histamine- independent itch pathways (Wilson, et.al.
2011). Another study found TRPA1to be a vital mediator in
chronic itch. Application of AEW (acetone/ether mixture with
water) to the mouse cheek causes chronic itch-like symptoms in mice. It causes dry skin and increases scratching. It
also causes epidermal thickening, a major symptom of chronic
itch due to psoriasis in humans. Compared to wild-type mice,
TRPA1-deficient mice showed significant reduction in scratching induced by AEW treatment. This is in contrast to TRPV1deficient mice who after AEW treatment showed no decrease
in scratching. Further, injection of TRPA1 inhibitor, HC-030031,
into cheeck also caused reduction in scratching in AEW treated
mice. These results show that TRPA1 is required in chronic itch.
(Wilson, et.al. 2013).
One study used a novel approach to test if there are distinct
histaminergic and non-histaminergic pathways. Instead of deleting certain receptors or neurons, this group used QX-314,
a sodium channel blocker, to selectively “silence” specific receptors. When QX-314 was inserted into the mouse along
with histamine, sodium currents in TRPV1 alone were blocked,
thus temporarily “silencing” TRPV1. QX-314 inserted along
with chloroquine had the same effect on TRPA1, silencing it.
When TRPV1 was silenced, histamine induced scratching was
stopped, but chloroquine induced scratching was regular, and
when TRPA1 was silenced, chloroquine induced scratching
was stopped. This confirmed the separate pathways for itch.
(Roberson, et.al. 2013)
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The above information has shown at least two DRG pathways
for itch- histaminergic and non-histaminergic. A few other itch
pathways were found, such as the pathway for β-alanine which
is unique (Liu, et.al. 2012 b). Some other receptors have been
found as well, such as toll-like receptor 7 (TLR7) and toll-like
receptor 3 (TLR3). Although TLR7 knockout mice showed
normal sensitivity to thermal and mechanical pain and showed
normal scratching response to histamine-dependent pruritogens, scratching response to non-histaminergic pruritogens
was significantly reduced (Liu, et.al. 2010). TLR3 knockout mice
showed reduced scratching response to both histaminergic and
non-histaminergic stimuli and TLR3 was found to be necessary
in the development of chronic itch (Liu, et.al. 2012a). Another
itch mediator found was the cytokine, interleukin-31 (IL-31).
IL-31 is produced by T-cells and mice generated to overexpress
it developed intense pruritus. IL-31 protein was fed to adult
mice and within 3-4 days the mice developed severe pruritus
(Dillon, et.al. 2004).
The separate histaminergic and non-histaminergic pathways
continue into the spinal cord. In a study done on monkeys, 57
dorsal horn, STT neurons were tested for responsiveness to histamine and cowhage. Nineteen responded either to histamine
or cowhage; none responded to both.This shows a continuation
of the separate pathways. Interestingly, all pruritogen-responsive
neurons also responded to capsaicin, further evidence against
the specificity theory. As pointed out above, the study done on
STT neurons that suggested the existence of histamine-specific neurons did not test for response to capsaicin, thus lacking
evidence that those neurons did not respond to pain stimuli
(Davidson, et. al., 2007).
Just like overlap was found in the neurons mediating pain and
itch in the dorsal root ganglia, overlap was also found in the
trigeminal ganglia (TG) and the trigeminal subnucleus caudalis
of mice. Mice TG neurons were tested with different pruritogens, i.e. histamine, PAR-2 agonist, and 5-HT, and algogens, i.e.
capsaicin and AITC. Using calcium imaging it was found that of
856 TG neurons, 15.4% responded to histamine and 5.8% to
PAR-2 agonist. Although a small percentage of the pruritogenic neurons only responded to one pruritogen, the majority of
those pruritogenic neurons responded to AITC or capsaicin as
well, another finding that is inconsistent with the specificity theory. Consistent with the findings of different histaminergic and
non-histaminergic pathways, most pruritogenic neurons were
responsive to only one of the pruritogens. The majority of TG
neurons that responded to pruritic stimuli were also responsive to algogens (Akiyama, et. al. 2010). Another study found
neurons in the superficial dorsal horn that were responsive to
PAR-2 agonist and 5-HT, yet most were also responsive to algogens (Akiyama, et.al. 2009).
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As can be seen from the information presented above, many
of the receptors in the itch pathways are also involved in the
transduction of pain. TRPV1, PAR-2, TRPA1, and the TLRs all
play roles in mediating pain. It has also been shown that algogens can activate pruritogenic neurons. It seems that there is
no itch-specificity. However, two neurons have been found that
seem to be itch-specific GRPR+ neurons and, more recently,
MrgprA3+ neurons.
At the spinal level, gastrin-releasing peptide receptor, GRPR, has
been found to be essential for mediating itch exclusively and
not pain. GRP is expressed in a subgroup of dorsal root ganglion
neurons. It is also colocalized with markers for unmyelinated
fibers. In addition, approximately 80% of GRP+ neurons express
TRPV1. GRP+ neurons are found only in the lamina I and II
outer layer in the spinal cord. This data points to a possible involvement of the GRP signaling pathway in itch and pain. GRPR
mutant mice were tested along with wild-type mice. GRPR
mutant mice did not show a significantly different response
from the wild-type mice to heat, pain, or mechanical stimuli.
The mice were then tested with three different pruritogenic
agents: 48/80, a PAR-2 agonist (SLIGRL-NH2), and chloroquine.
After the separate injection of each pruritogen, a scratch count
was taken from the mice. Although the GRPR mutant mice did
scratch as a response to the injection, the number of scratches
was significantly reduced, showing that GRPR mediates itch. To
test whether activating GRPR at the spinal level would induce
itch, GRPR agonist, GRP18-27, was intrathecally administered to
the wild-type mice. It induced scratching behavior. As expected,
the scratching response to GRP18-27 was significantly lower
in GRPR mutant mice. In addition, when GRPR antagonist was
inserted 10 minutes before the pruritogen in wild-type mice,
scratching behavior was significantly reduced. Interestingly, the
antagonist caused a lesser reduction in the effect of compound
48/80 than it had on PAR-2 agonist and chloroquine.This may be
because PAR-2 and chloroquine act through a histamine-independent pathway, unlike compound 48/80. Since GRPR mutant
mice showed regular pain responses to mechanical, thermal,
and pain stimuli, but significantly reduced itch responses to pruritogens, GRPR+ neurons seem to be itch-specific (Sun, Chen,
2007). However, this does not rule out the possibility that GRPR
neurons can also respond to pain and in GRPR mutant mice the
loss of these neurons is compensated for by the other nociceptive neurons and therefore pain is still felt.
In order for something to be considered completely itch specific it needs to fulfill three criteria. First and most obvious, the
neurons must respond to pruritic stimuli. Second, the loss of
these neurons should only cause a loss of itch, not pain. Last, and
most vital, only an itch response should be elicited when these
neurons are specifically activated, not pain. The study done on

the GRPR mutant mice fulfilled the first two criteria, but did not
test for the third.
One group of neurons that was found to fit all the criteria is
the MrgprA3+ neurons. These neurons only innervate the skin
and were found to be absent from all other tissues, one clue
that these neurons may be specific to itch, which is only felt on
the epidermis. These neurons were coexpressed with TRPV1.
They were also found to synapse with GRPR neurons in the
spinal cord. These neurons responded to all types of itch other
than β-alanine. When these MrgprA3+ neurons where ablated
from a mouse line, the mice still showed regular responses to
pain stimuli, though response to itch stimuli was greatly reduced. Mice have clearly distinct responses to itch and pain and
therefore it is easy to know what sensation is being felt. Facial
wiping with the forelimb is the response to pain, and scratching
with the hindpaw is the response to itch (Shimada, LaMotte,
2008). (One interesting find was that the itch response to β-alanine was regular in MrgprA3+ -ablated mice, confirming that
the neural pathway for β-alanine is unique.) In order to rule
out the possibility that MrgprA3+ neurons are not necessary
in pain response but can still be involved, MrgprA3+ neurons
were specifically activated to see what response the neuron
would elicit- pain or itch. The researchers used TRPV1-deficient
mice and transfected TRPV1 only on the MrgprA3+ neurons.
When capsaicin, an algogen, was injected into the cheek of these
mice, the mice responded with scratching. This is in contrast to
both wild-type mice that responded with wiping and TRPV1deficient mice that did not respond at all. Thus it was shown
that MrgprA3+ neurons coexpressed with TRPV1 elicit an itch
response, regardless of the stimuli (Han, et. al. 2013). This is the
first study to prove the existence of itch-specific neurons. No
matter what the stimulus was, the sensation transmitted by
those neurons was itch.

Conclusion
After the two initial studies that seemed to find itch-specific
neurons, the support for the labelled line theory weakened. As
seen above, many of the receptors for itch are also involved in
the transduction of pain. Even more, itch responsive neurons
in the DRG, TG, and the spinal cord also respond to algogens,
such as capsaicin. However, with the finding of the MrgprA3+
itch-specific neurons, it is possible that the labelled line theory is correct for at least some of itch transduction. GRPR+
may also be part of this itch-specific group that mediates itch
although further research would be necessary to confirm that.
The study done on TG neurons also found a small population
of pruriceptive neurons that only responded to pruritogens.
Perhaps these pruriceptive-specific neurons are enough to
mediate itch.
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Even if itch is mediated through the few pruriceptive-specific
neurons, it is still possible that the units that respond to both
pruritogens and algogens also signal itch. Pruriceptive neurons
are a subset of nociceptive neurons. Some hypotheses are that
if the brain only receives input from the pruriceptive neurons,
it processes the sensation as itch. However, if the brain is also
receiving input from the nociceptive neurons, the brain only
processes the pain and not the itch. So although those pruriceptive neurons are responsive to both pruritogens and algogens if
there is no activity in the nociceptive-specific neurons when an
itch stimulus is activating the pruriceptive neurons, itch will be
felt (quoted in Patel, Dong, 2010). Along the same lines, another
possibility is that the pain pathway activates mechanisms that inhibit itch transduction. Pain inhibiting itch is a familiar phenomenon, as it is well known that scratching relieves itch (Shmelz,
et.al. 2003). A similar inhibition mechanism was suggested in the
findings of a recent study. TRPV1 and TRPA1 both respond to
algogenic stimuli. However, the study found that silencing one of
them can cause algogens to elicit an itch response, i.e. scratching.This suggests that there can be inhibitors from the other ion
channel that do not allow the brain to process the feeling as an
itch (Roberson, 2013).
A final point for consideration is that most of these studies
were done on animal models. But pain and itch may be mediated differently in different animals. Therefore, although research
done on mice and other animals can give us an idea about the
pathways in humans, further studies must be done to see how
these mechanisms work in humans.
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Abstract
Modern Western societies seem to suffer from a veritable epidemic of serious diseases, two of the most serious of
which are cardiovascular disease and cancer. In contrast, hunter and gatherer groups have a very low incidence of
such diseases. Despite the diversity of hunter and gather diets, they all share the same characteristic: the absence of a
Western diet. This suggests that there is something uniquely inflammatory about a Western diet, which is high in both
fats and carbohydrates. Departures from a Western diet appear to result in better health. Experimental studies have
shown that heart disease can be reversed by adopting a very low-fat, high-carbohydrate, plant-based diet. The results
for cancer are less clear. A low-fat, plant-based diet seems to offer promising results, but so does a low-carb, high-fat
ketogenic diet. Perhaps forcing the metabolism into burning either fatty acids alone or glucose alone is beneficial, so long
as one does not mix fat and carbohydrates.
Introduction
In Western societies, heart disease is the leading cause of death
followed by cancer. In 2010, cardiovascular disease (CVD)
caused a total of 788,000 deaths, which makes up nearly 32 percent of all deaths. Heart disease is the leading cause of death in
blacks, but second to cancer in Hispanics, Asians, and American
Indians. In the United States alone, a national survey from 2007
to 2010 showed that an estimated 83.6 million people either
suffered from cardiovascular disease or were at risk for it. Of
this number, 77.9 million people had hypertension and 15.4 million people had coronary heart disease (NHLBI, 2012). As for
cancer, more than thirteen million people in the US had cancer
in a survey taken in 2012 (Seer, 2012).
Although important advances have been made in the treatment
and control of cardiovascular, lung, and blood diseases, these
diseases continue to be a major burden on the nation. It has
been estimated that in 2009, for example, we spent $313 billion
on treating CVD--$192 billion of which took the form of direct
health expenditures and the other $121 billion was in the form
of the indirect costs of mortality (NHLBI, 2012).
Might there be a way to allay these financial and human costs?
By way of an affirmative, this paper will explore the hypothesis
that dietary measures can prevent and/or ameliorate cardiovascular disease and cancer.

Methods
Articles were located on the Touro library, University of Austin
webpage, google scholar, and some journals found in the Touro
library. The articles were critically read, reviewed, compared,
and contrasted.

Discussion: Genes or Diet?
Genes, surely, have role to play in explaining susceptibility to
various diseases. For example, one of the risk factors for heart
disease, elevated cholesterol, sometimes has a genetic cause.
And with the rise of medical inventions, such as penicillin, people
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who might once have died young from infectious diseases now
live long enough to develop other diseases, such as cardiovascular ones and cancers. So it is possible that we are now seeing
genetic dispositions come into play.
However, it is unlikely that genes are the whole story. When
people of the same genetic stock change their diet, their risk
of getting serious diseases changes. For example, when Asian
men move to the United States, they develop prostate cancer
at a higher rate than their peers at home. (Cook, et. al. 1999).
Since the men who moved to the United States did not alter
their genes, the increased incidence of prostate cancer is likely
a product of a change of lifestyle, of diet, or of both. Further, in
the United States the annual number of deaths from cardiovascular disease increased substantially from 1900 to 1970 and
remains high(NHLBI, 2012) ( Figure 2).While during this period,
antibiotic use was on the rise, other changes were afoot. In particular, the way food was produced and consumed underwent
enormous transformations. At the turn of the twentieth century, refrigerators designed for home use had not been invented
and meals had to be made from scratch. By 1970, housewives
were able to buy packaged foods and fast-food restaurants were
becoming more and more popular.
It is plausible, then, that dietary and lifestyle factors might have
greatly contributed to the development of serious diseases. Not
only that, diet and lifestyle may also contribute to the disease’s
amelioration. If so, it is only logical that cardiovascular (and cancer) therapy should involve changes in diet and lifestyle.
The question then becomes: what type of diet and lifestyle is
most protective against, and most able to ameliorate, cardiovascular disease and cancer?

Non-Western Groups, Western Diseases
One place to look for answers is among groups of people who
have low rates of serious disease. One such place is among
hunters and gatherers, who have astonishingly low incidences
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of both cardiovascular disease and cancer. Weston A. Price’s
Nutrition and Physical Degeneration documents how agricultural and hunter-gather groups eating their traditional diets
tend to have very low rates of degenerative diseases. This hypothesis has been supported by studies of particular groups.
Only a few of them are listed here to give an idea of their lowered risk of disease. One study that surveyed blood pressure
among Tsimani forager-farmers found that they had low blood
pressure, and it remained low even as they aged—a finding that
opposes the “normal” trend whereby blood pressure tends
to increase with age.(Gurven, et al., 2012) Similarly, a study of
traditional hunter-gatherer Cameroon Pygmies found that they
had less aortic stiffness, lower LDL, and higher HDL than did
semi-urbanized Pygmies and African Bantous.(Lemogoum, et
al., 2012). The South Pacific commission of 1985 reported that
the rate of cancer incidence among Fijiian Melanesians is quite
low (Robertson, 1991). This finding is particularly striking since
even the rates of lung cancer is one-fourth less than that of
Polynesians and Micronesians, even though all groups smoke
regularly. It is possible that the Melanesians’ consumption of
leafy green vegetables, such as bele and taro leaves, is protective
(Robertson, 1991). And in the first half of the twentieth century,
Canadian and Alaskan Inuits eating their traditional diet had very
low cancer rates compared to Westerners or to Inuits eating a
non-traditional diet (Steffanson, 1960). However, in the second
half of the twentieth century, “Inuit have undergone noticeable
dietary changes from a diet mainly based on fish and sea mammals towards a diet more dependent on imported food” and
adapted, as well, to a Western way of life, at the same time, the
incidence of cancer of the lung, breast, and colon, has increased
(Friborg; Melbye, 2008).
What characteristics do groups such as these share that might
be protective against heart disease and cancer? The answer is not
a particular diet per se since diets among different non-Western
groups tend to vary quite radically. A traditional Melanesian diet,
for example, was mostly plant-based, which included both leafy
greens and starchy foods such as taro, but also included some
seafood and coconut. At the other end of the spectrum, the
Inuits traditionally subsisted on a high fat, high-meat diet that included very little plants and other carbohydrates. Nevertheless,
what they have in common is avoidance of a Western diet and
lifestyle. According to this view, a Western diet and/or lifestyle
is uniquely inflammatory and likely to increase risk factors for
heart disease and cancer.

Untangling the Lifestyle and Diet Hypotheses
What might account for the tendency of Western diets and
lifestyle to increase the incidence of cancer? There are many
hypotheses ranging from an intake of excess calories to micronutrient deficiencies produced by processed foods One

hypothesis, even, is that it is not a Western diet per se that
increases cancer rates, but a Western lifestyle. In contrast to
the high-stress Western lifestyle, non-Western groups tended
to provide people with a cohesive community, a clear sense of
purpose and/or identity, trust in a spiritual power, a more laid
back life that is closer to the rhythm of the changing seasons
and days. In support of this hypothesis, is the following evidence:
Amish adults in Holmes County, Ohio had a cancer rate that
was only 60 percent of the rate of cancer among non-Amish
white adults in Ohio. (Westman, et al., 2010). However, since
the Amish tend to prepare their own food, it is hard to know
whether their lowered cancer rate was due to their lifestyle
or to the benefits of a particular type of diet. Further complicating this scenario is a study of the Old Order Amish in
Pennsylvania, whose mean total serum cholesterol was 212 (and
a standard deviation of 45.2), a little above the recommended
cholesterol number (200). (Pollin, et al. 1991, Table 1). However,
the Old Order Amish are known for being exceptionally longlived. (Sorkin, et al., 2005). This may be due to genetic mutation
that protects them from the negative effects of high cholesterol.
(Pollin, et al., 1991).
Given these complicating factors, one way to test the hypothesis that lifestyle alone and not diet is what determines cancer
risk would be to study groups of people that have a cohesive
community, sense of purpose, and belief in God but eat a typical
Western diet. If we were to find out that people on such a diet
experienced rates of cancer similar to the general population,
then this would contradict the lifestyle hypothesis. But such
communities are very difficult to find, especially since people
who adopt a Western lifestyle—even religious groups of people—adopts, as well, the non-dietary accouterments of such a
lifestyle, such as 9 to 5 jobs, smoking, and sedentary habits. For
example, Seventh Day Adventists—who tend to be vegetarians—tend to have lower mortality rates from serious diseases
compared to the rest of the population. (Heuch, et al., 2005).
But it is hard to untangle the factors that might explain this,
since in the Seventh Day Adventist, this may be due to non-dietary factors, e.g. they are discouraged from smoking.
In the absence of such a stringent test, the next-best test
would be to compare differing religious groups that each have a
strong sense of community, purpose, and belief in God but that
have different diets. Such a study has, in fact, been attempted
in Denmark. A study of 11,580 Baptists, who have no dietary
restrictions, and Danish Adventists, who are lacto-ovo vegetarians, found, first, that both groups, especially, the Seventh
Day Adventists had cancer rates that were lower compared to
the general Danish population (66.95 percent for men and 85
percent for women), and that, second, overall “Adventists had
lower hazard rates than Baptists” (Thygesen, et al., 2012). These
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results suggest that both lifestyle and diet are protective or carcinogenic, since it turns out, first, that being part of a religious
group might, in fact, be somewhat preventive against cancer and
that, second, nonetheless certain kinds of diets may be more
protective than other kinds of diet (and perhaps even more
protective than the type of lifestyle one adopts).

currently do. So our bodies cannot convert all of it to various
hormones.

Seventh Day Adventists generally tend to consume a mostly
vegetarian diet, suggesting that it might be a beneficial diet even
among people who follow a Western lifestyle.

Given these dynamics, we would expect that diets that have
an abundance—not only of fat and cholesterol—but of sugar,
fat, and cholesterol, to be ones that are effective at increasing
the incidence of heart disease—which is the case in Western
countries. Conversely, we would expect that diets that reduce
our intake of fat and sugar would be beneficial at preventing and
reversing heart disease.

Heart Disease: Causes and Characteristics

Heart Disease and a Mediterranean Diet

While some heart attacks are due to arrhythmias or faulty
valves, endothelial injury, inflammatory oxidative stress, foam
cell formation, and development of plaque can all be an introduction for cardiovascular disease. In obstructive heart disease,
high cholesterol sometimes oxidizes, attaches to fatty acids,
and begins to clog the arteries (atherosclerosis). These plaques
sometimes calcify in the body’s attempt to stabilize them, but
this has the effect of further occluding the arteries. Occluded
arteries make it harder to pump blood through them, and so
blood pressure increases, in an attempt to ensure that adequate
blood reaches vital organs. When the arteries are obstructed,
or when the plaque is too unstable such that a clot forms and
breaks off, then that blocks the flow of blood. This prevents
enough oxygen from reaching the heart (as in ischemic heart
disease), the brain (as in strokes), the lungs (pulmonary heart
disease), or other vital organs.

There have been many attempts to find therapeutic diets that
might prevent and reverse heart disease. One commonly studied diet is the Mediterranean diet, which comprises of mostly
grains, fruits, vegetables, olive oil, nuts, some fish, dairy, and some
occasional red meat. Fat makes up roughly 30 to 40 percent of
the caloric intake and the fat itself was mostly monounsaturated
(McKeown, et al., 2010). The Lyon Diet Heart Study was the
first attempt to use this diet on 275 patients who had survived a first myocardial infarction. A test group was to follow
the Mediterranean diet, while a control group was to follow the
diet prescribed by their doctor. In patients who followed the
test diet, the rate of cardiac death was 1.32/100 patients after
27 months and 1.24 after 46 months. This was an impressive
reduction in mortality compared to the control group, which
had a mortality rate of 5.55 and 4.07 after 27 and 46 months,
respectively (de Lorgeril, et al., 1999). Many further studies
have attempted to replicate the success of the Lyon Diet Heart
Study, with varying success. One review of observational studies
estimated that a Mediterranean diet reduced the risk of heart
disease by 8 to 45 percent (Panagiotakos, et al., 2004).

In this scenario, high cholesterol starts an inflammatory cascade.
Dietary cholesterol is often the source of high blood cholesterol, as well as of the fatty acids that the cholesterol transports, but the liver, too, can produce cholesterol and fatty acids.
Further, when we take in too much sugar and starch than we
need or than can be delivered to our cells, the liver converts
them to fat. And insulin resistance, which prevents adequate disposal of glucose, is a predictor of heart disease (Yip, et al., 1998).
Insulin resistance shifts our metabolism from burning glucose to
burning fat, which means that the blood will have elevated levels
of circulating free fatty acids, which have also been implicated
in heart disease.
This picture is perhaps an overly simplified one. While it begins
with the premise that the problem is elevated cholesterol, in
a healthy body, ingested cholesterol generally should be converted to pregnenolone, estrogen, testosterone, progesterone, and cortisol. This raises the question: what is stopping or
slowing down such a conversion? We may not be able to fully
understand the genesis of heart disease without answering this
question, but perhaps the answer is simply that we were not
designed to ingest as much fat, sugar, and cholesterol that we
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It might seem that favoring the intake of monounsaturated to
saturated fats might account for these somewhat favorable results, but regardless of whether patients ate either type of fat,
the disease spread just at the same rate (Castelli, 1996). Further,
while compared to a control group, the results of adhering to a
Mediterranean diet seem impressive, we must keep in mind that
while it reduced the rate at which people died from coronary
heart disease, it did not actually stop or reverse the progression
of the disease. The disease continued to progress, albeit at a
slower rate compared to the control group (de Lorgeril, et al,
1999).

Heart Disease and a Plant-Based Diet
It is possible that the Mediterranean diet is not restrictive
enough or permits too much animal-based foods. In support of
this hypothesis, we can point to how during World War II, when
the Germans confiscated Norwegians’ livestock, the Norwegian
diet was effectively limited to plants. During this time, the death
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rates from strokes and heart attacks dropped considerably and
then returned to pre-war levels when livestock was abundant
again. This is an epidemiological study, but there is other evidence that supports the use of a plant-based diet to control
heart disease. First, on a jocular note, African green monkeys
apparently find a plant-based diet to be heart protective, especially when used in conjunction with cholesterol-reducing medication. Over a five-year period, these monkeys saw a halt to the
progression of coronary artery disease (Rudel LL et al. 1995).
But clinical studies have yielded positive results for human beings, too, who adopt a plant-based diet. In one study, patients
put on a plant-based diet that had less than 10 percent fat saw a
drop in their cholesterol: an average of fifty points, from 227 mg/
dL to 172 mg/dL. And there was a regression of heart disease
in 82 percent of the 28 patients (Ornish et al., 1990). In this
study, in addition to making dietary changes, the test patients
had to exercise for three hours each week, as well as spend an
hour a day on some type of stress-reducing exercise, such as
meditation.
It would have been useful to compare the effects of a regimen
of stress-reduction alone to a dietary regimen only; this would
allow us to better tease out the degree to which diet accounts
for the results. But we have a semi-answer in the form of clinical studies undertaken by Caldwell Esselstyn at the Cleveland
Clinic. Twenty two patients with cardiovascular disease were
put on a plant-based diet consisting of legumes, whole grains,
fruits, and vegetables; the total fat intake was around 8 percent
of total caloric intake. The 17 patients who adhered to this diet
all witnessed a complete halt to the disease, and in 4 of them
there were signs that the disease was reversed. One patient,
who was limping from obstruction of the arteries in the leg,
known as claudication, and who also had a low pulse volume
experienced total pain relief after ten months of being on a
plant based diet. Figure 3, below, presents the PET results of
the myocardium of another patient before the diet and three
weeks after: the restricted myocardial blood flow showed signs
of restored blood flow (Esselstyn, 2014).

Figure 3

Restoration of blood flow to myocardium after three weeks on
plant-based diet

While this study was a small one, a study consisting of a larger
sample size, a cohort of 198 patients was performed. The patients had medical issues ranging from hyperlipidemia, hypertension, and diabetes. These patients were then counseled on the
guidelines of the core of a plant-based diet.They were instructed
to eat only whole grains, legumes, and fruits and vegetables.They
were encouraged to take a multivitamin and a B12 supplement
and then assured that these food and vitamins would provide
all of their amino acid needs. Omega-6 and omega-3 essential
fatty acids were provided in the form of flax seeds so were
therefore also recommended as part of the diet. Foods that
contained oil, fish, meat, fowl, dairy, avocado, nuts, caffeine and
sugar were foods that were prohibited. Out of these patients,
twenty one patients were not adherent to the diet. Out of these
twenty one patients, 13 (62 percent) experienced at least one
cardiovascular disease event including sudden cardiac death,
heart transplants, and ischemic stroke. This is in glaring contrast
to the patients who did follow the diet. Out of the 198 patients,
177 (89 percent) followed these guidelines and ninety-three
percent of these adherent patients experienced improvement
or even resolution of symptoms. There was only one major
cardiovascular event that was related to disease progressions
within the patients who adhered to the diet (Esselstyn, 2007).
This is a 0.6 percent recurrent event rate.This contrasts sharply
to the 62 percent recurrence rate recorded from the nonadherent patients.
Because adherence is generally the hardest factor to maintain in
a diet, this study provided the patients with a five hour counseling seminar before the start of the diet to inform the patients of
the risks involved when ingesting animal products. The patients
were then called and given psychological support during a 3.7
year follow up to ensure they were adhering to the diet. This
may have contributed to the success of the study. But there are
some limitations to this study. First, it did not include a control
group. Second, the patients who made up the cohort were very
specific. They fell into a certain age range and all had history
of cardiovascular disease. Further study would be needed to
determine if complete prevention of cardiovascular disease can
be accomplished in patients who do not have a history of cardiovascular disease. Third, the sample size, even though larger
than the sample included in the Cleveland Clinic study, is still
rather small.
Despite these limitations, in both of Esselstyn’s studies, the
percentages of patients in which cardiovascular disease did not
progress are consistent. The percentage of patients in the study
who adhered to the diet and had a recurrence of cardiovascular
disease events is less than one percent. This is strong enough
data to be used in order to inform people of this cheap and
effective option of preventing and reversing cardiovascular
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disease. And it supports the hypothesis that a plant-based diet
can significantly affect the progression of the cardiovascular epidemic that is rampant in Western countries.
What might explain the impressive results of a plant-based
diet? One possibility is that plant polyphenols themselves are
heart-protective. Another is that a plant-based diet avoids the
negative effects that might result from eating red meat, such
as the production trimethylamine-N-oxide, a metabolite of
L-carnitine, which has been linked to coronary artery disease
(Tuso, et al., 2015). Another possibility is that by restricting a
macronutrient (fat), subjects ended up cutting out a huge source
of calories, and so perhaps a plant-based diet better cuts calories than does a Mediterranean diet. Another possibility is that
fat itself is harmful to the heart and so lowering dietary lipids
to under 15 or even 10 percent might be advantageous. Perhaps
even a zero-fat diet might not be ill-advised for some. One
man cured himself of his migraines, reduced his blood pressure,
and reduced his cholesterol from 252 to 206 by switching to a
completely fat-free diet. (Brown et al. 1938). This diet, however,
was not a plant-based one, but used sugar and defatted milk. If
the results of this diet were shown to be useful to more than
just one individual, then we might have found the mechanism by
which a plant-based diet reverses heart disease: it’s the absence
of high fat, not the plants themselves that are helpful.This would
be a surprising finding but its validity, of course, is a question for
further research to determine.

Cancer: Causes and Characteristics
Unlike the causes of heart disease, the causes of cancer are not
well understood. They tend to share several basic characteristics: angiogenesis (Baenke, et. al. 2013); altered fat metabolism
(McAnderew; Baenke, et.al.2013); a preference for anaeorobic
over aerobic metabolism (Warburg, 2009); and perhaps even
the capacity for immortality. What might lead an organism to
develop these characteristics? One hypothesis, forwarded by
Otto Warburg, is that cancers are caused by derangements in
respiratory function. Other hypotheses include the theory that
cancer is a type of viral infection, that cancer cells are stem cells
that (for some reason) have been unable to mature, and that
cancer is a product of localized and/or systemic inflammation.
But whichever hypothesis we choose, we would have to explain,
e.g., the cause of respiratory dysfunction, the inability of stem
cell maturation, or the causes of inflammation.

Cancer and a Plant-Based Diet
Seventh Day Adventists generally—not just, as we saw earlier,
Danish Adventists—have lower cancer rates compared to the
general population (Lemon, et al., 1964). Further, even among
Adventists, the type of vegetarian diet adopted affected their
cancer rates. Among 69,120 participants of the Adventist Health
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Study-2, there were 2,939 cases of cancer.While a vegetarian diet
is sometimes associated with cancers of the gastrointestinal tract,
here, vegetarians were less like to get such cancers, particularly if
they were lacto-ovo vegetarians. Likewise, vegetarians—particularly vegan vegetarians—had a lower risk of cancer compared to
non-vegetarians (Tantamango-Bartley, et al., 2012).
When we turn to studies assessing the relationship between
a plant-based diet and lowered cancer risk, we find that a vegetarian diet, in general, even among the non-religious, appears
to have protective effects. A 1990s prospective study of 63,550
people in the United Kingdom found that, compared to people
who ate meat, vegetarians were less likely to get cancer (except
for colorectal cancer). For vegetarians, “the incidence rate ratio
for all malignant neoplasms was 0.89” (Key, et al., 2009).
Further, increasing people’s consumption of vegetables and whole
grains may be beneficial even among people who have cancer.
Case histories of cancer patients have revealed, for example,
that pancreatic cancer patients who ate a low fat diet that included moderately high fiber and reduced calorie had a higher
1-year survival rate than patients who did not change their diets.
Likewise, patients with stage D2 metastatic prostate cancer who
followed such a diet survived longer and with improved quality of
life compared to patients who did not change their diets (Carter,
et al. 1993). Another study encouraged men with recurrent prostate cancer to eat more vegetables and whole grains. “Median
intake of whole grains increased from 1.7 servings/d at baseline
to 6.9 and 5.0 servings/d at 3 and 6 months, respectively. Median
intake of vegetables increased from 2.8 servings/d at baseline to
5.0 and 4.8 servings/d at 3 and 6 months, respectively.The rate of
PSA rise decreased when comparing the prestudy period (0.059)
to the period from 0 to 3 months (-0.002, P < .01) and increased
slightly, though not significantly, when comparing the period from
0 to 3 months to the period from 3 to 6 months (0.029, P =
.4316). These results provide preliminary evidence that adoption
of a plant-based diet is possible to achieve as well as to maintain
for several months in patients with recurrent prostate cancer”
(Nguyen, et al., 2006).
Additionally, a plant-based low-fat (10-15% kcal), high-fiber (3040 g per 1,000 kcal/day) diet, combined with daily exercise, in
just two weeks reduced overweight women’s risk factors for
breast cancer. This regimen reduced their serum estradiol, insulin, and IGF-I. Further, serum taken from these women after
two weeks proved able to induce apoptosis of several variants
of breast cancer cells in vitro (Barnard, et al., 2006).
These are just a few studies, but the evidence is quite suggestive.
Plants have a number of protective properties (such as polyphenols) so simply increasing plant foods may be protective.
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But part of the protection may be also the result of reducing
the consumption of other foods, particularly processed foods,
meat, and added fats. It is striking that people such as McDougall,
Ornish, and Pritikin emphasize the importance of keeping dietary fat low, not just of increasing the amount of plant matter.

There is not enough evidence to determine which one is more
effective, but it seems that a very high fat diet, just as a low
fat plant-based diet, might be effective, to some extent, against
cancer.

High Fat or Low Fat?
This makes sense to some extent since some fats themselves
might contribute to the development of cancer. For example,
prostate cancer is detected among men in the United States
at a rate that is fifteen times higher than the rate of detection
among men in Asian countries, who eat a lower-fat diet than
American men (Parkin, et al., 1990). And, as mentioned earlier,
when Asian men move to the United States and presumably
increase their intake of fat, they develop prostate cancer at
a higher rate than their peers at home (Cook, et. al., 1999).
Further, compared to subjects who ingested less fat compared
to the controls, lowering fat intake led to the development of
smaller tumors as well as to tumors that grew more slowly—at
least in immunodeficient mice who were able to eat ad libitum
(Tung, 2014). It is worth noting that different types of fat may
have different effects. In the study just cited, the mice on both
the high-fat and low-fat diets ingested omega-6 fatty acids in the
form of corn oil. In contrast, among mice whose main source of
fat was saturated, there was little difference in the development
of tumors in mice fed a diet high in fat (40 percent) versus those
fed a diet low in fat (12 percent). This would suggest, as the
authors of this study do, that lowering saturated fats does not
slow the growth of prostate tumors, but reducing omega-6 fats
might be beneficial (Lloyd, et al. 2010).

Cancer and Ketogenic Diets
Before we too hastily conclude that fat is carcinogenic, we should
recognize that there is some evidence that ketogenic diets, which
have been shown to be protective against epilepsy, might be protective against cancer too. Some scholars hypothesize that since
cancer cells thrive on glucose, depriving them of it might, in principle, lead to their eventual death. On the other hand, since normal
cells are able to run on ketones, a very high fat, low carb and low
protein diet should be harmful only selectively (to cancer cells, not
to normal cells) (Allen, 2014). There are very few human studies
that demonstrate the purported benefits of a ketogenic diet. One
of these studies included two young girls who had advanced-stage
brain tumors that remained even after they were subjected to
radiation and chemotherapy. Although the chemotherapy and
radiation were not successful, the tumors were able to be managed long-term by using a ketogenic diet. (Nebeling,1995).Thomas
Seyfried has replicated these results among mice with brain
tumors (Seyfried 2008; Seyfried 2003). Further studies on mice
suggest that a ketogenic diet reduces blood glucose and slows
the growth of tumors, a result that is compounded when used in
conjunction with hyperbaric oxygen therapy (Poff, 2013).

On first glance, this seems to be a surprising result: two diets
that could not be more different from each other both seem to
exert some protective effects against cancer. Perhaps the same
conclusions can be drawn as was earlier when confronted with
the fact that non-Western people who consumed radically different diets nevertheless had similar low rates of cancer: the
protective effects of different diets may be due less to their
component parts than to their shared avoidance of certain
foods, such as processed meats or artificial ingredients. Or it
might be that a ketogenic diet is protective against certain type
of cancers, but not others, while a low-fat, plant-based diet is
more protective against other types of cancers. It should be
noted that all of this is based on Warburg’s considering that all
types of cancer have the same type of causes. But it is possible
that each cancer has a different cause and that therefore resolving it would require a diet targeted for that particular cancer. It
might even be that cancers themselves might evolve in slightly
different ways so that someone who has stage-1 breast cancer
might respond well to one kind of diet while the same person
with a stage-4 breast cancer might respond badly to the same
diet.
However, bracketing that possibility for now, another hypothesis
might be that certain foods—or food groups—are protective
but only when taken alone such that combining them with another type of food might weaken their protective effects, or
even cause negative ones. According to this hypothesis, perhaps
a very high fat alone may be protective, as is high-carb plant food
diet. Combining both fat and plant-based carbs, on the other
hand, might have a different effect. This is a topic for future
research.

Conclusion
Western countries have the highest incidence of atherosclerosis. Not coincidentally, these countries have easy access to an
abundance of foods that are high in fat, sugar, starch, and cholesterol. If North America and Europe claim to have the most
advanced medical care, what are these health care systems
doing to prevent atherosclerosis, in particular, and heart disease,
in general? In 1989, the National Research Council created a
report called “Diet and Health,” which recommended keeping
cholesterol levels under 200 mg/dL and dietary fat to 30 percent of one’s caloric intake. However, these guidelines are contestable, since it is possible that “a greater reduction [of cholesterol and dietary fat] would confer additional health benefits.”
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(Ornish, 1998). The suggestion that cholesterol levels between
150 and 200 might be too high is supported by a study showing that 35 percent of patients with ischemic heart disease had
a cholesterol level between 150 and 200 (Castelli, 1996). The
National Research Council, the American Heart Association,
and the National Cholesterol Education Program recommend
a diet that includes oil, low-fat milk, butter, and cheese. But if
atherosclerosis and heart disease in general are closely linked to
high cholesterol, their recommended diet by may be too lax to
lower cholesterol levels. In light of the evidence, it would appear
that in order to prevent and reverse heart disease, we would be
well advised to adopt a very low fat, plant-based diet.
Adopting a low-fat, plant-based diet might also help reduce our
chances of getting cancer, but there is also evidence suggesting
that a high-fat ketogenic diet might be advantageous.Which diet
should we prefer? Given differences in our genetics and physiology, some people might be better off on a ketogenic diet while
others might fare better on a low-fat plant-based diet. Current
knowledge does not tell us who would do better on which diet,
but it is reasonable to suppose that people whose ancestors ate
a certain type of diet might be more adapted to that diet than
other people.The Inuit, for example, over the generations might
have evolved the capacity to be able to process huge amounts
of fat safely. But other than a few groups whose ancestral diet
is known, what should the average Indo-European person do?
Given our lack of knowledge about the long-term effects of
ketogenic diets, it might be best to adopt a low-fat diet instead.
We have no evidence comparable to that of long-term vegetarian diets, that a long-term ketogenic diet is safe or prevents
the development cancer (as opposed to attenuating its growth).
We cannot point to the Inuits in support of the safety of a
ketogenic diet since, although they ate a high-fat diet, it was
nevertheless not on a ketogenic one: they ate some carbohydrates and enough protein that could then be converted, via
gluconeogenesis, to glucose. Therefore, it is wise for many of us
to adopt a low-fat plant-based diet, especially since it appears to
be beneficial in reducing heart disease.

References

Brown William Redman, Arild Edsten Hansen, George Oswald
Burr, and Irvine McQuarrie. Effects of prolonged use of
extremely low-fat diet on an adult human subject. Journal of
Nutrition (1938), vol. 16, no. 6.
Carter JP, GP Saxe,V. Newbold, CE Peres, RJ Campeau, and L.
Bernal Green. Hypothesis: dietary management may improve
survival from nutritionally linked cancers based on analysis of
representative cases. J Am Coll Nutr. 1993: 12(7): 209
Cook, L. S., Goldoft, M., Schwartz, S. M., and Weiss, N. S.
Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. J. Urol., 161:
152–155, 1999.
de Lorgeril Michel; Patricia Salen; Jean-Louis Martin; Isabelle
Monjaud; Jacques Delaye; Nicole Mamella. Mediterranean
Diet, Traditional Risk Factors, and the Rate of Cardiovascular
Complications After Mocardial Infarction, the Final Report of
the Lyon Heart Study. Circulation 1999;99:779-785
Esselstyn CB Jr, Ellis SG, Medendorp SV, et al. A strategy to
arrest and reverse coronary artery disease: a 5-year longitudinal study of a single physician’s practice. J Fam Pract.
1995;41:560-568
Esselstyn CB Jr. Prevent and Reverse Heart Disease. New York;
New York: Penguin Group;2007
Esselstyn CB Jr. Updating a 12 year experience with arrest and
reversal therapy for coronary heart disease (an overdue requiem for palliative cardiology) Am J Cardiol. 1999;84:339-341, A8
Esselstyn CB Jr. Resolving the coronary artery disease epidemic through plant-based nutrition. Prev Cardio.2001;4:171-177.
Esselstyn Jr MD, Gina Gendy MD, Johanthan Doyle MCS,
Mladen Golubic, Michael F. Roizen. A Way to reverse CAD? The
Journal of Family Practice. 2014;Volume 63 No 7
Friborg Jeppe T, Mads Melbye, Cancer patterns in Inuit populations. The Lancet Oncology.Vol. 9, issue 9. September 2008:
892-900
Gurven Michael, Aaron D. Blackwell, Daniel Eid Rodríguez,
Jonathan Stieglitz, Hillard Kaplan. Does Blood Pressure
Inevitably Rise With Age? Longitudinal Evidence Among
Forager-Horticulturalists. Hypertension. 2012. DOI: 10.1161/
HYPERTENSIONAHA.111.189100

Baenke Franziska, Barrie Peck, Heike Miess, and Almut Schulze.
Hooked on fat: the role of lipid synthesis in cancer metabolism
and tumour development. Dis Model Mech. 2013 Nov; 6(6):
1353–1363.

Heuch Ivar, Bjarne K. Jacobsen, Gary E. Fraser. A cohort study
found that earlier and longer Seventh-day Adventist church
membership was associated with reduced male mortality.
Journal of Clinical Epidemiology 58 (2005) 83–91.

Barnard R. James, Jenny Hong Gonzalez, Maud E. Liva, and Tung
H. Ngo. Effects of a Low-Fat, High-Fiber Diet and Exercise
Program on Breast Cancer Risk Factors In Vivo and Tumor

Jansen, A.A.J., S. Parkinson, and A.F.S. Roberston. Food and
Nutrition in Fiji: A Historical Overview, vol. 2. Dept. of
Nutrition and Dietetics, Fiji School of Medicine; Inst. Of Pacific
Studies; U. of S Pacific. 1991.

Cell Growth and Apoptosis In Vitro. NUTRITION AND
CANCER, 2006; 55(1), 28–3.

138

A Dietary Approach to Cardiovascular Disease and Cancer

Key TJ, Appleby PN, Spencer EA, Travis RC, Roddam AW, Allen
NE. Cancer incidence in vegetarians: results from the European
Prospective Investigation into Cancer and Nutrition (EPICOxford). Am J Clin Nutr. 2009 May;89(5):1620S-1626S.

Panagiotakos DB, Pitsavos C, Polychronopoulos E et al. (2004)
Can a Mediterranean diet moderate the development and
clinical progression of coronary heart disease? A systematic
review. Med Sci Monit 10, 193–198

Lampe J.W. Interindividual differences in response to plantbased diets: implications for cancer risk. Am. J. Clin. Nutr. 2009.
Volume 89, Issue 5; Pages 1553S-1557S

Parkin, D. M., Pisani, P., and Ferlay, J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int. J. Cancer, 80:
827–841, 1999.

Lemon F, Walden R, Woods R. Cancer of the lung and mouth
in Seventh-day Adventists. Preliminary report on a population
study. Cancer 1964;17: 486–97.

Pollin Toni I., Wen-Chi Hsueh, Nanette I. Steinle, Soren Snitker,
Alan R. Shuldiner, Braxton D. Mitchell. A genome-wide scan of
serum lipid levels in the Old Order Amish. Atherosclerosis 173
(2004) 89–96.

Lemogoum Daniel, William Ngatchou, Christophe Janssen,
Marc Leeman, Luc Van Bortel, Pierre Boutouyrie, Jean
Paul Degaute, Philippe Van de Borne. Effects of HunterGatherer Subsistence Mode on Arterial Distensibility in
Cameroonian Pygmies. Hypertension. 2012. DOI: 10.1161/
HYPERTENSIONAHA.111.187757
Linher K and Singh G . Abstract P4-03-02: Establishing a
Relationship between Breast Cancer, Prolactin and Altered
Fat Metabolism. Cancer Res 2010;70(24 Suppl):Abstract nr
P4-03-02.
Lloyd Jessica C., Jodi Antonelli, Jean-Alfred Thomas, Tameika E.
Phillips, Susan H. M. Poulton, and Stephen J. Freedland. Effect
of Isocaloric Low-Fat Diet on Prostate Cancer Xenograft
Progression in a Hormone-Deprivation Model. Journal of
Urology. 2010 April; 183(4): 1619–1624.
McAndrew P. F.. Fat Metabolism and Cancer. Surg Clin North
Am. 1986 Oct;66(5):1003-12.
McKeown Pascal P., Karen Logan, Michelle C. McKinley, Ian S.
Young and Jayne V. Woodside. Session 4: CVD, diabetes and
cancer: Evidence for the use of the Mediterranean diet in
patients with CHD. Proceedings of the Nutrition Society
(2010), 69, 45–60.
Ngo Tung H., R. James Barnard, Pinchas Cohen, Stephen
Freedland, Chris Tran, Frank deGregorio,Yahya I.
Elshimali, David Heber, and William J. Aronson. Effect of
Isocaloric Low-fat Diet on Human LAPC-4 Prostate Cancer
Xenografts in Severe Combined Immunodeficient Mice and the
Insulin-like Growth Factor Axis. Clinical Cancer Research 2003;
9: 2734–2743.
Nguyen Jacquelyn Y., Jacqueline M. Major, Cynthia J. Knott,
Karen M. Freeman, Tracy M.
Downs, and Gordon A. Saxe. Adoption of a Plant-Based Diet
by Patients with Recurrent Prostate Cancer. INTEGRATIVE
CANCER THERAPIES 5(3); 2006 pp. 214-223.

Robertson A. F. S.., ed. Food and Nutrition in Fiji: Nutritionrelated diseases and their prevention (1991).
Rudel LL, Parks Js, Sawyer JK. Compared with dietary monounsaturated and saturated fat, polyunsaturated fat protects
African Green Monkeys from coronary artery atherosclerosis.
Arterioscler Thromb vasc Biol 1995;15:2101-2110
Sorkin John, Wendy Post, Toni I. Pollin, Jeffrey R. O’Connell,
Braxton D. Mitchell, Alan R. Shuldiner. Exploring the genetics of
longevity in the Old Order Amish. Mechanisms of Ageing and
Development 126 (2005) 347–350.
Stefansson Vilhjalmur. Cancer, Disease of Civilization (1960).
Tantamango-Bartley Y1, Jaceldo-Siegl K, Fan J, Fraser G.
Vegetarian diets and the incidence of cancer in a lowrisk population. Cancer Epidemiol Biomarkers Prev. 2013
Feb;22(2):286-94
Thygesen Lau Caspar, Niels Christian Hvidt, Helle Ploug
Hansen, Andreas Hoff, Lone Ross, Christoffer Johansen. Cancer
incidence among Danish Seventh-day Adventists and Baptists
Cancer Epidemiology 2012; 36:513–518
Tuso Phillip, MD, FACP, FASN; Scott R Stoll, MD; William W Li,
MD. A Plant-Based Diet, Atherogenesis, and Coronary Artery
Disease Prevention. Perm J 2015 Winter;19(1):62-67
Westman Judith A., Amy K. Ferketich, Ross M. Kauffman, Steven
N. MacEachern, J. R. Wilkins III, Patricia P. Wilcox, Robert
T. Pilarski, Rebecca Nagy, Stanley Lemeshow, Albert de la
Chapelle, Clara D. Bloomfield. Low cancer incidence rates in
Ohio Amish Cancer Causes Control (2010) 21:69–75
Yip Jeannie, Francesco S. Facchini, and Gerald M. Reaven.
Resistance to Insulin-Mediated Glucose Disposal as a Predictor
of Cardiovascular Disease. Journal of Clinical Endocrinology
and Metabolism. 1998.Vol. 83, No. 8

Ornish, D., Brown, S. E., Billings, J. H., Scherwitz, L. W.,
Armstrong, W. T., Ports, T. A., ... Brand, R. J. (1990). Can lifestyle changes reverse coronary heart disease? The Lancet,
336(8708), 129–133.

139

Cognitive Effects of Breastfeeding
Abraham Englard

Abraham Englard is graduating in September 2016 with a BS in Biology.

Abstract
This paper explores the cognitive effects of breastfeeding through Intelligence Testing and Imaging Testing that compares
IQ, success, and brain structure of individuals that were breastfed, formula fed, and both breastfed and formula fed.
Intelligence studies available are widespread for all age groups and signify a causal relationship between breastfeeding and
intelligence. However, imaging testing is not as extensive, but shows a strong correlation between cognitive development
and breastfeeding. The mechanism of breast milk’s impact on cognitive development is at an exploratory phase, with a
possibility that docosahexaenoic and arachidonic acids, along with other nutrients found in breast milk, contribute to
preferential neural development. Altogether, the biological principle that structure equals function, is supported by evidence from Intelligence and Imaging tests that structural differences in the brains of those who were breastfed, caused by
the components of breast milk, results in superior intelligence (than non-breastfed individuals) throughout life.
Introduction
The development of human beings, like any other organisms, is
affected by the method and means of feeding. Breastfeeding has
many undisputed benefits recognized across the board by the
medical community. However, modern life makes it that physical
breastfeeding effects are not an issue of life or death, or even
keeping serious illnesses away (Christakis, 2013). Consequently,
women need an alternative motive for choosing to breastfeed,
and continuing to breastfeed. This paper examines some of the
cognitive developmental findings related to prolonged breastfeeding. Indeed, intelligence testing and imaging studies show an
encouraging correlation between elevated IQ and babies who
were breastfed.
With all research indicating that breastfeeding is the superior
option when it comes to feeding babies, continued exploration
of the benefits may seem superfluous. Discovered benefits of
breastfeeding, however, are mostly limited to physical health
advantages, which is not enough to motivate women to breastfeed. Reason being, the physical benefits are usually limited to
early childhood, and do not have effects beyond that. Some
examples of benefits that do not extend past early childhood
include reduction of gastroenteritis, otitis media, and atopic eczema (Christakis, 2013,). On the other hand, cognitive effects
from breastfeeding have lifelong implications, starting at infancy,
and extending way beyond early childhood. This compilation
brings together research studies on IQ and brain structure of
different age groups to present a significant correlation between
breastfeeding and cognitive development.

Methods
The perusal of journal articles and research papers through the
Touro College online library system.

Breastfeeding and Infant Intelligence
Intelligence in infants is a difficult factor to determine, as much
of the cognitive functions of babies are shrouded in mystery.
Yet, we know that a baby’s visual acuity gradually increases until
it reaches a standstill at around twelve months. Consequently,
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researchers used visual acuity as a determining factor in intelligence to look for a correlation between breastfeeding and
early infant intelligence. Two groups of infants, one consisting of
breastfed infants and the other consisting of formula fed infants,
were assessed for intellectual ability using visual acuity as an
indicator. Behavioral testing analyzed infants’ tendencies to look
at patterned cards versus blank cards at ages one, two, three,
and four months. From the two groups that were assessed, both
improved significantly from the first to fourth month. However,
the group of breastfed babies significantly surpassed the formula
fed babies in visual acuity scoring. These results were parallel to
findings of “a decrease in docosahexaenoic acid (DHA) of red
blood cells in formula fed infants” (Michaelsen et al, 2003).
DHA is an omega-3 fatty acid found in breast milk. DHA seems
to play a role in cognitive development. This is evidenced by
the combination of results of the former study and a randomized intervention study that supplemented infant formula with
DHA and tested the visual acuity of these infants. When infants
took formula supplemented with DHA, their scores on the
visual acuity test were better than infants who were drinking
non-supplemented formula, but not as well as infants who were
breastfeeding (Michaelsen, 2003).
Yet, DHA cannot be the only ingredient in breast milk influencing cognitive development. If it were, the supplement of DHA
in infant-formula would be enough to produce the same visual
acuity results as breastfed infants. However, DHA along with
other nutrients can be responsible for the cognitive benefits of
breast milk over formula. These nutrients, which are not found
in cow milk or formula, have positive effects on cognitive development, and cannot be duplicated because they are not all
known elements. “Nobody has been able to reproduce human
breast milk because there are lots of elements in it that we
probably don’t even know about” (Lisser, 2002). At least until
we figure out how to duplicate all the nutrients found in breast
milk, breastfeeding will remain the single, most-effective way to
ensure the highest level of cognitive development in infants.

Cognitive Effects of Breastfeeding

Breastfeeding and Toddler Intelligence
Toddlers too, display higher levels of cognitive functioning when
they are breastfed for prolonged periods, compared to babies
who are breastfed for less than four months, or formula fed.
This was determined by assessing the cognitive development of
two-year olds via mental and psychomotor development, using
the Bayley Infant Developmental Tests. Psychologists administering the tests found that “at 24 months, infants breastfed for
longer than 4 months scored higher than those breastfed for 4
months or less and higher than formula fed infants” (GomezSanchiz et al., 2004). In another instance, toddlers who were
breastfed up to three months scored 4-5 points higher than
those who were formula fed on psychometric tests, determining
IQ (Jedrychowski, 2011).
Exclusive breastfeeding, as opposed to complementary breastfeeding also plays a positive role in the IQ of toddlers. The
younger the child, the more significant the difference in IQ is
between exclusively breastfed toddlers, and complementary fed
toddlers. In one year-olds, exclusive breastfeeding resulted in
a .0547 disparity between intelligence scores of toddlers that
were exclusively breastfed, and toddlers that were complementary breastfed. At two years, a notable disparity between the
intelligence scores of the two groups still remained, but shrunk
to .0386. Exclusive breastfeeding affects IQ in toddlers positively, even if the time period of exclusive breastfeeding is short
(Jedrychowski et al., 2011).

Breastfeeding and Intelligence in
School-Aged Children
During the first year of school, children who are breastfed
have an academic advantage over children who are formula fed.
According to teacher-assessed education assessments of five year
old children in England, using FSP (Foundation Staged Profile), duration of breastfeeding influenced the children’ academic success.
In areas of personal, social, and emotional development, as well
as communication, literacy, and language, longer breastfeeding
caused higher scores to be more likely (Heikkilä, 2014). Duration
of breastfeeding was divided into four categories; never, less than
two months, two to four months, and longer than four months.
Children breastfed for up to two months were 9% more likely
than children never breastfed to receive good overall achievement scores. Additionally, the longer a child was breastfed, the
more likely he/she was to receive good overall achievement
scores. Putting the three categories of breastfeeding together,
and comparing it to children who were never breastfed, shows
a 10-16% greater chance of good overall achievement scores for
children who were breastfed (Heikkilä, 2014).
Notably, the relationship between breastfeeding and cognitive
development is not exclusive to academic success. Rather,

breastfeeding affects cognitive development in areas that include
emotional and social intelligence, as well. Emotional and social
intelligence first begin to influence success in earlier grades of
school, but continue through high school and adulthood to
have a more significant impact on success. Consequently, the
influences of breastfeeding on emotional and social cognitive
development are more prevalent throughout adulthood, compared to early childhood. This directly supports the notion that
positive cognitive effects of breastfeeding are long-term, and a
better reason than the well-known, short-term physical health
effects of breastfeeding, for which women choose to breastfeed
(Heikkilä, 2014).

Breastfeeding and Intelligence in Adolescents
The effects of breast-feeding on cognitive development also extend into the realm of adolescent intelligence, which is a long
way off from the actual act of breastfeeding. “In New Zealand,
breastfeeding duration was positively associated with performance in secondary school tests in students aged 18 years”
(Victora et al., 2015). Students who are breastfed are also more
likely to finish a higher grade of school. A study of 2,000 male
Brazilian adolescents ages 18, found an increasing trend in finishing higher grades
with students who were breastfed. “Those breastfed for 9
months or more were ahead by 0.5-0.8 school grades, relative
to those breastfed for less than 1 month” (Victora et al., 2005).

Breastfeeding and Intelligence in Adults

Various studies on the effects of breastfeeding positively influencing adult intelligence found a correlation between the two.
In Brazil, intelligence, educational attainment, and income were
all higher in 30 year-olds who were breastfed as infants. The
table on the left shows that IQ mediated 72% of all incomes,
with external factors only mediating 28% of income (Victora
et al., 2015).
.This was after base cofounders, including family income at birth,
parental education, household score index, genomic ancestry,
maternal smoking during pregnancy, and birth weight, were
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taken into account. The post-cofounder (educational attainment) was also taken into account. The results of this study
strongly supports the notion that breastfeeding influences IQ,
which in turn influences income and educational attainment
(Victora et al., 2015).

“Each infant was scanned using the mcDESPOT (multicomponent Driven Equilibrium Single Pulse Observation of T1 and T2)
white matter imaging technique which provides a quantitative
measure of the myelin water fraction (VFM) at each imaging
point throughout the brain” (Deoni et al., 2013).

Other studies found a positive correlation between breastfeeding and IQ in adults. For example, an IQ test administered to
27 year old Danish citizens in Copenhagen found a six-point
difference in the IQ scores of people breastfed for a while versus people who were not breastfed for a long period of time.
“Babies breastfed less than a month had a mean IQ of 99, compared with an average of 106 among infants breastfed seven
to nine months” (Lisser, 2002). Similarly, in Belarus, IQ scores
were on average 7.5 points higher in 65 year-old adults who
were breastfed. Another study also shows that 53 year olds in
Britain who were breastfed scored better on the National Adult
Reading Test than their non-breastfed counterparts (Victora
et al., 2015). Altogether, the studies on adult intelligence and
breastfeeding support the thesis that breastfeeding affects intelligence at all ages.

Results found that breastfed toddlers, in comparison to both
formula fed, and to those that were breast and formula fed, had
more VFM in many regions of the brain associated with visual
reception skills, and receptive language scores. “In contrast with
children who

Breastfeeding and Brain Structure
Now that a comprehensive analysis of breastfeeding effects
on overall intelligence, from infant through adulthood, is understood, it is important to examine the physical effects of
breastfeeding on the brain structure. Since we know structure
parallels function, the development of an organ should correlate
with the function it carries out. Consequently, if the brains of
children who are breastfed have higher IQs, then something in
their brains’ structure ought to represent the higher functioning
intelligence emitted from the brain. Moreover, finding a specific occurrence in the brains of people who are breastfed that
cannot be found in the brains of those who are not breastfed
would solidify the conclusion that breastfeeding has long lasting
cognitive effects.

Breastfeeding and Brain Structure in Toddlers
The brain structure of breastfed toddlers compared to the
brain structure of non-breastfed toddlers show increased myelin water fraction (VFM) in the brain structure of the breastfed
infants. Myelinated white matter makes up the backbone of the
brain’s neural systems, and facilitates “rapid and synchronized
brain messaging” needed for higher levels of cognitive functions
(Deoni, 2013). “Aberrations in myelination, or deficiencies in
myelin content or integrity, can have profound deleterious effects on brain function” (Fields, 2008).

received both breast milk and formula, exclusively breastfed
children had significantly greater VFM (p < 0.05, FER corrected)
in brain regions including: left optic radiation adjacent to the angular gyrus; right inferior parietal lobe, near the somatosensory
cortex; bilateral premotor cortex; and right prefrontal cortex”
(Deoni, 2013). Additional brain regions expected to mature
later on had more VFM including the corpus callous, internal
capsule, corticospinal tract, cerebellum, and left optic radiation. The results of this study support the researchers’ initial
hypothesis that docosahexaenoic and arachidonic acids found in
breast milk, and not present in formula, causes preferential brain
development in breastfed toddlers (Deoni, 2013).

Breastfeeding and Brain Structure in Adolescents
The brain structure of breastfed adolescents compared to the
brain structure of non- breastfed adolescents shows a notable
difference in cortical thickness. From an MRI analysis of cortical
regions associated with cognitive abilities relating to general
intelligence, cortical thickness was assessed. Findings suggest
that exclusive breastfeeding predicts cortical thickness in the
superior and inferior parietal lobules of the parietal cortex
(Kafouri et al., 2013). Even after adjustments were made for age
and sex, findings show that the longer the duration of breastfeeding, the thicker the cortex (Kafouri et al., 2013). Although
the mechanism for a correlation between cortical thickness and
breastfeeding is unclear, one possibility was recently suggested: “long-chain polyunsaturated fatty acids (LC-PUFAs), mainly
docosahexaenoic acid (DHA), underlie neurodevelopmental
benefits of breast milk” (Kafouri et al., 2013). This possibility
is supported by Deoni’s hypothesis that docosahexaenoic and
arachidonic acids found in breast milk causes preferential brain
development. Michaelson’s finding of “a decrease in DHA of red
blood cells in formula fed infants” also supports this possibility
(Michaelson, 2003).

Conclusion
A study investigated brain white matter maturation in 133 toddlers, ages 10 months to 4 years. Imaging times lasted 19 minutes in the younger toddlers, and 24 minutes in the 4 year olds.
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Relative to breastfeeding, intelligence testing on all age groups
establishes a causal relationship between breastfeeding and IQ.
Once imaging testing gets involved, however, the relationship

Cognitive Effects of Breastfeeding

between cognitive development and breastfeeding is solidified.
According to the basic biological principle that structure equals
function, the function of greater intelligence, paired with different brain structure in people who are breastfed, confirms, beyond a reasonable doubt, that breastfeeding has widespread and
long-term positive effects on cognitive development. Indeed,
studies conducted thus far are enough to conclude breastfeeding’s effects on cognition. However, more studies on the
structure of the brain might help us conclusively determine the
mechanism of how breast milk positively influences cognitive
development.
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Abstract
Research has proven that vaccines prevent disease. Important medical organizations conclusively support and advise
the administration of vaccinations to prevent diseases that once caused devastating effects both in the individual who
contracted, and in communities where these diseases spread. While some groups protest against the constitutionality
of vaccinating, others counter that failure to do so subjects the unvaccinated to illness and death by contracting and
spreading of the sickness. Despite statistics on reduced incidence of diseases with few consequences as a result of
vaccine-induced passive immunity, fears of harm secondary to vaccination loom. In the 21st Century, many people are
unaware of diseases that still occur in undeveloped countries due to herd immunity through a majority vaccinated population. The diseases, however, are only a plane ride away. Due to globalization, vaccine preventable diseases can land in
anyone’s kindergarten. Although the link between vaccination and autism was pinned to research that was subsequently
retracted, the rate of not vaccinating children continues to rise and these unvaccinated children pose risk to others
who are unable to receive vaccines and compromise the core herd immunity.As modern science strives to demonstrate
vaccine safety and efficacy, despite the rare but undisputed adverse effects, individual decisions to vaccinate remain a
complex process with differences in perception, beliefs, and values to consider. These tenets will manage to produce
research and evidence to support both pro-vaccination and against-vaccination in an attempt to determine if the potential benefits of getting vaccinated outweigh the detrimental side effects that may result. Further, a better understanding
of the ramifications secondary to original research that noted negative correlations among vaccinated individuals and
the vaccines they received will be understood. These controversies are the ripples experienced as a result of retracted
and unethical research.
Introduction
We live in an age of incredible technology, discovery and medicine. Smartphones, spaceships, and bionic eyes are no longer
reserved for science fiction.Vaccinations are among the groundbreaking medical discoveries which “allow us to engage our
adaptive immune systems to produce highly specific antibodies
and immunological memory against a potential future infection”
(Federman, 2014).Through exposure to an inactivated pathogen
in a safe way, the body’s innate immunity learns how to properly
adapt to the previously deadly pathogen. Still though, over two
hundred years following Edward Jenner’s successful use of cowpox material to create immunity to smallpox, in 1796, there are
still those hesitant to make use of vaccinations for themselves
and their children (Riedel, 2005). Consequently, it is quite concerning that an anti-vaccination movement persists. Particularly,
people are concerned over a potential correlation between
vaccinations and autism (Federman, 2014). Is vaccination so
harmful that it is worth not getting vaccinated? Abstaining can
put others at a higher risk of developing the given disease because there will be more disease carriers in the population. Or
is vaccination harmless, or at minimum, do the benefits greatly
outweigh the potential harmful side effects? Further, is it a matter of science or simply emotion discomforting those against
vaccinations?

Methods
The research obtained regarding the potential side effects and
benefits of various vaccinations was collected from a variety
of sources. Most notably was the use of Touro’s online library
which provides access to databases such as Pubmed, Proquest,
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and more. Further, additional articles were found through
Google Scholar searches of relevant original and peer reviewed
articles on the topic. After reviewing an adequate number of
articles on the good and bad of vaccinations, evidence was compiled which attempts to answer the research question.

Potential Benefits of Vaccinations
An important example of an efficacious vaccine is the Smallpox
vaccination. In fact, the only way to be protected from Smallpox
is through vaccination. Though Smallpox was once a virulent
disease taking the lives of over one third of those infected, it has
since been eradicated by means of vaccinations (Fenner et al.,
1988). The protection from Smallpox, influenza, polio and many
other diseases and viruses are already well-known vaccination
benefits. Consequently each specific type of vaccination will not
be directly expressed in this paper; rather, on the CDC website
(2015) the entire list of dozens of possible vaccinations can be
located. Instead, further benefits associated with vaccination
uptake will be presented.
Are vaccinations effective at eradicating diseases? Regarding
the effectiveness to eradicate an epidemic, there is a concept
known as “herd immunity.” Fine (1993) explains that “If an infection is to persist, each infected individual must, on average,
transmit that infection to at least one other individual. If this
does not occur, the infection will disappear progressively from
the population.” Note, there are those who are too young or
too sick to become vaccinated, without herd immunity, many
people will be at risk. Therefore, the higher percentage of those
vaccinated, the higher the efficacy of any given vaccination in
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protecting not only those vaccinated, but also the population
as a whole.
Are vaccinations worth the expense? Vaccinations are cost effective and also save considerable amounts of money in healthcare costs. Zhou et al. (2014) determined that for children born
in the United States in 2009, the nine vaccinations included in
their study will prevent 20 million cases of disease and save
42,000 children from early deaths. Further, the same vaccinations will yield a savings of $13.5 billion in direct medical and
non medical costs, including factors such as treatments for a
primary infection, travel costs, special education and equipment
costs for children disabled by disease, as well as further costs
in extended hospital stays caused by medical complications.
Furthermore, an additional $68.8 billion will be defrayed in total
societal costs, most notably lost wages. The net savings would
total a staggering $82.3 billion.
Though $82.3 billion is no small price, still this study did not
include the Influenza vaccination, in their estimate. Therefore,
the determined financial benefits of vaccinations may be understated. For example, during the eleven influenza epidemics
in the United States from 1969 until 1994, there were between
130,000 and170,000 influenza-associated hospitalizations per
epidemic with more than 20,000 influenza-associated deaths in
5 of epidemics; and over 40,000 influenza-associated deaths occurred during the other 6 epidemics. (Pleis & Gentleman, 1998).
Furthermore, this study is limited to the United States, globally
there exists a more vast market for saving.The additional money
that is saved in healthcare costs, the further resources that can
be allocated for vaccine research. For example, it is believed
that diseases like cancer, epilepsy, and many more potentially
can be prevented with vaccines but more research is needed.
Regardless if these cures are a future possibility, there are plenty other worthy uses for the extra money that can be saved
through becoming vaccinated.
Today healthcare workers are able to be protected from their
sick patients with vaccine preventable viruses. Healthcare workers can be immunized and safely care for sick patients.They need
protection not only from airborne viruses but also blood borne
viruses contractible via shared needles. In the United States, it is
estimated that there are 385 thousand cases of reported needle
stick injuries per year. Incidentally, this number is an underestimation because it is expected that a significant number is unreported (Elmiyeh et al., 2004). People need to continue working
and do not report needle stick injuries because they fear getting
reprimanded for using equipment improperly.
Another potential benefit of vaccinations is to protect unborn
children. Mothers who have received vaccinations can protect

their unborn children from birth defects caused by certain viruses and further, vaccinated communities can help eradicate
diseases to benefit future generations. Between 1963 and 1965,
prior to the licensing of the rubella vaccine in 1969, a global
rubella outbreak caused the deaths of 11,000 babies, and also
birth defects in 20,000 babies in the United States. Therefore
when women are vaccinated as children against rubella, they
have significantly decreased the chance of passing the virus to
their unborn or newborn children. This potentially eliminates
the numerous birth defects associated with rubella, such as
hearing and or vision loss, heart problems, congenital cataracts,
liver and spleen damage, and mental disabilities (CDC, 2011).
These birth defects can decrease quality of life and often require
resources to help improve outcomes.
The last benefit is that research indicates that some viruses
cause cancer. For example, the human papilloma virus (HPV)
has been associated with cervical cancer (Marur et al., 2010).
Therefore, it is important to realize that vaccinations are important to immunize against diseases to prevent the onset of
side effects that can result; some of these may ultimately be
lifesaving.

Potential Side Effects of Vaccinations
Regarding the possible negatives of vaccinations, it is important
to consider the evidence for a correlation between vaccinations
and developing autism. During the late nineties the link dissuaded people from taking vaccinations and now almost twenty
years later the fear lingers. A clinical study found that “behavioral problems had been linked, either by the parents or by the
child’s physician, with measles, mumps, and rubella vaccination”
(Wakefield et al., 1998). This early report became widespread
and propelled the anti-vaccination movements taking place even
today. The study was preformed using twelve children ranging
in ages three to ten, with eleven of them male. Prior tests determined that all twelve children showed satisfactory achievement of early milestones. These children all lived normal lives,
but then lost certain skills, notably the ability to communicate.
Further, they all had gastrointestinal symptoms. e.g. diarrhea and
abdominal pain. The children underwent assessment and review
of their gastroenterological, neurological, and developmental
records. Results indicated all twelve children had intestinal
abnormalities, ranging from aphthoid ulceration to lymphoid
nodular hyperplasia. Additionally, “onset of behavioral symptoms
was associated, by the parents, with measles, mumps, and rubella vaccination in eight of the twelve children with measles
infection in one child, and otitis media in another” (Wakefield
et al., 1998). They each developed autistic behavioral disorders,
nine of which developed autism. Disintegrative psychosis and
possible post-viral or vaccinial encephalitis were less prevalent,
representing one and two cases respectively.
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It is suggested that autistic-spectrum disorders have a direct
connection to intestinal dysfunction (Wakefield et al., 1998).
In addition to this study, there are previous studies that link
the connection between a dysfunctional or inflamed intestine
and autism. For example, the “opioid excess” theory of autism,
proposed originally by Panksepp (1979) explains that autistic
disorders result from “incomplete breakdown and excessive
absorption of gut-derived peptides from foods, including barley, rye, oats, and caesin from milk and dairy produce.” These
remaining peptides can stimulate the formation of harmful
peptidase enzymes which break down endogenous central-nervous-system opioids, leading to disruption of neuroregulation
and brain development (Shattock, et al., 1991). Interestingly,
it has been observed that following removal of a provocative
enteric antigen, the children achieved symptomatic behavioral
improvement (Lucarelli, et al., 1995).
Still, the debate around the cause of autism remains controversial, and some, like Wakefield, postulate the incidence is correlated with childhood vaccination. To examine this hypothesis
a retrospective study of 537,303 randomly selected children’s
cases were examined to determine association of the Measles,
Mumps, Rubella (MMR) vaccine and autistic disorder. Of the
group, a total of 440,655 children had received the MMR vaccine, with only 758 children diagnosed with some degree on
the autistic spectrum, of which 316 were diagnosed with the
most severe on the spectrum, autistic disorder. The incidence
rate was 0.17% which is insignificant compared to the 7.7% to
11% range among various unvaccinated groups. Madsen et al,
(2002) therefore concluded that there is no scientific causation
between vaccination and autistic disorder or other autistic
spectrum disorders.
Regarding the two conflicting studies, the size of their corresponding test groups is incomparable. Wakefield (1998) performed the study on just 12 children in one time frame, while
Madsen conducted a retrospective study on almost half a million vaccinated children over the course of a few years. Though
Wakefield seemingly proves a correlation between developing
gastrointestinal problems following an MMR vaccination, more
research is required to be conclusive that vaccinations can
cause autism. However, in Madsen’s (2002) study utilized about
half a million children studied over multiple years. Therefore,
Madsen’s conclusion can be trusted that autism is not a side
effect of vaccinations.
In an addendum to reinforce his conclusion, Wakefield added
another 40 patients to his study, with 39 having the autistic syndrome. Still, his total of 52 patients is not as significant as the
broader study done by Madsen. Another potential issue with
Wakefield’s study is that he quotes Lucarelli who explains that
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autism is reversible; this is a powerful claim that has yet to be
confirmed. Furthermore, the Lancet released an official statement retracting Wakefield’s study. Here is their full statement:
Following the judgment of the UK General Medical
Council’s Fitness to Practice Panel on Jan 28, 2010, it has
become clear that several elements of the 1998 paper
by Wakefield et al are incorrect, contrary to the findings of an earlier investigation. In particular, the claims
in the original paper that children were “consecutively
referred” and that investigations were “approved” by
the local ethics committee have been proven to be false.
Therefore we fully retract this paper from the published
record (the Editors of the Lancet, 2010).
In spite of this retraction, people clung to this concept that
there is a relationship between vaccinations and a development
of autistic spectrum disorders. It is astounding that the very
Wakefield paper which led people to believe the MMR vaccination causes autism was retracted due to ethical misconduct. In
addition the Lancet retracted the Wakefield paper for nondisclosure of financial interests. They reported that their sampling
was randomized, however, in fact, it was selective. For example,
in order to attract subjects, the researches offered a fee for
parents of children who received the MMR vaccine and also had
a previous diagnosis within the autism spectrum.(Sathyanaraya
Rao & Andrade, 2011).
Not only does Madsen (2002) amply prove there is no correlation between vaccinations and autistic disorders, Wakefield’s
study has since been completely retracted. Perhaps the most
appalling long-term affect is that the myth is so deeply ingrained
that parents are refusing to vaccinate their kids out of fear of
harm, and, unfortunately, some of these kids will or have already
succumbed to the greater danger of contracting a vaccine-preventable illness. Because the official retraction was a mere paragraph in length and lacks detailed explanations, it slipped under
the radar of the common folk and now people still believe
Wakefield has legitimacy.
There is a potentially serious complication from vaccine administration known as Guillain–Barré Syndrome (GBS), which is a
paralysis that begins on the lower extremities and migrates up
the body. The legs become numb and as it ascends the body it
leaves paralysis of muscles in its wake. An immune response is
triggered that directly destroys either the myelin sheath surrounding the peripheral nerves or even the axon itself, leaving
scar tissue in its midst. Unfortunately, if not promptly treated
it will paralyze the breathing center, which is located at C3 of
the cervical spinal column and breathing will require mechanical assistance (Koski, 1994). Dr. Tamar Lasky and her colleagues
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studied the 1992-1993 Influenza Seasons and did in fact discover
a direct increase in cases of Guillain–Barré Syndrome within the
first six weeks following vaccination. At first glance, this discovery should shy people away from getting vaccinated. However,
Lasky determined the increased risk to be only an additional
0.61 cases per million vaccinations. Further, even after an adjustment to include four factors that would make the original
estimate conservative, their most accurate estimate of the attributable risk would be 1.1 case per every million vaccinations.
Therefore Lasky argues that, “Even if Guillain–Barré syndrome
were a true side effect in subsequent years, the estimated risk
for Guillain–Barré syndrome of 1 to 2 cases per million persons
vaccinated is substantially less than that for severe influenza,
which could be prevented by vaccination in all age groups, especially persons aged ≥65 years and those who have medical indications for influenza vaccination” (Lasky et al., 1998). Therefore,
despite the reality of the GBS complication caused by vaccinations, many still opt to prevent serious diseases by vaccination.
Although avoiding vaccinations still remains controversial to
many, the relative risk of experiencing a complication is low, and
it could be considered neglect by parents to abstain from vaccination of children in an era where vaccines can protect these
children from many serious diseases. As was aforementioned in
this paper, the disproportionate number of 20,000 lives that
would be saved from influenza epidemics alone far outweighs
the minimal risk of contracting GBS (Pleis & Gentleman, 1988).
Each year there are 30,000 Vaccine Associated Events (VAE)s
reported, with 13% comprising disability, hospitalization, serious
illness, or death. While most of the reactions were classified as
mild involving fever, irritability, or local reactions such as mild
redness at the site of the injection that is sometimes caused by
the preservative thimerosal or other innocuous inflammatory
response (Vaers.hhs.gov, 2015). Even with the reporting system,
many events are thought to occur by coincidence, as other syndromes such as Sudden Infant Death Syndrome (SIDS) occurs
without any etiological basis (Vaers.hhs.gov, 2015). As Hardt et.
al. (2013) point out, vaccine associated disease incidence is reduced in populations to the point of inability to remember what
these diseases are and how they can harm. This phenomenon
may cause vaccine adverse reactions to loom as predominant
errs in how we provide healthcare and disproportionately
place fear of harm above disease prevention in the minds of
well-meaning caregivers.
An additional potential side effect from vaccinations can stem
from the actual vaccinations. As was explained, a vaccination is
effective through exposure to inactivated harmless pathogens.
In some cases, though, the pathogen can potentially become
harmful in the future. An example is varicella, commonly known
as chickenpox, a vaccine-preventable illness which is a very

common and usually benign childhood disease. Chickenpox
however can cause serious painful complications in those who
contract the illness in adulthood, in the form of Zoster, commonly known as shingles. The vaccine immunity wanes as one
ages, and the dormant virus introduced with the vaccination can
strike. As the body’s ability to mount an immune response declines, the people will be more dependent on re-administering
of the given vaccine (Shuette & Hethcote, 1999). This side effect
may scare off potential patients, though in light of this potential
side effect, maybe it is in fact more beneficial to withhold from
the chicken pox vaccination. Though, a simple solution would
be to receive a new vaccination every number of years. Further,
Shuette and Hethcote (1999) discovered that even when those
vaccinated for Chickenpox develop Shingles as adults, the symptoms are milder, since they still have some immunity, compared
to those never vaccinated. Even if chicken pox vaccinations have
a reason to be withheld, this side effect is not a reason to refrain
from other types of vaccinations, such as Polio, Smallpox or the
MMR vaccinations.

Discussion
In conclusion, research has not been able to produce a correlation between autism spectrum disorder and vaccination. Still,
it is important to acknowledge the presence of fears, distrust,
and other reasons to oppose vaccines. Although the adverse
reactions are minimal, to the person who suffers an adverse
event that is one too many. The Food and Drug Administration
(FDA), Centers for Disease Control and Prevention (CDC)
and American Academy of Pediatrics (AAP) all support vaccine administration, and have successfully reduced prevalence
of vaccine preventable diseases. However, we must ensure that
appropriate education is disseminated to caregivers of children
to protect the safety and lives of others by supporting vaccine
administration so people with inability to receive vaccines will
be better protected against vaccine preventable diseases. By ensuring a robust vaccination program, and supporting the expansion of research on vaccine preventable diseases, we can help
develop vaccines for illnesses and diseases that currently remain
untreatable. Perhaps new vaccine research might dispel vaccine
myths which will increase the rates of vaccination, protecting
more of the population.
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Abstract
Parental concerns about the safety of childhood vaccinations began in the 1990’s and continue until today. A primary
concern of many parents is whether the adjuvants and preservatives added to the vaccines have the potential to cause
neurodevelopmental disorders in young children. An overview of various studies was done to determine if thimerosal
affects childhood neurodevelopment with studies suggesting that thimerosal potentially causes neurodevelopmental
disorders. However, some studies suggest the opposite. As a result it is impossible to conclude whether thimerosal
affects childhood neurodevelopment. However, measures should be taken to remove thimerosal from the childhood
vaccination schedule. Additionally, the studies must be done to determine if other components of vaccines can have
adverse effects on the developing nervous system.
Introduction
Thimerosal, a mercury-based vaccine preservative, has been a
source of controversy since the 1990’s. Many parents worried
that the presence of mercury in vaccinations could lead to autism spectrum disorder and other medical problems.The Center
for Disease Control and the American Academy of Pediatrics
collectively decided, in July 1999, to remove thimerosal containing vaccines (Baker, 2007). According to the Food and Drug
Administration thimerosal has undergone various studies and it
“has a long record of safe and effective use preventing bacterial
and fungal contamination of vaccines, with no ill effects established other than minor local reactions at the site of injection”
(FDA, 2015). In the United States, the only vaccines that currently
contain thimerosal are MPSV4-Menomune (vaccine for meningitis), Td (booster for tetanus and dipthereia) manufactured by
Decavac,Td (Mass Biologics), Dt (Sanofi) and three of the influenza vaccines (Hamborsky et al., 2015). Some researchers posit that
there may be a link between thimerosal and neurodevelopmental
problems. Other studies demonstrate that thimerosal does not
have such effects.This study was done to determine if thimerosal
poses a risk on childhood neurodevelopment.

Purpose of Preservatives and Adjuvants in Vaccines:
The United States Code of Federal Regulations (CFR) mandates
the addition of preservatives to vaccines in vials containing
multiple doses to prevent contamination of the vaccine after
multiple needle insertions. Previously, some vaccines became
contaminated during the manufacturing process. As a result, the
CFR required the addition of preservatives to kill the microbes
that contaminated the vaccine.With the advancement of aseptic
manufacturing of vaccines, the necessity of putting preservatives
in vaccines has decreased. As a result, many vaccines do not
currently require the addition of preservatives into them (Geier
et al., 2010). Adjuvants are added to vaccines to help the body
develop immunity after injection of killed vaccines. Adjuvants
are added to minimize the amount of antigens the body needs
to be exposed to in order to generate an immune response
(Petrovsky, Aguilar, 2004).

Methyl Mercury vs. Ethyl Mercury
The main question behind the debate over thimerosal is the

comparison between ethyl and methyl mercury. Mercury exposure has been found to cause severe health problems such as
damage to the nervous, digestive and immune systems. Methyl
mercury specifically has been found to affect the developing
brain and nervous system. The most susceptible individuals
to methyl mercury are fetuses exposed to methyl mercury in
utero (WHO, 2013). Methyl mercury has been proven to cause
neurotoxicity since the 1960’s. Mothers who ate fish in water
contaminated by methyl mercury during their pregnancy, gave
birth to children with mental retardation, blindness, and spasticity. However, mothers exposed to methyl mercury were less
adversely affected than the infants. A study on New Zealand
neonates born from mothers who had hair concentrations of
mercury greater than six micrograms per gram found that infants with greater mercury exposure had a lower Intelligence
Quotient (IQ) by three points. The United States National
Academy of Sciences decided that fetal exposure to methyl
mercury can be toxic even at low concentrations (Grandjean,
Landrigan, 2006).
The Food and Drug Administration states that the legal guidelines for mercury exposure were decided based on studies
on methyl mercury. However, thimerosal’s derivative is ethyl
mercury which as a result of being slightly chemically different can have different effects on the body than methyl mercury. Additionally, high levels of ethyl mercury were found to
have severe neurological effects on both adults and children.
However, the effects of low dose ethyl mercury exposure have
not been determined (Offit, Jew, 2003). As there is no definitive
study with a safe exposure concentration of ethyl mercury and
the differences in the effects of methyl and ethyl mercury are
not known, the FDA considers ethyl mercury to be as toxic
as methyl mercury (FDA, 2015). Ethyl mercury was found to
increase the tissue concentration of inorganic mercury more
than methyl mercury does in rhesus macaques (Hornig et al.,
2004). Ethyl mercury levels in the brain post exposure are lower
than those of methyl mercury (Clements, 2004). A main source
of the controversy on thimerosal is the question if methyl and
ethyl mercury have the same or different effects on the body.
Some studies show that thimerosal’s ethyl mercury does indeed
have neurotoxic effects, while others argue that it does not.
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Methods
A variety of research papers on the subject were collected from
Google Scholar, EBSCO and ProQuest. Access to EBSCO and
ProQuest was given through the Touro College Library System.
Key words used, were thimerosal, neurodevelopment, adjuvants,
vaccines, adverse effects and immunizations.

Results
Thimerosal and Neurodevelopment:
Thimerosal Causes Neurodevelopmental Disorders
In the 1990’s many infants had mercury exposure higher than
that recommended by the EPA, FDA, and the United States
Agency for Toxic Substances and Disease Registry (ATSDR) for
methyl mercury.This was a result of both Thimerosal Containing
Vaccine (TCV) and environmental exposure. Methyl mercury is
a compound that is closely related to ethyl mercury, one of
the derivatives of thimerosal. A study of 278,624 infants born
between 1990 and 1996 and recorded in the Vaccine Safety
Datalink was done in order to determine if thimerosal indeed
has neurotoxic effects on infants and young children. During
those years the main vaccines containing thimerosal were the
Haemophilus Influenza Type b (Hib), hepatitis B, acellular DTaP
(Diptheria, Tetanus, acellular Pertussis), and whole-cell DTP. The
amount of mercury exposure was calculated for each individual
based on the amount and concentration of mercury in each
of the mercury containing vaccines. The mercury exposure was
measured between two intervals, birth and 7 months and birth
and 13 months. The rate of increase in six neurodevelopmental
disorders were calculated for each additional 100 microgram of
mercury the children were exposed to. Three control disorders
were also observed for each 100 microgram increase in mercury exposure due to thimerosal containing vaccines. (Young et
al., 2008)
The six neurodevelopmental disorders observed were Autism,
Autism Spectrum Disorders (ASD), Hyperkinetic syndrome of
childhood (ADD/ADHD), Developmental/Learning Disorders,
Disturbances of emotions specific to childhood and adolescence, and tics. The control disorders observed were pneumonia, congenital anomalies, and failure to thrive. The study determined that the ratios of each of these disorders increased
with the increased exposure to Thimerosal containing vaccines.
The rate ratios were measured with a confidence interval of
95%. For each 100 microgram increase in mercury exposure
the ratio of hyperkinetic syndrome of childhood increased by
a ratio of 3.15 and Autism and Autism Spectrum disorders increased by ratios of 2.87 and 2.44 respectively. Developmental
and Learning disorders had the lowest ratio of increase, while
hyperkinetic syndrome had the highest. The control disorders
did not have a relatively high increase as a result of higher mercury exposure (Young et al., 2008).
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The levels of autism corresponding to each year in the study
directly correlated to the amount of mercury exposure via vaccine. In 1990 and 1991, hepatitis B and Hib had been added
to the vaccine schedule. After 1992, the DTP vaccine was
combined with Hib vaccine, thus leading to a lower mercury
exposure than there had been when the two vaccines were
kept separate. The levels of autism in those years fluctuate directly with the fluctuations of mercury administered via vaccine
(Young et al., 2008).
Another study compared the toxicities of the four most common preservatives added to vaccines in the United States.These
four compounds were 2-phenoxyphenol, phenol, Thimerosal,
and benzethonium chloride. These compounds were administered to human neurons in vitro and to bacterial cells. The
toxicities to each type of cell were measured. The cytotoxicity towards human neuroblastoma cells was measured after
24 hours of incubation. Thimerosal was found to be the most
toxic of the four preservatives added to vaccines. Each of the
four compounds was also tested on bacterial cells. A thimerosal
concentration of ten times the amount added to vaccines was
not able to sufficiently kill bacterial cells within twenty minutes
(Geier et al., 2010).
While there is room to question the certainty of the thimerosal’s effects on children, it his highly likely that thimerosal does
adversely affect the neurodevelopment of susceptible infants. In
some of the studies thimerosal was the only measured variable, while in others thimerosal was taken into account with
other possible neurotoxic environmental exposures. Using the
Gesell Development Score, investigators found no correlation
between thimerosal exposure from vaccines and neurodevelopmental disorders, if the child nursed for the first six months
of life. The GDS was also measured from birth to five years
and once again there was no correlation between thimerosal
exposure and neurodevelopmental disorders. The studies that
took environmental exposure to neurotoxic elements into consideration as well as thimerosal, found that ethyl mercury, one
of the byproducts of thimerosal, has adverse effects on neurodevelopment. The controlled variables were the environmental
factors that were known to affect neuroplasticity. For example,
secondhand smoke, cord blood Hg, and lead (Dorea, 2015).
The Vaccine Adverse Events Reposting System (VAERS) database was used to determine if indeed the rise in childhood
neurodevelopmental disorders was caused by thimerosal exposure due to vaccinations. A comparison was made of the
prevalence of neurodevelopmental disorders after exposure
to either thimerosal containing or thimerosal free DTaP vaccines. Three neurodevelopmental disorders were observed in
this study; autism, personality disorders and mental retardation.
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The participating patients were split into two groups, the first
group had an average mercury exposure of 37.5 microgram,
while the second group had a mercury exposure of 87.5 micrograms. Some of the control adverse events were fever, pain, and
vomiting. The United States Department of Education report
from 2001 was also evaluated to find out how many children
in different age groups suffered from a variety of conditions;
autism, speech disorders, orthopedic or visual impairments, and
deaf-blindness. The amount of mercury the children were exposed to was also compared to the maximum possible amount
of mercury exposure allowed by the FDA (Geier, Geier, 2003).

concentration of thimerosal tested was lower than that found
in TCV, while in some the concentration ranged from nano
to micromolar concentrations. An In vivo study administered
different concentrations of thimerosal to suckling Wistar and
Lewis rats at 7, 9, 11 and 15 days. The thimerosal was found to
decrease pain sensitivity and to significantly accumulate in rat
brains. The concentration of thimerosal found in vaccines had
neurotoxic effects on human neurons in vitro and in laboratory
animals (Dorea, 2011).

Comparing the prevalence of autism, personality disorders and
mental retardation following exposure to thimerosal from the
DTaP vaccine and the thimerosal-free DTaP demonstrated a
linear correlation between mercury exposure and neurodevelopmental disorders. The odds ratio of autism increased by
.029, personality disorders by .012, and mental retardation by
.048 for each microgram of mercury. The odds ratio for each
of these disorders was higher for each of them after exposure
to the DTaP containing thimerosal than for that without it.
The United States Department of Education report also had
increasing ratios in autism and speech disorders. The amount
of febrile seizure, fever, pain, edema, and vomiting was higher
for the thimerosal containing DTaP vaccine group, however the
amount it rose and the increasing amount of mercury exposure
do not directly relate to one another. The study also demonstrated that the amount of mercury the children were exposed
to due to the childhood vaccine schedule in different years had
3.2-32 fold higher amount than that recommended by the FDA
for oral methylmercury. Exposure to mercury intravenously has
more adverse effects on the body than if it has been orally ingested (Geier, Geier, 2003).

A study was done in Poland to determine if there is a correlation between exposure to Thimerosal containing vaccines and
cognitive development in the children’s’ first nine years. All of
these children had been given the DTP and hepatitis B vaccine,
some of which contained thimerosal and some which didn’t.
At different points during the first nine years of life, tests were
done to assess the level of each child’s cognitive development.
All the vaccines that the children were exposed to contained
aluminum as an adjuvant. In the first month of life 69.2% of
the children were exposed to thimerosal, and between the first
month and the 6th month 86.2% of the children were exposed
to thimerosal containing vaccines. The results of each psychological test done were similar for both children who were and
were not exposed to thimerosal. In fact the IQ levels of those
exposed to thimerosal was higher overall than that of the control group. The results of the study displayed no correlation between thimerosal exposure and lower cognitive developmental
levels. (Mrozek-Budzyn et al., 2014).

A study surveying British children found there to be a relationship between hyperactivity and behavioral problems, motor
development and the necessity for speech therapy. Other studies have found that there were significant differences in the
impact of thimerosal on different genders. Male children were
found to have a higher IQ upon exposure, but the exposure
also hampered their behavioral regulation and motor tics. In a
study in Italian children thimerosal was found to detrimentally
affect girls in the areas of language and motor function (Curtis
et al., 2015)
An overview was done by analyzing the results of in vivo and in
vitro studies of the thimerosal’s effects. In the in vitro studies
thimerosal was found to cause mitochondrial damage, reduce
oxidation-reduction activity, cause cell degeneration and cell
death, and increase the levels of fragmented DNA in human
neuroblastoma cells. In some of the overviewed studies the

Thimerosal Does Not Cause
Neurodevelopmental Disorders

Various studies had been done testing thimerosal containing
vaccines on rodents, with results demonstrating that thimerosal
had no neurodevelopmental effects. However, on the rare occasion that there was a problem with the vaccine, a very high dosage of thimerosal had been administered, 250 fold higher than
contained in vaccines. A study was done to compare the effects
of different vaccine schedules on a non-human primate model.
These were chosen as their anatomy and length of development
stages are very similar to those of humans. Neurobehavioral
tests were done on the primates to see the effect of a variety of
vaccine schedules on the primates’ neurodevelopment (Curtis
et al., 2015).
In the study seventy-nine rhesus macaques were split into six
groups. The first group, the control, received saline injections.
The second group received only the MMR vaccine, the third
TCV’s excluding the MMR vaccine. The fourth group was administered the vaccine schedule from the 1990’s, while the fifth
group received the same vaccines with accelerated timing at
a ratio of 4:1. The sixth group was administered the vaccine
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schedule from 2008. In the 1999 vaccine schedule, the TCV’s
were Hepatitis B, DTaP, and Hib. In the 2008 vaccine schedule,
the multiple-dose influenza and meningitis vaccines contained
thimerosal. The pregnant macaques in the 2008 group were
given the influenza vaccines a month before the expected delivery date. (Curtis et al., 2015).
Each of the infant macaques was tested on the Neonatal
Behavioral Assessment Scale to check for nineteen neonatal
reflexes. There was no significant difference in the results of
each of the six groups for the NBAS test, except in one of the
criteria. The macaques were also tested for their object concept performance, their social behavior and the discrimination/
reversal learning and learning set. In each of these tests there
were no significant differences in the results among the groups.
The animals given TCVs reached their goal in fewer trials than
animals in the control group in the reversal learning part of
the test.Thereby demonstrating that thimerosal did not hamper
this area of neurodevelopment.At the age of 12 months the fifth
group had a significantly lower amount of exploring behaviors
than did the control macaques. The fifth group also had a lower
amount of positive behaviors at 2 months, while at 12 months
they had a higher amount of positive behaviors than did the rest
at two months of age the fourth and sixth groups had significantly fewer negative behaviors, however at 12 months there
were no major differences between the six groups (Curtis et
al., 2015).
A study in Denmark, used data from the Danish Psychiatric
Central Research Register to determine if thimerosal exposure leads to autism spectrum disorder. This study was done to
determine if removing thimerosal from vaccines decreased the
incidence of autism. The rates of autism diagnosed from 1971
to 2000 for children in three age groups, ages 2-4, 5-6, and 7-9,
were reviewed. From the years 1961 to 1970 the children were
administered 400 micrograms of thimerosal. From 1971-1992
children were exposed to 250 micrograms of thimerosal. After
1992, vaccines without thimerosal were administered to Danish
children. During this period, 956 children had been diagnosed
with autism. From 1971 to about 1990 the rates of autism remained stable. After 1991, the rates of autism began to increase,
peaking in the year 1999 with the highest incidences occurring
in the first two age groups, between 2 – 6 years of age. Each
of these children had been born after thimerosal containing
vaccines had been removed from the Danish vaccine schedule.
Thereby indicating, that the increase of autism does not relate
to thimerosal exposure (Madsen et. al, 2003).

Aluminum and Neurodevelopment
Studies have demonstrated that in vitro aluminum exposure has
the potential to cause cell death in human neurons. However,
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aluminum has been found to be less cytotoxic than thimerosal (Dorea, Marques, 2009). A study was done to determine if
aluminum exposure as a result of its use as a vaccine adjuvant
is a cause of the rise of autism. Data was taken from the US
Department of Educational Annual Reports to Congress to determine the rates of autism from 1991-2008 for individuals age
6 – 21.The rates of autism were also compared to the aluminum
exposure in regards to the vaccine schedule in other countries.
The data was compared to the concentration of aluminum exposure from pediatric vaccines, below 6 years of age. Results
demonstrated that the highest level of aluminum in comparison was at age 2 months in the United States. Interestingly, the
countries with higher aluminum adjuvant exposure had higher
rate of autism (Tomljenovic, Shaw, 2011).

Discussion
Based on the reported studies there is room to question the
effects of the Thimerosal and vaccines containing it on human
children. Studies done in vitro demonstrate that thimerosal
does cause apoptosis and neurotoxic effects to human neurons (Dorea, 2011). However, results occurring in vitro are not
always a directly comparable to those in vivo, as in vivo it is
difficult to accurately evaluate the concentration of mercury
reaching the individual’s neurons. Additionally, studies done
on Rhesus macaques seem to point out that thimerosal does
not hinder neurodevelopment, in some cases the exposed animals had scored higher than the control (Curtis et al., 2015).
However, the primate model is not necessarily an exact indication as to what would happen to humans when they would be
exposed to the same concentrations of thimerosal, though the
results would be similar as the two bodies function similarly.
Only seventy-nine macaques were surveyed and then split into
six groups, thereby only a small number of macaques represented each vaccine schedule. Therefore, even though the macaque
functions similarly to humans, the validity of the results in comparison to human would need a higher number of macaques in
each group to demonstrate the efficacy of the results.
The study using the Vaccine Safety Datalink uses a large sample
of children, and demonstrates a direct correlation between thimerosal exposure and neurodevelopmental disorders. However,
the study does not take into account environmental exposure
to mercury and other neurotoxins, thereby making it harder to
say with certainty that thimerosal does indeed cause different
neurodevelopmental disorders (Young et al., 2008). The study
also does not take into account the genetics of the children and
the possible predisposition to neurodevelopmental disorders.
However, there does seem to be a strong indication that thimerosal has neurodevelopmental effects, as the prevalence of
autism in various years was directly related to the fluctuations
of mercury in the childhood vaccine schedule, thus indicating
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that children born in years that a vaccine schedule with a higher
concentration of mercury had increased rates of autism.
Additionally, the primate model is not a direct representation
of what would happen in the human models because studies
show that the rate of elimination in the blood and brain differ
for methyl and ethyl mercury in primates and human infants
(Hornig et al., 2004). As a result, ethyl mercury in humans may
cause different mercury levels than it would for the rhesus macaques used in two of the above studies.
Based on the above studies it is hard to conclude whether or
not thimerosal containing vaccines cause neurodevelopmental
disorders. However, some studies do seem to indicate that thimerosal causes autism among other neurodevelopmental disorders. Additionally, thimerosal containing vaccines were found to
cause a significant amount of damage to human neurons in vitro,
including cell death. As a result, further study must be done
to determine with certainty the true effects of thimerosal on
human neurodevelopment.
As one study demonstrated that the concentration of thimerosal found in human vaccines was not sufficient to kill bacterial cells, the question arises as to the necessity of placing
thimerosal into vaccines. Additionally, after administration of
multiple does DTP and Td vaccines that contained thimerosal
as a preservative there were outbreaks of pyogenic infections.
Indicating that despite the addition of preservatives to vaccines,
microbial contamination can still occur (Ball et all, 2001). One of
the main vaccines today currently containing thimerosal is the
multiple-dose influenza vaccine.Thimerosal is added as a preservative to prevent bacterial contamination of the vaccine. If the
concentration of thimerosal needed to effectively rid the vaccine of bacteria is higher than the concentration of thimerosal
in the vaccine, then it is likely that the thimerosal is not doing its
job. Steps should be taken to remove thimerosal from vaccines
as there is a strong potential that thimerosal does indeed cause
neurodevelopmental problems. If thimerosal is kept in vaccines,
it should be determined whether the benefits thimerosal brings
to the vaccine outweigh the risks brought onto children when
they are vaccinated.
Fetuses, neonates, and other small children are the most susceptible to neurodevelopmental damage, as these are the periods of brain growth (WHO, 2013 and Dorea, 2015). The World
Health Organizations states a fetus is the most susceptible to
neurotoxic factors (WHO, 2016). Additionally, during the prenatal and early postnatal stages the Blood Brain Barrier (BBB)
is not fully developed. As a result, the likelihood of neurotoxins
crossing the BBB is higher in fetuses and newborns (Tomljenovic
and Shaw, 2011). As the risks of thimerosal exist and there is

not conclusive proof that there is not neurotoxicity, injecting
pregnant woman and babies with vaccines containing thimerosal
should be avoided, as these are the ages most critical to childhood neurodevelopment. For example, the Center for Disease
Control currently recommends that the influenza vaccine be
administered to pregnant woman as a woman suffering from influenza during her pregnancy is at great risk (Center for Disease
Control, 2015). Pregnant woman are more likely to have longer
stays at the hospital as a result of respiratory illnesses, than
when not pregnant (American College of Obstetricians and
Gynecologists). There seems to be a clear benefit of a pregnant
woman being immunized to influenza. However, based on the
information above, there is clearly a potential that thimerosal
causes neurodevelopmental disorders, and this stage is where
the fetus is the most susceptible to neurotoxins. As a result,
measures should be taken to ensure that pregnant woman are
given the influenza vaccine that does not contain thimerosal.
Additionally, the postnatal stages till adolescence are still stages
of neurodevelopment. As thimerosal potentially causes neurodevelopmental disorders, the benefits of thimerosal containing
vaccines must be evaluated to see if they actually outweigh the
risks presented by thimerosal exposure.

Conclusions
There is no definitive evidence to conclusively determine if
thimerosal causes neurodevelopmental disorders in young
children. However, the potential for thimerosal to cause neurodevelopmental disorders gives rise to question the potential
harm of the other agents used as preservatives and adjuvants
in vaccine today. One of the main adjuvants used in vaccines
today is Aluminum, which does seems to have the potential to
affect neurodevelopment, specifically causing autism spectrum
disorder. As vaccines are being administered to susceptible individuals, further studies should be done to all the chemicals
added to vaccines to determine if they are really safe, and if the
benefits they bring to the vaccine outweigh the risks.
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Abstract
Anti-mitotic therapies are a form of therapy used to treat cancer patients. The use of these treatments on females
can result in fertility complications. Therefore, prior to treatment, women must seek ways to preserve their ability to
conceive children after receiving treatment. This study analyzes the outcomes of oocyte cryopreservation and its many
variables. Three important variables that can affect the outcome of oocyte cryopreservation are age, cryopreservation
method and cryoprotectants. Evidence indicates that human oocyte cryopreservation can enable a woman to preserve
her ability to give birth to a healthy child, following anti-mitotic therapies. Hundreds of babies have been born as a result
of oocyte cryopreservation. Oocyte cryopreservation can even enable a woman with ovarian cancer to have a healthy
offspring, post treatment.
Introduction
Early detection of cancer along with modern medicine has led
to a rise in the survival rates of young cancer patients. This
results in many cancer survivors who are capable of childbearing. However, since chemotherapy and radiation given during
the cancer curing process can result in various fertility issues,
patients must find a method to preserve their ability to give
birth to children.
One method of preservation is oocyte cryopreservation.
Human oocyte cryopreservation is a procedure in which a
woman’s oocytes are extracted, frozen and then stored. When
the woman desires to become pregnant the eggs are thawed,
fertilized and transferred in to the uterus.
This type of preservation is preferred by many for various reasons. Many single cancer patients prefer freezing unfertilized
eggs, as opposed to fertilized ones, as they don’t need any male
donors at the time. Another reason women may want to freeze
eggs is due to the fact that oocyte quality and quantity diminishes with age. This can cause a lack of healthy eggs to allow for
pregnancy. Considering this, many women may prefer to freeze
their healthy young and vital oocytes, which are more likely to
produce pregnancies.
Furthermore, people may consider oocyte cryopreservation
due to ethical, legal and religious hindrances that prevent them
from doing embryo cryopreservation. Couples may not want to
cryopreserve embryos as the embryos may have to be disposed
if the cancer patient dies. (Noyes, et. al. 2010)
The goal of this study is to determine if oocyte cryopreservation is a means that enables women to have healthy offspring,
post anti-mitotic therapy.

Methods
Pub med.gov, google scholar and Touro databases such as,
EBSCO host, were used to research relevant studies and reviews for the background, process and results of oocyte cryopreservation. The review paper’s references were used to find
additional original papers that were relevant to the question
proposed above. Key words such as oocyte cryopreservation,

oocyte cryopreservation in cancer patients, slow freezing and
vitrification were used in order to find articles.

Discussion
Various studies were done on oocyte cryopreservation. In one
experiment, twenty-two cancer patients, between ages 21 and
38, underwent cycles of oocyte cryopreservation. After drug
stimulation, oocytes were harvested from sixteen of the twenty-two infertile women, subsequently fertilized and implanted in
them. The other six infertile patients received donor eggs. Only
mature oocytes were preserved. The eggs were preserved by
two methods, slow cooling method and vitrification. A total of
295/355 oocytes were recovered with a 92% survival rate.
At the time of publication of the study, fourteen of the patients
had become pregnant, one had miscarried, and three pregnancies were still ongoing. A total of thirteen babies were born to
the other expectant ten patients. Eleven of these babies were
completely healthy, however a set of twins were born prematurely due to premature dilatation of an incompetent cervix.
These twins suffered some complications of prematurity, but
upon reaching two years of age, the twins were thriving within
the average norms. Besides for two cases of gestational diabetes, no other complications were reported (Grifo, Noyes, 2010).
Gestational diabetes is common in women during pregnancy.
According to the CDC, the ratio of women with gestational
diabetes ranges between one in every twenty to one in every
fifty of expectant women.
Additionally, Dr. Nicole Noyas and other researchers pooled
together data to see how many oocyte cryopreservation’s resulted in normal babies. Any incomplete data was left out. A
total of six hundred and nine births were reported between
the years 1986-2008. All the babies born were a result of oocyte cryopreservation. However, the oocytes in those six hundred and nine births were preserved using different methods
of cryopreservation. Three hundred and eight went through
the process of slow freezing, two hundred eighty nine were
preserved using vitrification and twelve had a combination of
slow freezing and vitrification. A total of eight anomalies were
reported. There were also three hundred twenty seven cryopreserved oocyte births published, totaling nine hundred thirty
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six births. Out of the nine hundred thirty six babies, twelve babies were born with birth defects. Overall the anomaly rate is
1.3%. According to the CDC, three percent of babies are born
with major structural or genetic defects.The twelve defects and
the total incidents statistically occurring in natural conception
babies compared to oocyte cryopreservation babies are listed
in table 1. (Noyes, et. al. 2009)

Table1
Birth Anomaly

Approximate
incidence in
natural conception births

Incidence in total
of 936 oocyte
cryopreservation
births (n)

All

One in 33

Skin hemangioma

One in 50–225

1

Cardiac defects

One in 125

3

Neural tube defects

One in 385

0

Cleft lip and palate

One in 710

1

Clubfoot

One in 735

3

Arnold-Chiari syndrome

One in 1200

1

Choanal atresia

One in 7000

1

Biliary atresia

One in 10,000–
15,000

1

Rubinstein-Taybi
syndrome

One in
100,000–
125,000

1

12 (one in 78)

Birth anomalies in natural conception versus oocyte cryopreservation,
listed most common to most rare.
Adapted from N. Noyes, E. Porcu & A. Borini, 2009

From the table one can assess that there were no neural tube
defects and that the defect of skin hemangioma is the same
range as babies born from natural conception. Additionally, cleft
lip and palate as well as cardiac defects occurred less in the
babies born as a result of oocyte cryopreservation.
Researchers have tried to improve the process of oocyte
cryopreservation. One issue that arose from freezing the eggs
was that extensive intracellular ice formed during freezing.
Extensive intracellular ice can cause cellular disruption in the
oocyte during the oocyte cryopreservation process. This can
possibly be improved by using cryoprotectants such as, propanediol and sucrose to increase the extent of the dehydration
process. The aim of the study done by researchers in Infertility
and IVF Center of Buda was to introduce their preliminary clinical results with oocyte cryopreservation.They used slow cooling as the procedure to freeze the eggs. They specifically used
propanediol (1.5M) and sucrose (0.3 M) as the cryoprotectants.
After incubating the oocytes for 4-6 hours, the oocytes were
thawed, fertilized and embryos were transferred into twenty-nine patients. Out of one hundred ten cryopreserved eggs,
eighty-four survived. This is a 76% survival rate, which is high
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but not optimal. From fifty-two embryo transfers, seven resulted in clinical pregnancies, which is 7.3% implantation rate per
egg thawed. Chorion biopsies that were performed indicated
that there were no chromosomal abnormalities. Out of the
seven pregnancies, five of them resulted in four singletons and
one set of twins. One was still ongoing at the time of the study
and the seventh spontaneously aborted in the tenth week. No
abnormalities were indicated in the study. Additionally, there
was only a small difference in the pregnancy rate, 33% versus
24%, between those pregnancies that resulted from frozen oocytes and those that resulted from fresh oocytes. As indicated
from published literature at that time of the research, fifteen to
thirty oocytes were needed in order to achieve one pregnancy.
Previously, one hundred to one hundred fifty were needed to
achieve one pregnancy. (Konc, et. al. 2008) The results show
that oocyte cryopreservation is improving over time.
Vitrification is also known as ultra-rapid cooling. In recent years,
vitrification has proven the superior method. Compared to
slow freezing, vitrification results in higher oocyte survival and
fertilization. (Cil, et. al. 2013) In a study done to compare the
outcome of the two methods, the survival, fertilization, pregnancy and implantation rates were 57.9% versus 78.9%, 64.6%
versus 72.8%, 7.6% versus 18.2% and 4.3% versus 9.3% correspondingly.The rates were higher in all steps for the vitrification
method. (Fadini, et al., 2009)
The duration of cryostorage doesn’t undesirably affect the
thawing of frozen oocytes. A study was done to see if there is
any influence on the outcome of thawing cryopreserved oocytes. There were three groups in the experiment. Group A’s
eggs were cryostored for one to three months, group B’s eggs
were cryostored for four to six months and group C’s were
cryostored for seven to forty eight months. Group C was further divided into three subgroups. Group C1, was cryostored
for seven to nine months, group C2 was cryostored for ten
to twelve months and group C3 was cryostored for a total of
thirteen to forty eight months. The researchers found no significant difference, from groups A, B and C, in the main outcome
measurements, which were oocyte survival after thawing, fertilization, implantation, embryo development and quality and birth.
Oocytes can be cryopreserved for numerous years without
having an effect on the oocytes quality and performance after
thawing. (Parmegiani, et. al. 2009)
One factor that may affect the outcome of oocyte cryopreservation is the age.The value of freezing an older woman’s oocytes
is controversial. (Zhang, et. al. 2015) The rate of implantation of
the fertilized egg that resulted from the slow freezing and vitrification methods declines with age. A study was done to collect
data on the probability of live birth as of function of age. The
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researchers found that live births occur from the slow freezing method until age forty-two, and until age forty-four from
the vitrification method. They limited their results to the age
range of twenty five to forty two years old, as there were only
few cycles that were above or below the twenty-five through
forty-two year old range. This study’s data was on patients that
were infertile. The study was not specifically performed on post
cancer patients. (Cil, et. al. 2013)
Furthermore, a study was implemented in order to report the
oocyte cryopreservation experience in women aged forty and
older. One hundred fifty eight women, aged forty to forty-nine,
underwent minimal ovarian stimulation to retrieve their eggs. A
total of five hundred thirty two eggs were retrieved and frozen.
Four of the women did not have any oocytes retrieved. A total
of four hundred eighty five embryos were formed. Out of the
four hundred eighty five embryos, only fifty-seven were relatively
healthy. Six clinical pregnancies were achieved. Only three resulted
in live births. There was a 5.3 % live birth rate per embryo transfer. The other three pregnancies were spontaneously aborted. As
per the data, a woman aged forty and older can give birth to a
baby after undergoing the process of freezing her eggs. However,
there is a low chance that it will indeed happen, as there is a 5.3%
chance that the woman will give birth. (Zhang, et. al. 2015)
A woman who has ovarian cancer may risk surgical menopause.
Oocyte cryopreservation can be an option for woman facing
ovarian cancer. It could also help patients that need to have a
one or both ovaries removed. A twenty six year old woman
with borderline ovarian tumors had her oocytes cryopreserved
after a right adnexectomy. Seven mature eggs were retrieved
and frozen. Thirty-nine months later, the woman underwent
a left ovariectomy. Three embryos were transferred into the
woman’s uterus. Endometrial growth was achieved with the
help of hormonal replacement treatment.The woman gave birth
to healthy twin babies. (Porcu, et al., 2008)
Oocyte cryopreservation can help women have healthy babies
even when they don’t have their own healthy eggs. Remaining
eggs from oocyte cryopreservation cycles can be saved and
donated to another couple that are experiencing fertility complications. A study was done in which twenty-eight infertile
women froze their oocytes. Twelve of the twenty-eight women
had their frozen oocytes thawed.Three of the women used their
own eggs in IVF treatment and the other twelve donated their
eggs to other women. Premature ovarian failure, physiological
menopause, abnormal karyotype and poor ovarian reserve are
the reasons that the twelve women needed to receive oocytes
from other women. Seven women became pregnant. Six of the
seven used donated oocytes. A total of 6 healthy babies were
born including a set of twins. The other 2 pregnancies were

aborted due to a blighted ovum. (Li, et al., 2005)
Oocyte cryopreservation may not be for everyone. Women
with cancers that need to be treated immediately after diagnosis, may not be a candidate for oocyte cryopreservation. This is
because oocyte cryopreservation requires ovarian stimulation
and retrieval. This can take an average of twelve days. (Noyes,
et al., 2011) Additionally, some women that have breast cancer
might run into issues with preserving their eggs. This is because
estrogen levels rise during ovarian stimulation. High levels of
estrogen might not be safe for women with breast cancer.
(Rodriguez-Wallberg, Oktay, 2010)
Furthermore, some women may not want to undergo oocyte
cryopreservation as it can cause a woman to have a risk having of intra-abdominal bleeding and ovarian hyper stimulation
syndrome. However, there is a very low percentage rate of this
risk. (Noyes, et al., 2011) Additionally, women with cancers may
not be able to cryopreserve their eggs due to economic issues.
It is a very expensive procedure. According to NYU Langone
Medical Center’s website, oocyte cryopreservation can cost
about $16,000- $20,000. This includes initial office consultation, egg cryopreservation cycle, prerequisite blood testing and
screening medication. As of 2010, cancer patients are generally
not offered insurance coverage for oocyte cryopreservation.
(Noyes, et al., 2011) Consequently, cryopreservation may not
be an option for people that are struggling financially.

Conclusion
Oocyte cryopreservation is a viable method that enables
women post mitotic therapies to have healthy offspring. As per
the research discussed above, many women were able to have
a healthy baby because they froze their oocytes. Even when
abnormalities were reported, they were basically within normal range. Oocyte cryopreservation has even enabled a woman
with borderline ovarian cancer to have a healthy offspring.
Even though the value of freezing an older woman’s oocytes is
controversial and the rate of implantation of the fertilized egg
declines with age, data has shown that oocyte cryopreservation
can enable older women to have healthy babies.
There are different variables that may increase the outcome of
oocyte cryopreservation. The vitrification method has shown
to be the efficient and more reliable method. Cryoprotectants
such as, propanediol and sucrose can increase the extent of
the dehydration process and thereby prevent the oocytes from
disrupting. Furthermore, the duration of cryostorage doesn’t
undesirably affect the outcome of oocyte cryopreservation.
Oocyte cryopreservation may not be for everyone due to economic reasons and timing of the anti-mitotic therapies. However,
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it is a means that enable women to have healthy children even
after their oocyte quality and quantity diminish as result of the
cancer treatment.
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Abstract
Clostridium difficile infection, an increasingly prevalent and virulent condition, is often resistant to treatment. Standard
antibiotic therapy is rarely efficient when used to treat recurrent C. difficile infection. Fecal microbiota transplantation
(FMT) is a safe, effective and inexpensive treatment that has a cure rate of about 90%, according to clinical trials and
reports. This approach may also be applicable in treating ulcerative colitis, a type of inflammatory bowel disease, on the
basis of the restoration of flora imbalances. Additionally, recent data suggests that a disproportion in composition of the
gut microbiome may contribute to obesity. FMT, may restore a healthy balance. Using information from Touro College’s
database, this article discusses the reason behind the success of fecal microbiota transplantation when used to treat
Clostridium difficile infection and ulcerative colitis. The effect of diet, environment and geography on the bacterial flora
is also explored.
Introduction
The human gut microbiome consists of over 100 trillion microbial cells, exceeding the amount of human cells by a factor of 10.
Bacteria are found in various parts of the body including nasal
passages, oral cavity, skin, urogenital system and the gastrointestinal tract. The gut microbiota carries out a variety of valuable
tasks for their human hosts; it assists in the development of innate and adaptive immunity, serves as an energy source, and kills
foreign organisms. (Dave, et al. 2012). The quality and composition of the gut microbiome depends largely on diet, medication
and weight of its host. The microbiota is capable of secreting
or altering the production of molecules that affect both weight
gain or loss and fat mass. (Rosenbaum, et al. 2015)
Colonization of the microbial microflora of the internal and
external surfaces in a human begins at birth and is termed indigenous bacterial microflora. (Van der Waaij, 1989) The route
of delivery when a baby is born determines which type of bacteria will develop. Infants delivered vaginally have microbiota
comparable to their own mother’s vagina, whereas infants born
via Cesarean section develop microbes similar to the bacteria
found on the skin surface. (Dominguez-Bello, et al. 2010) After
birth, microbes develop and colonize, benefitting both themselves and their host, each contributing something vital to the
other. (Van der Waaij 1989) For example, the anaerobic bacteria in our distal gut breaks down complex polysaccharides and
ferments the resulting monosaccharides into short chain fatty
acids. This is a mutually beneficial relationship; the microbes live
in a sheltered anaerobic environment and receive a rich assortment of glycans while offering the host a source of carbon and
energy. (Backhed, et al. 2005)
Of all the microbial communities being studied by human microbiome researchers, the gastrointestinal tract (GI) holds a promising future for the discovery of new concepts and therapies.
The large colon holds the most abundant and diverse communities of microbes; it has both local and systemic effects on the
body. (Dave et al. 2012) The gut microbiota can be thought of as
a “microbial organ placed within a host organ,” it plays vital roles

in metabolism and immune system function. It is known that
the microbial communities have a method of communication;
they also can consume, store and redistribute energy. (Bakhed,
et al. 2005)
Fecal Microbiota Transplantation (FMT) is an FDA experimental
drug targeted to treat Clostridium difficile associated diseases
(CDAD). It has been successfully used to treat patients with ulcerative colitis (UC) and different forms of inflammatory bowel
diseases (IBD). Additionally, by comparing and analyzing the
gut microbiome of lean and obese individuals, researchers have
been able to hypothesize a cause for obesity and other weight
issues. Using this knowledge, microbiologists can manipulate
the microbiome and formulate a therapy to decrease obesity
worldwide. This research can result in a new kind of pharmacopeia; implanting a more refined probiotic to combat infection,
inflammation and dysbiosis.

Methods and Materials
To investigate the mechanism of fecal bacteriotherapy and how
it can be utilized to treat Clostridium difficile associated diseases and other gastrointestinal disorders, many original research
articles and reviews have been read. Touro College’s online database was employed, particularly EBSCO, PubMed, ProQuest
and Google scholar. Further research was done by perusing
the footnotes and references in review papers to find original
research.

Discussion
Fecal Microbiota Transplantation
The indigenous microbiota is vital to the human host, yet it
can be altered by various factors of modern day life, most
commonly repeated doses of antibiotics. (Van der Waaij, 1989).
Dethlefsen et al. tested the fecal microbiota of adults before
and after oral administration of ciprofloxacin for five days using
pyrosequencing. A rapid reduction in richness of bacterial phyla
was seen, resulting in decreased diversity, fullness and balance
in the microbiome. Four weeks following the completion of
the antibiotic, the microbiota returned to baseline. However,
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in some individuals, it took 6 months for the bacterial phyla to
completely return to normal. (Dethlefsen et al., 2008) Infectious
diseases of the past were thought to be linked with bacteria capable of causing disease in a susceptible host. However, present
day infectious diseases are linked to host interaction with potentially pathogenic bacteria that make up the microflora of the
digestive tract (Van der Waaij, 1989). A particular infection that
results from a disruption of the gut microbiota is Clostridium
difficile infection. Clostridium difficile is an anaerobic, spore
forming bacillus that produces 2 exotoxins that damage the intestinal mucosa. It is the most commonly recognized cause of
anti-microbial associated diarrhea. Clostridium difficile associated disease mainly affects the large colon, causing diarrhea and
pseudomembranous colitis. If progressed, the infection can lead
to toxic megacolon, sepsis and death (McDonald et al., 2006).
The microbial colonies that regularly control the Clostridium
difficile communities are inhibited and blocked by antibiotics.
Because C. difficile spores are generally resistant to antibiotics,
this allows them to germinate back into their vegetative state
after antibiotic treatment has ended. If the remaining microbes
in the intestine cannot get rid of the infection, Clostridium difficile can multiply and release the toxins that return the disease
symptoms. (Bakken et al., 2011)
There are different treatments that exist for recurrent
Clostridium difficile infection, many of which involve the use
of stronger antibiotics, such as vancomycin and metronidazole. However, as Dr. Johan Bakken says, “the use of antibiotics represents a double-edged sword by suppressing both the
pathogen as well as the protective microbiota.” In other words,
repeated and extended uses of antibiotics have negative effects
on the natural gut flora. It is a possible risk factor for further
infection due to the continuously altered state of gut microbes.
(Bakken et al. 2011)
Another approach to treat recurrent Clostridium difficile infection is to restore the damaged microbial communities using
probiotics. Saccharomyces bouldarii is a yeast that colonizes in
the colon within 3 days of ingestion, survives gastric acids of
the stomach and is cleared from the colon once treatment is
discontinued. The effectiveness of the probiotic as an add-on
to antibiotics was tested in two trials. The treatment did not
decrease recurrence rates in those with their first episode of
Clostridium difficile infection but it did decrease the frequency of relapses in those with the recurrent infection. The second trial showed effectiveness only in patients that were on
a high dose of vancomycin. (McFarland et al., 1994) (Bakken
et al., 2011) Thus, probiotics may have a role in treatment of
Clostridium difficile infection, but their effectiveness is less than
ideal. (Kelly, LaMont 2008)
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Fecal Bacteriotherapy, or fecal microbiota transplantation
(FMT), is an innovative and effective treatment for Clostridium
difficile infection and other infections of the colon, including ulcerative colitis. It involves implanting stool from a healthy donor
into a recipient’s diseased colon, thereby allowing a newer and
healthier microbiome to develop and flourish. From the trials
done and the case studies reported, it seems that recurrent
Clostridium difficile infection can be cured with a single treatment of FMT. The logic behind FMT is straightforward: strong
antibiotics can cause an imbalance in the normal intestinal flora
and reduce colonization resistance, which allows C. difficile to
grow and cause symptoms of infection.With the introduction of
healthy donor feces, the imbalance can be corrected, the cycle
interrupted and the normal colon function returns. (Bakken, et
al. 2011)
Although the first four patients to be treated with FMT in the
20th century was in 1958 for pseudomembranous enterocolitis,
(Bakken, et al. 2011) the use of fecal material as a treatment
for diseases dates back more than 2500 years ago in ancient
China. During the Dong-jin dynasty in the 4th century China, Ge
Hong, a well-known doctor described the use of human fecal
suspension by mouth for people suffering from severe diarrhea
or food poisoning. This treatment was considered a medical
miracle that brought patients back from the brink of death. In
the 16th century, during the Ming dynasty, Li Shizen prescribed
a series of fecal material doses to treat abdominal diseases that
caused severe diarrhea, fever, pain, vomiting, and constipation.
This treatment was called “yellow soup” for aesthetic reasons.
(Zhang, et al. 2012)
Nowadays however, the procedure is done in a more sterilized
manner and reported to have been successful via colonoscopy
(Persky, Brandt 2010), nasogastric tube, (Aas, et al. 2003) nasoduodenal tube, (van Nood, et al. 2013) and self-administered
fecal enemas. (Silverman, et al. 2010) One method of implantation was not found to be superior over the other. (Rohlke,
Stollman 2012)
Currently, the only FDA approved drug to treat C. difficile infection is the antibiotic vancomycin, which is inadequate for patients suffering from recurrent CDI. It is estimated that 80% of
patients treated with the standard antibiotic therapy are cured,
however, the remaining 20% are likely to recur 3-28 days after
discontinuation of antibiotics. Disease caused by C. difficile has
been shown to increase the length of stay of patients by a mean
of 7 days, incurring an additional $10,500 in health care charges
for every infected patient. (McFarland, et al. 1994) Alternative
treatments, including probiotics, surgery and administration of
different antibiotics, have been suggested, but none were effective, safe and inexpensive. Fecal microbiota transplant seems to
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fit the criteria of being inexpensive, highly effective and safe. In
fact, a study done to compare 4 different treatments for CDAD;
metronidazole, vancomycin, fidaxomicin and FMT demonstrated that FMT was the “most cost-effective strategy.” The incremental cost-effectiveness ratio (ICER) was $17, 016 relative to
oral vancomycin. (Konijeti, et al. 2014) It is “the only therapy
that restores the phylogenic richness of the recipient’s intestinal
microbiota without prolonging the perturbation of the normal
microbiotic composition.” (Bakken, et al. 2011)
A study comparing the fecal material of a patient before and
after FMT illustrates the effectiveness of the transplant. Before
FMT, the patient’s fecal material was composed of atypical bacterial populations including Veillonella, Clostrudium, Lactobacillus,
and Streptococcus. Two weeks after FMT, Bacteroidetes began
to appear and four weeks after the transplant, the stool studies were culture negative for C. difficile. The recipient’s fecal
bacterial composition greatly resembled the donor. Throughout
the months following FMT the patient reported issues of loose
stool, but those issues were resolved within two weeks without
therapy. Six months later, the patient was completely cured from
C. difficile infection. (Khoruts, et al. 2010)
Further data is needed to assess the effectiveness of FMT, yet
given the promising data to date and anticipated research data
on the intestinal microbiome, it seems to be the most reasonable treatment for recurrent C. difficile infection (CDI). Bakken
et al. put together a guideline for the proper administration of
FMT. Included in the guideline is a detailed description of primary indication, donor selection and directions for preparing and
administering the stool. Many trials and studies that involving
FMT used this guideline as instructions on how to proceed. In
order to be eligible for FMT, a patient either has to have recurrent or relapsing CDI with at least three episodes of mild-moderate CDI and a failure of a 6-8 week taper with vancomycin.
Patients on major immunosuppressive agents, decompensated
liver cirrhosis or have had a recent bone marrow transplant
cannot receive the fecal microbiota transplant as it may cause
adverse effects.
Currently, little or no data is available to suggest that any reasons, other than the exclusion criteria based on medical history
and laboratory testing, would recommend a specific donor over
another. However, using intimate contacts as donors minimizes
the risk of transmitting an infectious disease. Donors are interviewed thoroughly and must answer a detailed questionnaire
regarding their past medical history. Donors are disqualified
if they test positive for HIV, Hepatitis B or C infections or had
exposure to HIV or viral hepatitis. Individuals that have high
risk sexual behaviors, use illicit drugs, had tattoo or body piercing within 6 months or have a history of incarceration cannot

donate stool for FMT. Once a donor passes the medical and laboratory tests, their stool is screened for enteric pathogens such
as C. difficile toxin A and B, fecal Giardia and Cryptosporidium
antigens and Helicobacter pylori fecal antigen. (Bakken, et al.
2011)
The stool donor may or may not take an osmotic laxative the
night before the procedure.The stool should be used as soon as
possible, preferably within 6 hours. The choice of diluents may
vary among practitioners, but either preservative-free normal
saline or 4% milk is combined with the stool in a household
blender. It should be mixed until it reaches a homogenous slurry consistency and filtered to remove particulate. The slurry
stool mixture is to be used immediately. The optimal volume
for transplantation has not been established yet; however if by
nasogastric tube or via other routes from above, smaller volumes (25-50 mL) should be used and if by colonoscopy or other
routes from below, larger volumes (250-500 mL) may be used.
(Bakken et. al. 2011)
This is a basic outline on how a practitioner would administer
fecal microbiota transplant. However, “practical and aesthetic
barriers” have slowed down the widespread use of FMT, despite
its success in dramatically resolving CDI after one treatment.
Enrollment and screening of donors is a tedious process linked
with substantial costs, thereby inhibiting the use of FMT in severe situations. Youngster et al. suggests that by establishing a
repository of prescreened frozen donor stool, this treatment
may be more easily obtainable from a broader population. He
conducted a trial to evaluate the efficacy of FMT in treating
relapsing CDI in a pilot cohort of 20 patients, comparing colonoscopic and nasogastric tube administration.
The donors for the study underwent extensive physical examinations and general laboratory screening tests to ensure that all
results were within normal range for age and sex. Renal function
and electrolytes, complete blood count with differential, complete
liver function tests and fecal occult blood testing were some of
the tests that fecal donors underwent. All fecal donations were
set aside for four weeks to allow retesting of donors for HIV and
hepatitis B and C before the feces was inoculated.To facilitate manipulation of the fecal material, donors were asked to take milk
of magnesia the day before the donation. The feces was mixed in
a commercial blender with normal saline and then were passed
through 4 sieves to get rid of any particulate. The final product
was concentrated 3-fold by centrifugation and then resuspended
in sterile saline with 10% glycerol added as a cytoprotectant. The
resulting mixture was frozen at -80°C. Each filtered sample was
calculated to have come from 41g of fecal material. Inocula were
stored frozen for up to 156 days and thawed in a 37°C water
bath, then kept on ice until delivery.
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Patients were ordered to stop taking antibiotics for 2 days before the procedure. Recipients designated for a colonoscopic
administration underwent a standard bowel preparation with
4 liters of polyethylene glycol electrolyte solution. Then, 90 cc
of the thawed inoculum was placed in the right colon via endoscopy. The fecal material was further diluted to 250 cc for
adults and 160 cc for pediatric recipients. Patients were given
a single dose of loperamide at the time of the procedure in
order to retain the material for as long as possible. The patients assigned to nasogastric tube administration were given
omeprazole orally for 2 days before the procedure, to ensure
that the fecal bacteria will not be affected by the acids in the
stomach. After inserting the nasogastric tube, 90 cc of inoculum
was administered. In order to minimize vomiting and aspiration,
the inoculum was not diluted. (Youngster, et al. 2014)
The goal of the trial was the clinical resolution of diarrhea off
antibiotics for C. difficile infection, without a recurrent episode
within 8 weeks. Patients who showed no improvement were
offered a second FMT by their preferred route of administration, using the same donor inoculum to minimize exposure to
infectious agents.
Of the 20 patients in both study arms, 14 were cured after the
first FMT; 8 of them were in the colonoscopy group and 6 in the
nasogastric tube group. One patient refused a second transplant
but the remaining 5 patients were given a second infusion via
NGT using feces from their original donors. Four patients were
cured after the second FMT, resulting in an overall cure rate of
90%. No patient relapsed within the 8 week period following
the initial cure.
There were some serious adverse effects that were deemed
unrelated to the trial by investigators and the Institutional review board, which may have been caused by the poor health
of the patients with recurrent CDI. 2 patients died; one from
an obstructive pulmonary disease and another from metastatic
laryngeal cancer. A third patient was diagnosed with adenocarcinoma of the esophagus and a fourth (treated via NGT) was
hospitalized for Fourier gangrene.
This trial demonstrated that the transplantation of unrelated
frozen donor stool is effective in treating recurrent CDI with
an overall cure rate of 90%. Additionally, NGT appears to be a
feasible route of administration for elderly patients with the
infection. One 89 year old female patient had 16 documented
cases of CDI in the previous 15 months. She was hospitalized
4 times and placed on the intensive care unit twice due to the
infection. After two infusions, she was cured and was free from
any symptoms of the disease off treatment for 12 months.
(Youngster, et. al. 2014)
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Seeing the success with frozen inocula, Youngster et al. directed another study evaluating the effectiveness of oral capsulized
frozen fecal microbiota transplantation in treating relapsing C.
difficile infection. The donors were thoroughly screened, as
described in the previous study (and the guideline by Bakken,
et al. 2011) and similar processing of the fecal material took
place.To ensure that the acidic environment of the stomach will
not destroy the capsule, commercially available acid-resistant
hypromellose capsules were used. The stability of the capsules
was tested by mimicking the acidic environment of the stomach.
Trypan blue filled capsules were used, at a temperature of 37°C
and a pH of 3 or less, and the capsules were stable for 115
minutes before the dye was released.
From July 2013 through January 2014, a total of 20 patients
were treated using stool obtained from four donors. The recipients followed up six months later in July 2014. The goal of the
study was the clinical resolution of diarrhea, while not receiving
antibiotic for C. difficile, without relapse within 8 weeks.
The procedure went as follows: each patient was given 15 capsules, directly from an investigator on 2 consecutive days. 2 days
prior to FMT, patients were ordered to stop all antibiotics. They
were asked to fast 4 hours prior to and 1 hour post taking the
capsule for both days. If there was no improvement after 72
hours, patients were retested and offered another treatment
for positive test results.
From the 20 patients treated, 14 had clinical resolution of diarrhea after the first FMT. The remaining 6 patients were retreated 7 days after the first procedure. 5 of the 6 had resolution of
diarrhea after the second FMT, however one patient relapsed
within the 8 week follow up time period. Thus the overall rate
of diarrheal resolution was 90%. (Youngster et. al. 2014)
Fecal microbiota transplantation used to treat C. difficile infection is a highly effective, safe and inexpensive method as described studies and research. Very few, if not any, complications
were caused by FMT. The fecal material can be manipulated and
can be transplanted as a liquid via NGT or colonoscopy and can
also be ingested as a capsule. FMT is currently an FDA experimental drug and therefore the trials and studies are with small
samples and lack of placebo or other trial to compare. Granted,
the trials and studies done are encouraging, however this may
be due to the small sample size. Furthermore, even with careful
screening, there is a potential risk of transmission of infections
via microbiota transplantation. Larger studies would be needed
to confirm these outcomes and to evaluate long-term safety
and effectiveness. (Youngster et. al 2014)
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Fecal Microbiota Transplant for Ulcerative Colitis
Encouraged by the success for fecal microbiota transplant in
the treatment of C. difficile infection, researchers looked to
other conditions related to GI microbial imbalance, such as
inflammatory bowel disease (IBD), obesity and diabetes mellitus. (Borody, et al. 2103) Inflammatory bowel diseases are
thought to be caused by an overall community dysbiosis rather than a single underlying pathogen. In patients with IBD, an
increase in Actinobacteria and Proteobacteria and a decrease
of Lachnospiraceae, Bacteroidetes, Clostridium leptum, and
Bifidobacteria are observed. (Clemente, et. al. 2012)
Ulcerative colitis (UC), a type of IBD, is a chronic devastating
inflammatory bowel disease that affects the large intestine.
Unfortunately, the current medications used to treat UC have
significant adverse effects; they mainly target the inflammation
without focusing on the dysbiosis. (Kunde, et al. 2013) The
colonic microbiome in UC patients lacks diversity and is dysfunctional. The cause of inflammation of the colon in UC is
hypothesized to be caused by inappropriate stimulation of the
innate mucosal immune system because of dysbiosis in a genetically susceptible individual. Borody et al. asks the following
question: C. difficile infection causes reduced microbial diversity
which results in symptoms of colitis; if FMT can reverse this,
perhaps a similar treatment can be used to treat ulcerative colitis? (Borody, et al. 2013)
Borody et. al. conducted a trial assessing the clinical, histological
and colonoscopic effects of “human probiotic infusion” (HPI), or
fecal material transplant in six selected patients with ulcerative
colitis. All patients had suffered from severe recurrent symptoms of UC and each, respectively, were on series of moderate
to high dose steroids and anti-inflammatory medications. The
donors were chosen by the recipient patients and screened
thoroughly to prevent any transmission of parasites or bacterial
pathogens. The feces (200–300 g) was diluted in 200 to 300
mL normal saline and administered to the patient via retention
enema within 10 minutes of its preparation. This process was
repeated daily for 5 consecutive days. One week following HPI,
some symptoms of ulcerative colitis had resolved in several patients. A complete reversal of symptoms was achieved in all
patients 4 months post HPI, by which all other UC medications
had been discontinued. From 1 to 13 years later, patients remained asymptomatic with a healthy colonoscopic appearance
and normal histology.
However, the pathogenesis of UC is unknown since it is characterized by persistent inflammation. It is suggested that the
disease is driven by a chronic infection caused by the absence
of vital luminal anaerobes. If the ability of the normal flora to
resist colonization by pathogens is hindered, for example, by

previous antibiotic use, the numbers of protective anaerobes in
the colon, such as Bacteroides, decrease. This would allow the
establishment of other pathogenic anaerobes or spore bearing
bacteria and a form of recurrent, chronic colitis.The persistence
of UC may be due to the implantation of spores in the mucosal
surface, analogous to Clostridium difficile infection. Antibiotics
may help briefly but are unlikely to be curative because the
spores are not eliminated. (Borody et. al. 2003)
Kunde et. al. conducted a pilot study to evaluate the efficiency
and safety of fecal microbiota transplantation in children with
ulcerative colitis. Ten children, ages 7 to 21 with mild to moderate UC according to the pediatric ulcerative colitis activity
index (PUCAI) were enrolled in the study. Clinical response and
improvement was defined as decrease in PUCAI by more than
15 points on the index. A decrease in PUCAI to less than 10
points was considered clinical remission. Each donor produced
a 90 gram stool sample every day which was blended with 250
mL normal saline and filtered through 2 gauze pieces to remove
sediments. It was then separated into 4 aliquots of 60 mL each
and kept in a warm water bath (37°) until administration. Each
patient received FMT as retention enema for 1 hour (60-mL
enema every 15 minutes) daily for 5 days. One subject however,
was not able to tolerate the retention enema for 3 consecutive
days and was therefore not included in the results. Within one
week following the procedure, 7 of the 9 subjects (78%) showed
clinical response. Four weeks after FMT, six of the nine patients
(67%) maintained the clinical response. However, 3 of the nine
subjects (33%) went into clinical remission one week following
FMT. All of the adverse events related to FMT, besides fever,
were self-limiting, and did not require intervention from health
care providers. The majority of them were similar to subjects’
baseline symptoms of UC such as bloating and diarrhea.
The dramatic response to FMT after one week was not achieved
in all subjects, perhaps due to the severity or duration of the
disease, or the ability to retain larger FMT volumes for longer
periods. Using FMT via fecal enema to treat UC in children is
feasible, as proved in the trial. However, the sample size was small
and therefore limits future indication. In order to improve FMT a
standardization procedure would need to be arranged for donor
selection and ideal routes of administration. (Kunde, et al. 2013)

The Gut Microbiota and Obesity
The World Health Organization (WHO) reports that in 2014,
more than 1.9 billion adults, 18 years and older were overweight
and of these, over 600 million were obese. Obesity is a growing,
worldwide epidemic that has been accompanied by increases in
obesity related disorders, including type II diabetes, hypertension
and nonalcoholic fatty liver disease. Much emphasis has been
placed on the dietary excess or host genes in obese individuals.
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Yet, in addition to increased calories or shifts in host metabolism,
the composition of the intestinal microbiota can contribute to
the progression of obesity. Both diet induced obesity and gene induced obesity have microbe independent and microbe dependent
pathways. (Baackhed et al. 2004, Cox, Blaser 2013)
A study was done to investigate the effect that diet has on shaping the gut microbiome. The fecal material of 15 European children and that of 14 children from a rural African village, Bukina
Faso were compared and tested with 16S rRNA sequencing,
and biochemical analysis. The goal of the study was to explore
three questions: the split of bacterial diversity between the two
populations, the connection between the gut microbiota and
diet, and the distribution of well-known bacterial pathogens
within the two populations given the different hygienic and geographic conditions.
The diet of Bukina Faso children is mostly vegetarian; rich in
plant polysaccharides, starch and fiber and low in fat and animal protein. All the food was grown and harvested nearby the
village by women. The European children were eating a typical
Western diet high in animal protein, sugar, starch and fat and
low in fiber. A dataset consisting of 438, 219 of filtered, high
quality, classifiable 16S rRNA was generated. Of all of the sequences in all the Bukina Faso and European samples 92.4%
were found to belong to the most populated bacterial phyla:
Actinobacteria, Bacteroidetes, Firmicutes, and Proteobacteria.
However, it was the proportions that stood out: Actinobacteria
and Bacteroidetes were more abundant in the Bukina Faso children than the European children 10.1% versus 6.7% and 57.7%
versus 22.4%, whereas Firmicutes and Proteobacteria were represented more in EUROPEAN than BUKINA FASO children,
63.7% versus 27.3% and 6.7% versus 0.8%. Since Prevotella,
Xylanibaeter (Bacteroidetes) and Treponema (Spirochaetes)
were exclusively found in the Bukina Faso children. De Filippo
et. al. hypothesized that these 3 genera could be a result of high
fiber intake due to the environmental factors distinguishing the
two populations (diet, hygiene, climate and geography). Perhaps
these three groups contribute to the extraction of metabolic energy from ingested plant polysaccharides. It is reasonable
to deduce that the increase in the Firmicutes to Bacteroidetes
(F/B) ratio in European children possibly triggered by their
high-calorie diet might predispose them to future obesity. This
Firmicutes/Bacteroidetes ratio may also be considered a useful
obesity biomarker. (De Filippo, et al. 2010)
A study done by Turnbaugh et al. further demonstrates the
effect of diet on the gut microbiota. Mice raised in a germ free
environment without any exposure to microbes, and then colonized at specific life stages with different microbial communities are referred to as gnotobiotic animals. Adult human fecal
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microbiota was transplanted into the recipient mice to establish
a stable gut community similar their donors. An aliquot of the
fecal dilution was introduced by gavage to the 15 recipient mice.
These mice were maintained on a low fat plant polysaccharide
(LF/PP) rich diet and fecal samples were collected 1 day, 1 week
and 1 month after colonization. Half of the mice were then
switched to a high-sugar, high-fat Western diet. The LF/PP and
Western diet were maintained for 2 additional months, after
which the mice were killed. Results showed that when the diet
of the mice were switched from a LF/PP regimen to a highfat, high sugar “Western” diet the structure of the microbiota
was shifted within a single day. The representation of metabolic
pathways in the microbiome were changed and the microbiome gene expression was altered. The mice fed a Western diet
had an increased representation of the Erysipelotrichi class of
bacteria within the Firmicutes phylum relative to mice fed the
LF/PP diet. In mice that consumed a Western diet, the Bacilli,
another class of the Firmicutes was abundant and a significant
decrease in member of Bacteroidetes was found. These mice
increased adiposity, demonstrating that this trait is transmissible
via microbiota transplantation. Using germ free mice, researchers were able to see a clear correlation between the foods the
mice were fed and its effect on the composition of their gut
microbiota. Gnotobiotic technology is a promising tool for discovering new classes of probiotics that affect nutrient harvest in
a given diet. (Turnbaugh, et al.2008)
A study comparing the fecal material of 31 adult female monozygotic and 23 dizygotic twin pairs and their mothers, concordant
for obesity or leanness, was performed, to address how host
genotype, environmental exposures and host adiposity influence
the gut microbiome. All twins were 25-32 years old of European
or African ancestry. Analysis of 16S rRNA datasets produced
by the three PCR-based methods, plus shotgun sequencing of
community DNA, revealed a lower proportion of Bacteroidetes
and a higher proportion of Actinobacteria in obese versus lean
Europeanropean and African individuals. Overall, across many
methods, obesity was associated with a decrease in diversity
of the gut microbiota. “This reduced diversity suggests an analogy: the obese gut microbiota is not like a rainforest or reef,
which are adapted to high energy flux and are highly diverse,
but rather may be more like a fertilizer runoff where a reduced
diversity microbial community blooms with abnormal energy
input.” (Turnbaugh, et al. 2009)
There is an interesting case study regarding the transmission of
“obese bacteria.” A 32 year old female patient with recurrent
CDI elected to undergo FMT after many failed antibiotic therapies. Around the same time, she tested positive for Helicobacter
pylori.
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The patient chose her 16 year old daughter, who was approximately 140 pounds to be her stool donor, and, subsequently, her
weight increased to 170 pounds. The patient herself was 136
pounds at the time of the transplant. The patient was retreated for H. pylori with metronidazole, tetracycline, bismuth and
proton pump inhibitor, and two weeks later she had the FMT.
Six hundred cc. of the suspension of the donor stool in sterile
water was infused through a colonoscope. The patient dramatically improved after the procedure and CDI did not recur.
However, 16 months later, the patient presented again, and reported an unintentional weight gain of 34 pounds. Despite a
medically supervised liquid protein diet and exercise program
she had been unable to lose weight. Her weight continued to
climb despite the diet and exercise and at 36 months post FMT
she weighed 177 pounds.
Alang and Kelly offer a several of hypotheses to explain the
rapid weight gain following FMT. There is a known link between
H. pylori treatment and weight gain, resulting from the increase
in appetite after the suppression of the bacteria.Yet, the patient
was never obese before FMT and the fact that the stool donor
also gained weight leads to the possibility that her obesity resulted from the transplant (Alang, Kelly 2014).
This hypothesis is supported in a study testing the fecal material of twins discordant for obesity. This experiment offers
an opportunity to examine connections between obesity and
its associated metabolic disorders, diet, and the gut microbiota. Ridaura et al. conducted a study by transplanting the fecal
material of twins discordant for obesity into mice in order to
replicate the donors’ microbiota community in the colon. The
impact of these differences on the body composition and metabolic phenotypes were able to be detected, and the effects
of diet-by-microbiota interactions analyzed. The mice harboring
the transplanted microbiomes from the obese twins exhibited
higher expression of microbial genes involved in detoxification
and stress responses, in biosynthesis of cobalamin and metabolism of essential amino acids. In contrast, the transplanted
microbiomes from lean co-twins exhibited higher expression
of genes involved in digestion of plant-derived polysaccharides,
fermentation to butyrate and propionate. The results suggest
that the transplanted microbiota of the lean co-twins had greater capacity to breakdown and ferment polysaccharides than the
microbiota of their obese co-twins. (Ridaura, et al. 2013)
From these studies, it is evident that the gut microbiota reflects
the health, diet and metabolism of its host. It seems that the composition of the phyla that make up the gut microbiome in healthy
individuals is properly balanced. However, a disrupted microbiome
can contribute to obesity by altering energy extraction from food.

Conclusion
By transplanting stool from a healthy donor into a recipient’s
diseased colon via fecal bacteriotherapy, a newer and healthier
microbiome can flourish and the function of the large intestine
can be restored. Fecal microbiota transplant has been proven
by many clinical trials to be a safe, effective and inexpensive
procedure. FMT has been successful in treating many cases C.
difficile infection, as well as ulcerative colitis and has a promising
future in the field of diet and obesity. The stool material can be
readily administered in different ways, as a slurry consistency
administered via colonoscopy or nasogastric tube, or packaged
in a pill and taken orally; this therapy is easily accessible to almost all populations.
However, one potential drawback of FMT is the small sample
size in many of the clinical trials done. Additionally, fecal bacteriotherapy may not be the ideal treatment for every individual
suffering with GI tract disorders, for example, it may not be
ideal in immunocompromised patients. However, FMT is an FDA
approved drug and will undergo further standardization regarding donors and the preparations and administration of the stool.
The future of the gut microbiota related treatment is an active
topic of research; much is anticipated from this exploration into
the microbiome.
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Abstract
Our world has developed an obsession with weight control and, as a result, has begun replacing high calorie foods with
low-fat and non-caloric substitutes. Artificial sweeteners are a widely used solution to this growing problem.Though the
intention when using artificial sweeteners is to lose weight, studies have shown that the opposite sometimes occurs.
Researchers attempt to explain this surprising phenomenon with multiple hypotheses. Lack of appetite suppression and
reward response may cause individuals to search for more food and to consume more calories. Artificial sweeteners
can also have negative affects on biological mechanisms such as resting metabolic rate, as well as the gut microbial
environment.These changes can cause improper energy absorption and storage, which leads to weight gain. Sociological
effects of artificial sweeteners have lead consumers to enjoy products that are super sweet. They have also convinced
consumers that they can eat more (food) but consume less (calories), a misconception that has left the world with a
big “fat problem”.
Introduction
In a society plagued by obesity, diabetes and overeating, we
search for ways to counteract these negative effects. Early
research into these problems led to the assumption that the
major cause of these maladies was over consumption of sugar.
The food industry was taken by storm with the introduction
of non-caloric artificial sweeteners (AS) such as saccharin, sucralose, and aspartame, which are widely used to replace sugar
in the average western diet. However, are these sweeteners
fighting or feeding the problems they were intended to combat?
Studies conducted in this area of science see a direct dose-response relationship between artificial sweetener use and weight
gain.This relationship begs an explanation. Researchers propose
that the weight gain caused by artificial sweetener can be due
to natural circumstances, flawed gut microbial activity, or altered
neurometabolic functions. Artificial sweeteners have been connected to both an increased appetite, and inefficient energy absorption. This combination can lead to weight gain and obesity.

use went down in the general population until the new products surfaced. Aspartame was found in 1965 by James Schlatter
at Searle while researching ulcer drugs. This was the first AS
that could be metabolized, and the FDA approved it in 1981.
Next came acesulfame potassium in 1967 and sucralose in 1979.
Neotame was later approved for use is 2002 by the FDA.
In the years between 1999 and 2004 more than 6,000 new
products have been created using artificial sweeteners. These
sweeteners are most commonly used in carbonated drinks.
Sucralose is the most widely used due to its close mimicry of
real sucrose taste. The wide use of these sweeteners in countless products ensures that sweeteners affect most aspects of
our dietary life (Yang, 2010).

Discussion

History of Artificial Sweetners

Artificial Sweetener use and Weight Change:
The perpetual debate surrounding the effects of artificial
sweeteners on the human body gave rise to a lengthy list of
studies that attempt to determine the risks as well as the
benefits. A controversial matter that has taken priority in these
studies is the question regarding weight change in relation to
artificial sweetener use. Due to their lack of calories, sweeteners have been used to control diseases such as diabetes as
well as prevent diseases such as obesity.Yet, studies have found
a substantial dose-response relationship between artificial
sweetener use and weight gain. These studies range from 4 day
studies to 10 year epidemiological events.

The first sweetener to be discovered was saccharin. A scientist
named Constantine Fahlberg stumbled upon it in 1879 at Johns
Hopkins University. For nearly half a century saccharin was the
only artificial sweetener on the market. Originally, it was for
diabetics only, later it was used for anyone wanting to limit their
sugar intake. Fifty years later, in the University of Illinois, Michal
Sveda discovered Cyclamate. Combining cyclamate with saccharin improved the taste and soon became common practice. By
1969 the FDA banned cyclamate because of its link to cancer,
while they deemed saccharin safe to use. Artificial Sweeteners

One of the largest scale studies performed was the San Antonio
Heart Study (Fowler et al, 2008). The study included 5,158
Mexican and non-Hispanic white Americans between the ages
of 25 and 64. All the members of the study lived in randomly
selected homes in the San Antonio area. Consisting of 2 cohort
studies, the first of which was from 1979 to 1982, the second
was from 1984 to 1988. Of the 4,998 surviving individuals, took
part in a follow-up study 7- 8 years later. This study focused
on artificial sweetener consumption in beverages. Participants

Methods
The studies and information in this paper were acquired through
the PubMed government database and the Touro College Library
databases such as J Store, Ebsco Host, and Proquest. To answer
the present questions the articles and reviews have been read
through; only the relevant information has been included.
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were asked to answer a series of questions regarding amount
of cans, bottles or cups of beverages, such as soft drinks, diet or
regular, and coffee, sweetened with sugar or AS, they consumed
per week. Based on their answers participants were placed in
either a user or nonuser category. Dieting status and exercise
frequency were recorded at baseline as well. Each participant
was categorized by weight at baseline. A BMI of <25 was categorized as normal weight (NW), _>25 but _<30 was overweight
(OW) and _>30 was obese (OB). Incidence of OW/OB was
defined as the percentage of originally NW participants who
entered the OW/OB category by follow-up.

1997), who have conducted studies attempting to find a reason
for this phenomenon, have seen increased hunger, appetite, and
food consumption as a result of AS users. However, reviews
written by Rolls

Results of the study show a strong dose-response relationship
between AS beverage consumption and change in BMI. In Cohort
1 AS users had a 78% greater change in BMI than non-users and
Cohort 2 experienced 74% and 83% greater change in BMIs
in quartiles 3 and 4 respectively. The change in BMI followed a
consistent pattern within the user subset. The more artificially sweetened beverages consumed per week the greater the
change in BMI. Less than 3 ASBs consumed per week resulted
in an average change of 1.2 kg/m2 while 22+ ASB per week
resulted in 2.0 kg/m2 change and up. Participants who started
out as users then chose to discontinue use experienced 58%
lower BMIs than those who continued use. Once gender, ethnicity, weight category at baseline, diabetes, dieting status, exercise
and cohort were factored in, change in BMIs were 47% higher
in artificial sweetener users than non-users, suggesting greater
gains, or smaller loses, for users versus non-users. Limitations of
the study include a lack of sweetener specific study ability, fruit
juices were not included, neither were artificial sweeteners consumed in products including food, other beverages, cosmetics
and pharmaceuticals (which can contain aspartame) (Theodore,
2006).

When researchers saw the incongruent results of these studies
they chose to conduct a study of their own. In a 10-week study
they tried to prove their claim that “short term studies are not
very informative because appetite regulation and macronutrient balance probably do not correct for the missing energy and
sucrose until the individual has consumed the diet for several
days” (Raben et al, 2002). Their results, however, proved their
hypothesis wrong. For 10 weeks overweight individuals were
placed into either a sucrose group or an artificial sweetener
group. The study found no increased hunger or appetite in the
AS group compared to the sucrose group, and weight gain was
observed in the sucrose group while weight loss occurred in the
artificial sweetener group.

The San Antonio Heart Study is far from the only one performed on this topic. Many studies have lead to the same
conclusion showing a relationship between artificial sweetener consumption and weight gain. The list is never ending. The
American Cancer Society Study (Stellman, Garfunkel, 1986),
which focused on 78,694 women, was conducted in the early
1980’s. At a one-year follow-up 2.7 compared to 7.1% more
AS users gained weight than non-users. The average difference
in the amount gained was just shy of two pounds, nevertheless
it was statistically significant. A third well known study was the
Nurse’s Health Study (Colditz et al, 1990) conducted between
the years of 1976 and 1984. In this study 8 year weight gain was
associated with saccharin use in 31,940 women.
Researchers such as Blundell (Blundell, Hill, 1986), Rogers
(Rogers et al, 1988)(Rogers, Blundell, 1989), Tordoff (Tordoff,
Alleva, 1990)(Tordoff, Friedman, 1989), and Lavin (Lavin et al,
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91991) and Malik et al, (2006), which consist of multiple short
term studies, have seen either no weight gain, or even increased
weight loss in users. A meta analysis of nine interventional studies summarized by De La Hunty (De La Hunty et al, 2006) saw
significantly greater weight loss in aspartame users versus non
users.

The lack of consistent results in these studies can obviously
be due to the human components. The controlled short term
studies consisted much more of restricting diets and exercise
regiments. The long-term studies, spanning multiple years, thus
allowing natural eating habits and appetites to develop, were
more likely to see increased BMI amongst artificial sweetener
users. There is a possibility that those using AS are those who
are more susceptible to weight gain, and therefore, we see these
results. But research doesn’t stop with speculation. Scientists
are now trying to understand how non-caloric sweeteners
could lead to weight gain.

Biological Response to Sweet Taste
Natural Sugars:
Many different explanations have been suggested as to why artificial sweeteners would cause an increase in weight. The first is
the suggestion of increased appetite or lack of appetite suppression. As stated previously, AS use has been continuously linked
to hunger and overeating. The debate lies in how sweeteners
can cause these biological reactions. In order to understand the
specific way in which the body reacts with artificial sweeteners
we must first understand how the body acts with natural sugars.
There are 2 pathways of glucose absorption (Mace et al, 2007).
One is active transport through the Na+ glucose co-transporter
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SGLT1. This pathway reacts only with glucose and is thus unaffected by artificial sweeteners. The second route is known as
the apical GLUT2 pathway. This pathway reacts at high concentrations of glucose and can have 3 to 5 times more rapid and
precise absorption than the classic SGLT1. The GLUT2 route
is mediated by Ca2+. Depolarization of the apical membrane
through glucose transport via SGLT1 allows Ca2+ to enter the
L-type channel Cav1.3, this causes the terminal web to contract.
This is essential for insertion. Little insertion occurs at low concentrations of glucose, in which case the SGLT1 transporter
dominates. However, at 30 mM (millimoles) of glucose or more
the GLUT2 pathway takes over as the main absorption pathway
for unknown reasons.
The calcium concentration goes up as a result of the G- protein coupling receptor, α-gustducin, activated phospholipase c
β2- dependent pathway. The GCPR is coupled with the T1R2
and T1R3 sweet taste receptor heterodimer. When these receptors, found in both lingual cells on the tongue and intestinal
brush cells in the duodenum, sense sweet taste they release the
α-gustducin and set this reaction in motion.
The α-gustducin also induces the secretion of glucagon-like
peptide (GLP)-1 and peptide YY from enteroendocrine L-cells
(Ford et al, 2011). Both GLP-1 and PYY have been observed
to be satiety factors in humans (Flint et al, 1998, Gutzwiller et
al, 1999). GLP-1 is known to raise insulin sensitivity as well as
increase leptin levels in the hypothalamus, thus increasing satiety in the brain. The sweet taste path continues eventually terminating in the insula/frontal operculum and the orbitofrontal
cortex (Small, 2006). The mesolimbic system sends the feeling
of satisfaction received for the good taste (Stice et al, 2008).
The metabolic products of the ingested foods determine this
post-ingestive effect. Therefore, when sugar, enters the body it
stimulates the sweet taste receptors, which activate both the
absorption pathway and the satiety pathway, providing both an
energy source for the body and a reward for the brain. The
combination of these factors means the person is no longer in
search for food; he is satisfied.

Biological Response to Sweet Taste
Artificial Sweeteners:
In 2010, Ford and Peters conducted an experiment to determine if artificial sweeteners invoke this same response as sugar
does in the body (Ford et al, 2011). They conducted a signal
blind, randomized, crossover study in eight healthy volunteers
over a 4 day period. The volunteers consisted of seven females
and one male ages 22-27, all in the normal body weight range.
The subjects were randomly selected to receive one of four
solutions: 50ml of either water, sucralose, maltodextrin (a

non-sweet caloric substance, matched for the sweetness of sucralose in this experiment) or a modified sham-feeding protocol
of sucralose (used to study oral stimulation of sweet taste receptors in the mouth versus those in the gastro-intestinal tract).
The dose of sucralose used was based on the observed average
intake of sucralose per day. Observations were made on four
separate days with a minimum of three days left in between
each solution study. Participants initial blood work was taken
on arrival, they then ingested one of the first three solutions
followed by the MSF of the solution that they had swallowed.
Blood samples were taken -15 minutes and 0 minutes prior to
ingestion and then 15, 30, 45, 60, 90, and 120 min after ingestion.To analyze cephalic phase insulin response as well as GLP-1
release, samples were taken at 2, 4, 6, 8, and 10 minutes after
ingestion. Participants were asked to rate their appetites using
visual analogue scores for 120 minutes following ingestion, after
which time they sat down to a meal and their food intake was
noted.
Researchers found that there was no increase in appetite or
energy intake after the 2-hour waiting period, however, what
they found in the blood samples, is quite fascinating. The plasma
insulin and GLP-1 showed no significant change in the first 10
minutes and GLP-1 and PYY concentration were similar in all
groups. The stimulation of T1R receptors did not occur in the
case of sucralose ingestion. As a result GLP-1 and PYY were not
secreted and appetite suppression did not occur. Perhaps the
most interesting part is that in vitro sucralose did stimulate the
receptors and, as a result, the L-cell secretions of GLP-1 and
PYY occurred. The reason for this disparity is still unknown at
this point in time.
Though artificial sweeteners don’t stimulate these receptors on
their own, a study done on rat intestinal tracts was very informative as to the mechanism that is used. In this study on rat
intestinal tracts, it was demonstrated that, when combined with
a small amount of glucose, AS stimulate the GLUT2 response
in a similar way to that of large amounts of glucose (Mace et al,
2007). The rapid absorption of glucose through this pathway is
only first observed at a threshold value of 30 mM of glucose,
even then it is a minimal response. However, when 20 mM of
glucose were ingested in conjunction with just 1 mM of sucralose the rate of glucose absorption doubled (as compared to
just 20 mM of glucose). This effect was equivalent to the effect
of 75 mM of glucose ingestion.The rapid absorption may lead to
a feeling of satiety, but blood glucose levels sky rocket as a result
as well. High glucose levels will lead to fat production as a means
of conserving all the extra energy in the body. Therefore, trying
to save calories “part of the time” can actually have worse repercussions for weight gain and obesity than natural sugars can.
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In another study examining a connected response, Graaf et al,
studied the functional magnetic resonance images (fMRIs) of
subjects who had recently ingested glucose, water, maltodextrin,
or aspartame (Graaf et al, 2005). The objective of the study was
to examine the separate effects of energy content and sweet
taste on the hypothalamic responses, such as cephalic phase
insulin response, and ghrelin (the hunger hormone) response
suppression, which contribute to a sensation of satiety.

et al, 2008). And like other addictions a period of abstinence
can lead to a period of over indulgence. Avena et al. noted that
after a period in which rats were denied sucrose, an increase
in sucrose self-administration occurred (Avena et al, 2005),
quite similar to binge eating in humans. Applying this concept
to artificial sweetener use, one can assume that replacing sugar
with non-caloric sweeteners can actually result in an increase
in caloric intake.

Five participants were scanned for 37 minutes at a time on
4 separate days. The participants were healthy normal weight
males. A questionnaire was used to assess the general level
of health in their daily lifestyle. Solutions were randomly assigned to participants by picking lots the day before each visit.
The aspartame and maltodextrin solutions were matched for
sweetness to that of the glucose solution. The subjects didn’t
know which solution they were receiving. One blood sample
was taken before entering the fMRI machine, others were taken
once the subjects were inside. The first was taken -5 minutes
and -3 minutes before ingestion and then 1, 3, 5, 7, 10, 20, and
29 minutes after ingestion of the substance. Each subject’s hypothalamus was segmented into four regions. The regions of
interest (ROI) were the upper anterior hypothalamus (UAH)
and upper posterior hypothalamus (UPH) because these are the
regions known to respond to glucose (Smeets et al, 2005). At
each time slot the mean gray matter value of the hypothalamus
was calculated and compared to the 7-minute reference period
of each participant.

Gut Microbial Adaptation to Artificial
Sweeteners:

Results of the study show that glucose was the only one of the
four substances that resulted in a prolonged decrease in the hypothalamic hunger signal (ghrelin response). Neither the sweet
taste of aspartame alone, or the caloric intake of maltodextrin
alone elicited this same response. The results blood samples
showed that both glucose and maltodextin ingestion resulted
in a cephalic phase insulin response and 6increased blood glucose levels. However, the glucose response was much stronger.
Increased glucose levels result in leptin release, which is itself
associated with a decrease in ghrelin signals, ultimately giving
the person a feeling of satiety. Aspartame and water had no
such effects. In a similar study, saccharin was tested in place of
aspartame, the saccharin did not result in a CPIR either (Teff et
al, 1995).
What these studies suggest is that artificial sweeteners do not
send the same signals to our brain as real sugars. As a result one
doesn’t feel satisfied or rewarded after eating. In the absence
of these biological reactions there is typically an increase in fat
and protein calorie intake (Benton, 2005, Beaton et al, 1992). It
has also been noted that the reward system for food shares the
behavioral paradigm with all different forms of addiction (Avena
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In the early 1980’s it was suggested that there might be a link
between the commensal flora of the gut and obesity. This suggestion came about when a noted change occurred in the gut
microbiota composition after weight loss (Bjorneklett et al,
1981). In 2005 a well known study stated that obesity can result
from a higher Firmicutes : Bacteroidetes ratio (Ley et al, 2005),
further studies found that there is definitely an altered biome
in the GI tract of obese people (Payne, er al., 2012). The debate on this topic is a cause or consequence question. Is it that
individuals who have altered gut microbes become obese, or
does the micro-biome only change once the person is already
obese? Payne suggests that the cycle begins by not eating properly, thereby destroying the natural gut environment. The new
ecosystem reacts differently to the substances that enter the
system; this behavior can contribute to obesity.
Payne says that our non-diverse “fructose-and sugar substitute-laden, plant polysaccharide- poor Western diets” force the
microbiota to adapt to the new and unknown substrates such
as artificial sweeteners while being bombarded by familiar substances like fructose. These conditions force the environment
to adapt, changing structure, enzyme production and patterns
of energy absorption. This survival mechanism, called adaptive
metabolism, was demonstrated in rat and pig models for Dtagatose fermentation (Laerke et al, 2000). At the same time
that this diet creates new adaptive forms of bacteria, the normal
diversity that exists begins to diminish. The link between obesity and a lack of diversity of gut microbiota is widely accepted
(Turnbaugh et al, 2008; Ley et al, 2005; Turnbaugh et al, 2006).
Turnbaugh et al’s. study suggests that the typical western diet
promotes growth of Firmicutes while it depletes Bacteroidetes
contributing to the unhealthy ratio. Bacteriodetes are the ones
most well equipped for the digestion of starch and sucrose.
This newly formed ecosystem evolved in order to promote
efficient energy extraction. While the body can only absorb as
much energy as was ingested, increased exposure to unknown
substrates can put the body into panic mode. As a result of
over exposure to unfamiliar substances the bacteria react by acquiring supplementary metabolic energy sources. For example

Artificial Sweeteners and Weight Gain

short chain fatty acids (SCFAs) taken up by the intestine can be
converted to energy via the Krebs cycle (Leng et al, 1963). The
idea of efficient energy extractions has been observed in obese
individuals (Turnbaugh et al, 2006).The extra absorption creates
more energy; energy that is unnecessary. The extra energy then
has to be stored as adipose tissue, over time this can lead to a
build-up and cause someone to become overweight and possibly obese.

Resting Metabolic Rate Adaptation to Artificial
Sweeteners:
The resting metabolic rate (RMR) of a person’s body has a large
effect on total energy expenditure (Ravussin et al, 1982) and
low RMR (calculated by using fat-free mass as a reference point)
puts them at a greater risk of obesity (Ravussin et al, 1988). In a
study done by Kiortsis et al, obese children were put on a calorie restricting diet for six weeks (Kiortsis et al, 1998). After the
six week period, weight loss occurred and lower BMI and FFM
were calculated. RMR at this time averaged around 10.1% lower
than the starting metabolic rate. As RMR went down so did the
Serum tri-iodothyronine (Serum T3) levels. A correlation is not
well understood but this may be an adaptive response attempting to conserve energy during a period of caloric deprivation.
The data gathered in this study can be applied to this discussion.
Artificial sweetener use is a form of calorie reduction. When
depriving the body of proper energy sources the RMR decreases. When a person goes back to eating the way they did before
the calorie withdrawal period, their new, lower RMR will not
be able monitor proper energy expenditure. The low metabolic
rate also greatly increases an individual’s risk of obesity, so the
short term weight loss may not be all that successful.

or low carb form. Studies show that these labels can distort
a person’s perception of serving size, and calories per serving
(Wansink, Chandon, 2006). These assumptions then mold his or
her anticipated pleasure, from the taste of the food, and/or guilt,
from the calorie intake, that they will feel for consuming this
product.The guilt experienced by consumers is a product of the
conflict of interest that goes on in their heads. On the one hand
they want the pleasure for the taste of the food, on the other
they know the long-term health risks of eating unhealthy foods.
These factors combined then determine how much the person will actually eat. When the guilt is decreased or completely
erased from the equation, consumers make decisions that are
extremely detrimental to their health.
A study was performed to see if this theoretical phenomenon
proved to be real. It took place at a university open house to
allow for diversity, 361 participants were included in the study.
Upon arrival participants were brought to one of two bowls
of regular M&M’s. The first bowl was labels “Regular M&M’s”
while the second was labeled “Low-Fat M&M’s”.The participants
were told to serve themselves what they thought was an average serving size, and their bowls were weighed. They were
then asked to estimate how many calories they believed were in
their serving size.After eating their M&M’s the participants were
asked how guilty they felt for eating them.

“The Sweetening of the World’s Diet” (Popkin,
Neilsen 2003)

The results of the study show that low-fat labels can be extremely hazardous. Participants ate 28.4% more M&M’s when
they were labeled “low-fat”, their perceived serving size was
25.1% greater and their calorie estimates were nearly 300 calories lower as compared to regular M&M’s. All participants felt
guiltier for eating the regular M&M’s than for eating the lowfat ones, however, overweight individuals felt less guilty about it
than the normal weight individuals. The overweight individuals
actually said they felt no guilt at all for eating the low-fat M&M’s.

The Sweeteners that have been approved by the FDA are intensely sweet. So much so that very little has to be used to
achieve the sweetness of sucrose. Sweetners, from aspartame,
which is 180 times sweeter than sucrose, to neotame, which can
be 7,000 to 13,000 times sweeter, have desensitized the present
day palate.We are so used to products with this uber sweetness
that companies that use real sugars are forced to manipulate
their products so our trained palates recognize them as sweet.
This extreme use of sugar in such large quantities is not healthy
for anyone and, of course, contributes to the obesity epidemic.

The larger problem that this presents is that low-fat does not
necessarily mean low calorie. In a survey done on 17 brands that
sold a regular and low fat version of the same product, it was
determined that though low-fat products had, on average, 59%
less fat than the regular products, they only had 15% less calories. Applying these statistics to the previous study outcomes
would mean that though consumers had 48% less fat (based
on the average lower fat percentage of low fat products) they
would have had 9% more calories.

“Low- Fat” Syndrome:

Conclusion

As the prevalence of obesity rises and people become more and
more aware of the dangers of being over weight a new culture
has been born. Nearly every product known from chocolate
to pasta to alcohol can now be found in a low fat, sugar free,

This review was written as an attempt to understand the
correlation between artificial sweetener use and weight gain.
Multiple scientific and sociological/ psychological hypotheses
were studied. Each one can explain this surprising phenomenon.
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However, they don’t have to stand alone. Combined the multiple
hypothesis can tell the life story of an obese individual. It is a
vicious cycle that has no real beginning and it can start at any
point. But each leads to the next. If you begin at “The sweetening of the worlds diet” you can see an individual enjoying
himself with all his overly sugary snacks, because that is what
his palate has become accustomed to. Soon he notices his jeans
have gotten a little snug so he begins eating “low-fat” products
to reduce the guilt he feels for what he’s doing to himself. The
low-fat products, which contain artificial sweeteners, increase
his appetite because they do not stimulate his taste receptors
to provide a reward response in his brain. But, maybe this works
for him for a while and he drops a few pounds. By then resting
metabolic rate will have lowered putting him at a higher risk for
obesity. When he can’t deprive himself of sugar any longer he’ll
binge eat those calories that he’s been missing. The lower RMR
that was created can no longer handle these massive amounts
of sugar and cause fat storage to occur. All the while he’s been
destroying his gut microbe environment. Now, whatever he ingests his body searches for additional energy sources because
it fears the lack of sucrose will deplete its energy storage.
Combining this glucose intake with AS use also leads to stimulation of the GLUT2 pathway for rapid unnecessary absorption.
And so, more and more adipose tissue accumulates. Slowly, day
after day, year after year this cycle occurs. Soon he finds himself
obese, with metabolic syndrome, diabetes, and chronic heart
disease. Though further research is necessary to understand
how this affects different age groups, ethnicities, and genders,
this can occur. And it’s all a result of an attempt to create a
non-caloric, healthier sweetener.
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Abstract
There has been a worldwide increase in autism cases in the past few decades, but the cause of it is unclear. It has
been suggested that vaccines may be contributing to the rise in autism rates. One claim is that the MMR vaccine can
cause intestinal inflammation that may lead non-permeable peptides to be transferred to the brain where it will affect
neurodevelopment. This may lead to autism with symptoms of developmental regression and gastrointestinal problems.
Another major hypothesis that has received much attention is that a mercury-containing compound, thimerosal, found
in many vaccines, can have toxic effects on the central nervous system. By retrieving studies from databases such as
Ebsco, Proquest, and Pubmed found in the Touro College Library, this review investigates if there is any truth to these
claims. No evidence of a direct link between vaccines and an increase in autism cases have been found.
Introduction

Methods

There has been a worldwide increase in autism cases in the past
few decades, but the cause of it is unclear. It has been suggested
that vaccines may be contributing to the rise in autism rates.
One claim is that the MMR vaccine can cause intestinal inflammation that may lead non-permeable peptides to be transferred
to the brain where it will affect neurodevelopment. This may
lead to autism with symptoms of developmental regression
and gastrointestinal problems. Another major hypothesis that
has received much attention is that a mercury-containing compound, thimerosal, found in many vaccines, can have toxic effects
on the central nervous system. By retrieving studies from databases such as Ebsco, Proquest, and Pubmed found in the Touro
College Library, this review investigates if there is any truth to
these claims. No evidence of a direct link between vaccines and
an increase in autism cases have been found.

Information and research was obtained through databases such
as Ebsco, Proquest, and Pubmed. Access was provided by the
Touro College Library. Google Scholar was also used to find
research articles. Keywords like vaccines, autism, and thimerosal
were used to search for relevant material. In addition, references in these articles were retrieved and used as additional
sources for further research.

Introduction
Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder that impairs a child’s ability to interact and communicate
with others. It is commonly associated with certain behaviors
such as difficulty making conversation, delayed language acquisition, and poor motor skills. Autism seems to originate from
very early brain development. The most obvious symptoms of
the disorder, however, usually begin to show between the ages
of 2 and 3. (Autism Speaks, 2016) Autism diagnoses have greatly increased in the past few decades. According to statistics
from the U.S. Centers for Disease Control and Prevention, the
prevalence of autism in 1000 children was approximately 6.7 in
the year 2000 and 14.7 in 2010, a significant increase. (Data &
Statistics, 2015).The cause for this dramatic increase is unknown
and has been the subject of much investigation. It is believed
that genes play a role in an increasing risk for autism (Mascarelli,
2010). However, environmental factors play a part in most cases
of autism too. There has been a growing concern of a possible
link between vaccines and autism. Two separate theories have
been proposed over the years. One is that the Measles-MumpsRubella (MMR) vaccine causes autism. The other is that thimerosal, a mercury containing preservative found in many vaccines
can lead to damage in the brain. Researchers have sought to
discover if there is any truth to these claims.
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Discussion
MMR Vaccine
In 1968 a link was suggested between the Mumps, Measles, and
Rubella (MMR) vaccine and the onset of ASD. Unusual bowel
symptoms were described among 12 children who showed developmental regression like losing acquired skills despite previous normal progress. Eight out of the twelve children who had
gastrointestinal signs had reported their first symptoms of autism within a month of receiving the MMR immunization. It was
concluded that the MMR vaccine caused intestinal inflammation
allowing usually non-permeable peptides to be translocated to
the bloodstream and ultimately to the brain, where they affected development. (Wakefield, et al. 1998) Although the sample
was small with only a dozen children and the results were never
replicated, the study received lots of attention from the public, and served as the foundation for much controversy in the
years to come. Parent’s anecdotes of their own personal experiences were enough for many to keep this alive. As a result,
many refused to vaccinate their children worrying about their
safety, and outbreaks of vaccine preventable diseases began reappearing in certain areas. The MMR-autism controversy was
responsible for a significant decrease in immunizations following
that year. The MMR immunization rates in the United Kingdom
dropped from 90% in 1988, when they were first introduced,
to 80% in 2004, after the article had been read by the public.
(Kolodziejski, 2014)

Possible Developmental Regression and
Gastrointestinal Symptoms Associated with MMR
Whether MMR is really associated with autism has been under
constant debate. There have been many studies done to see if
the link exists. Fombonne and Chakrabarti (2001) tested out
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the hypothesis that a form of autism existed involving developmental regression and gastrointestinal symptoms caused by
the MMR vaccine. It was proposed that if one or more of the
following predictions were proved by the data collected, the hypothesis could be validated. The first prediction was that childhood disintegrative disorder (CDD) had become more common. Another is that the average age of first parental concern
in autistic children in those who received the MMR vaccine is
closer to the mean age of immunization than in those who were
not vaccinated with MMR. The third prediction was that developmental regression in those who are vaccinated with MMR
had become more frequent. If the age of onset of autism with
regression is closer to MMR-vaccination as opposed to those
who did have autism without regression, it could also prove
that MMR could have caused autism. Another prediction is that
those with regressive autism have different symptoms. Finally,
those with regressive autism would have gastrointestinal signs
and/or inflammatory bowel disorder.
Three samples, 1 epidemiological (n=96) and 2 clinical samples, a pre-MMR (n=68) and a post-MMR (n=98) were used
to gather information. In order to assess age of first onset of
autistic signs, the parents were asked how old their child was
when they first became concerned with his/her development.
Regression was noted when a loss of skill, such as language
was confirmed based on certain criteria. Assessment of bowel
symptoms was done by retrieving data from both the parents
and pediatrician.
The first prediction of childhood disintegrative disorder (CDD)
increasing was not supported by the data as only one boy met
the criterion for CDD, which seems likely to have originated
from brain pathology before the MMR immunization was even
given. In this epidemiological sample where nearly all the children were vaccinated, it can be assumed that CDD is not increased with vaccine exposure. Second, there was no difference
in age of first parental concern in two of the samples exposed to
MMR (19.3 and 19.2) compared to the pre-MMR clinical sample
(19.5). Third, the rate of regression for the post-MMR sample
(15.6%) was lower than the rate in the pre-MMR sample (18.4%).
This rules out MMR-induced regressive autism as a cause for
the dramatic increase in autism cases. In the epidemiologic
sample, 18.8% had gastrointestinal symptoms. Constipation was
the most common symptom (9.4%), and no inflammatory bowel
disorder was reported. Only 2.1% of the sample experienced
both developmental regression and gastrointestinal symptoms,
a rate which shows no association between the two. None of
the 6 predictions were supported in this study, and no evidence
was found to show a distinct syndrome of MMR-induced autism.
(Fombonne E, Chakrabarti S, 2001).

Measles Virus RNA in Patients with Autism
There are studies that have reported Measles Virus (MV) RNA
in bowel biopsies in autistic children, showing a possible link
between intestinal inflammation and the measles virus. A study
done by Kawashima et al (2000), examined children with gastrointestinal problems to see if they have the measles virus and if
they did, if it derived from wild strains or vaccine strains. Eight
of the patients had Crohn’s disease, 3 had ulcerative colitis, and
9 had autistic enterocolitis. One of the patients with Crohn’s
disease, 1 with ulcerative colitis, and 3 of 9 with autism were
positive for the virus, while the controls were all negative. The
measles virus found in the patient with Crohn’s disease proved
to have characteristics of wild-strain virus, while the one with
ulcerative colitis and in the autistic patients had vaccine strains.
A study including 125 autistic children and 92 control children.
MMR antibodies were first measured by ELISA in sera of 24
randomly selected autistic children, 16 normal children, and 14
children with other developmental problems. Autistic children
had a higher number of MMR antibodies compared to the other
children. Soon after all of the 217 children were checked for
MMR antibodies by immunoblotting assay for serum screening.
They found that 75 (n=125) autistic children’s sera were positive
for an unusual MMR antibody, whereas none of the control sera
had the antibody. A protein band was detected in the antibody
which was immunopositive for measles HA protein but not for
measles nucleoprotein and rubella or mumps viral proteins. The
results showed that autistic sera detected measles HA protein
in the MMR antibody. It is suggested that an inappropriate antibody response to MMR might be related to the development of
autism. (Singh, et al, 2002)
However, despite those few studies, many studies have been
done that disprove the link between autism and MMR including
a few that failed to detect MV-RNA in cases of autism. A case
control study tested for the presence of measles virus (MV)
RNA in bowel tissue in children with ASD. The purpose was to
see if those with GI disturbances and autism are more likely to
have MV RNA in their bowel tissue than those with GI symptoms but no autism. This can determine if MMR is linked to this
type of autism. The ileal and cecal tissues of 25 children with GI
disturbances and autism and 13 children with GI disturbances
but no autism were analyzed for MV RNA in 3 different laboratories. The timing of the autistic and gastrointestinal symptoms
in respect to MMR immunization was also documented. The
results showed no difference in MV RNA findings in the case
group and the control group. The timing of the vaccine in regards to the GI symptoms and autism onset were inconsistent
with the theory that MMR triggers either the GI symptoms or
autism. (Hornig, et al, 2008)
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A 14 year prospective study reviewed the number of vaccines
that were given from the time The National Board of Health
and National Public Health Institute launched their MMR vaccination program in 1982 till the year 1996. 3 million vaccines
were given during that period of time and 31 cases of gastrointestinal symptoms were reported after vaccination, ranging
from 20 hours to 15 days. Fifty five percent (n=17) had symptoms of diarrhea and vomiting, 23% (n=7) had gingivostomatitis,
16% (n=5) had vomiting only, and (n=2) had abdominal pains.
The symptoms usually lasted about a week. None of the children developed autism. In this study, no association was found
between MMR and pervasive developmental disorder or inflammatory bowel disease. (Peltola et al, 1998)

Figure 1

Epidemiological Studies
Numerous epidemiologic studies have been done to see if there
is an association between MMR and autism. Taylor, et al (1999)
did a chart review of cases of autism diagnosed in a region in
England, in children born between 1979-1992. They identified
498 cases of ASDs in the population, of which only 293 could
be confirmed according to ICD-10 criteria. They analyzed the
data in different ways to test if autism was related to the MMR
vaccination. Data they collected included the age at which the
children were diagnosed, the age of first parental concern, and
age when regression became obvious. The trend of autism
was examined to see whether or not there had been a sudden
step-up in autism diagnoses in children who received the MMR
vaccine after it was introduced in England in 1988. They found
that the prevalence rates of autism began an exponential rise
starting with children born a couple of years before the introduction of the MMR vaccine, and that there had been no sudden
step-up after 1988. They concluded that this refuted a temporal
relationship.
A study done in California collected data regarding MMR coverage rates and age at the time of immunization for children
born between the years 1980-1994 from school immunization
records in California Kindergartens. The number of cases of
autism diagnosed during those years were retrieved from the
California Department of Developmental Services where they
were enrolled. The results did not show a correlation between
rates of autism and number of immunizations given. As can
be seen by Figure 1, autism cases increased from 44 cases per
100,000 live births in the 1980 cohort to 208 cases per 100,000
live birth in the 1994 cohort, a 393% increase. In contrast, MMR
immunization rates by the age of 24 months increased from
72% to 82%, only a 10% increase. Since the rate of increasing
autism cases does not compare with the only small rise in MMR
coverage, a correlation was not observed between the two.
(Dales, et al, 2001)
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Percentage of Children Receiving Measles-Mumps-Rubella (MMR)
Immunization in Second Year of Life and Caseload of Children With
Autism, by Year of Birth, California, 1980-1994 (Dales, et al, 2001)
A population study was done in Japan by Honda, et al (2005). It
examined incidence of ASD in children born from 1988-1996.
Japan’s MMR immunization program was launched in 1989 but
ended in 1993, due to suspected side effects of the mumps vaccine. This allowed for an opportunity to research the effect
of removing the MMR vaccine which was believed to cause a
rise in autism. If it was really the cause of the increased autism
caseloads when it was introduced, autism would drop after the
risk factor (MMR vaccine) was withdrawn. All children who had
been diagnosed with ASD were selected from a patient list of
the YRC Developmental Psychiatry Unit, which offers diagnostic
and intervention services to all those with ASD. The annual
trends for both typical autism and all other categories of ASD
were examined. According to the statistics, MMR vaccination
rates were 69.8%, 42.9%, 33.6%, 24.0%, and 1.8% respectively
in the years 1989-1993. As can be seen by this data, the rate
decreased significantly during these years, with only a bare minimum of 1.8% of children vaccinated with MMR in the year 1993.
The annual trends of ASD were compiled for the years 19881996. The ASD incidence rates ranged from 47.6 per 10000 in
1988 to 117.2 per 10000 in those that were born in 1996. The
rate of autism incidences continued to rise even after the MMR
vaccination program was terminated. This provides evidence
that it is highly unlikely that MMR is linked to greater autism
incidences. (Table 1) (Honda, et al, 2005)
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Table 1

Thimerosal
Since the 1930s, thimerosal, a mercury-containing preservative
has been used in many biological and drug products, including
multi-dose vaccines, to prevent bacterial and fungal contamination
Thimerosal is not found in live vaccines, such as MMR because of
the damaging interaction they can have with the active substance.
Before 1991, diphtheria-tetanus-pertussis (DTaP) vaccination was
the only common vaccine that contained thimerosal. Recently
though, more vaccines have been introduced that consist of thimerosal like Hepatitis B and HIB. (Nelson, Bauman, 2003) Too
much mercury can have toxic effects especially in little children,
where the brain is still developing. As can be seen by Table 2,
the FDA estimated that 6-month old babies could have received
doses of mercury as high as 187.5 µg in their vaccines and 2 year
olds as much as 237.5 µg. (Freed, et al, 2002)

Table 2

Because of the increasing amount of this chemical that babies
were being exposed to, there was a growing concern that the
ethylmercury which is found in thimerosal can cause brain damage and contribute to autism. Fearing this, the FDA removed
thimerosal from all vaccines in 1999 even though direct evidence of harm was not found. Since not much was not known
about ethylmercury at that point in time, assumptions were
made based on knowledge of methylmercury. Methylmercury
was known to have toxic effects and many assumed that

ethylmercury has similar consequences.
Since ethylmercury had not been extensively studied, researchers began to experiment with ethylmercury to see if it
can really have those damaging effects in
vaccines. (Straton, 2001)
Research was done by analyzing the
VAERS database, a database maintained by
the CDC which holds a record of all adverse reactions. The VAERS database was
used to compare the neurodevelopmental
disorders that were found following the administration of thimerosal-containing DTaP vaccines in contrast to thimerosal-free
DTaP vaccines. A close linear correlation was found between increasing mercury due to thimerosal vaccines and an increase in
the odds ratio of neurodevelopmental disorders. According to
the results in the baseline year of 1984, the odds ratio of autism
increased by 0.029 per mg of mercury, personality disorders by
0.012 per mg of mercury, and mental retardation by 0.048 per
mg of mercury. The total odds of developing autism increased in
those immunized with thimerosal-containing vaccines vs those
who received thimerosal-free vaccines. This study showed that
more research had to be done to see if there is indeed a correlation between mercury levels and higher risks of autism and
other developmental disorders. (Geier et al, 2003)
A study done used hair and urine analysis to detect heavy metal
exposure in those with autism compared to those who did not
have autism. It consisted of 25 autistic children and 25 controls. Metal testing was performed via ICP-MS spectroscopy
utilizing cell technique to detect levels of different metals in the
hair. The mean mercury level in the hair of autistic children was
0.47±0.42 while the levels in the control children was a lower
mean of 0.30±0.3. A similar observation was found of the mercury levels in the urine of autistic children compared to control
children, with means of 2.48±2, and 1.10±0, respectively. These
results seem to show an association between higher levels of
mercury in those with autism. Limitations in the amount of
mercury they ingest seems to be important for the safety of
these children. However, a larger sample size should be studied
on in order to validate these findings. (Blaurock-Busch, 2011)
A study was done by Pichichero et al, (2002) to measure the
concentration of mercury found in infants’ stool, blood, and
urine after they received vaccines. If high levels were found, it
would show that thimerosal can be potentially harmful in vaccines. In this experiment, 40 infants who were 6 months or
younger received thimerosal containing vaccines while 21 controls received thimerosal free vaccines. Samples of the infants’
stool, blood, and urine were obtained 3-28 days after and were
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tested for mercury levels. Blood samples contained low levels
of mercury with a range of 4.50-20.55 nmol/L. Fourteen out of
15 controls did not have quantifiable levels of mercury. Those
with the highest levels of mercury were infants who were measured soon after they were vaccinated. There was no mercury
found in urine samples, besides for one of the 2-month olds
and three of the 6-month olds who had received thimerosal
in their vaccines. The highest amount of mercury in the urine
was 6.45 nmol/L. No mercury was found in any of the control
infants. Detectable amounts of mercury were found in stool
samples in those who were exposed to thimerosal containing
vaccines. Those who did received thimerosal free vaccines were
not measured for mercury levels in their stool. (Table 3)

Figure 2

Table 3
can accumulate and get converted to inorganic mercury which
can cause neurodevelopmental damage. Ethylmercury, however,
which is found in thimerosal is rapidly eliminated through the
stool which prevents toxicity from accumulating that could be
detrimental to parts of the body including the brain. (Pichichero,
et al, 2002)

To determine if dietary intake could contribute to mercury
levels in the stool, samples were obtained from 9 infants who
were age-matched to those who received thimerosal containing
vaccines but were not exposed to thimerosal themselves. The
mean levels of mercury in these samples was 22 ng/g which
was considerably lower than those exposed to thimerosal. Out
of all these samples, however, no concentration exceeded 29
nmol/L which is known to be an accepted safe value. The results
did show an increased amount of mercury in those who were
vaccinated compared to those who did not receive thimerosal,
but the quantity was still below the harmful level. Before the
samples were measured, a prediction model was made of the
expected measurements of mercury corresponding to the possible half-life days ranging from 1-45. The best estimate of the
half-life of ethylmercury would be the difference between the
predicted value and the observed value.
The concentration of mercury in the blood not long after vaccination suggests that the half-life of ethylmercury is not nearly
as long as the half-life of methylmercury. As we can see from
Figure 2, the estimated half-life for ethylmercury was 7 days.
This contrasts with the half-life of around 40-50 days in methylmercury. The long half-life of methylmercury can allow the
organic-mercury to cross over the blood brain barrier where it
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Since creating controlled experiments is not possible in an existing vaccination program, determining if there is an association
between thimerosal and autism is not so simple. Several epidemiological studies have been done to see if there is a causal
relationship between receiving thimerosal containing vaccines
and an increase in autism cases. A population cohort study of
children in Denmark who were born in the years 1990-1996
was done to compare children who received thimerosal in their
vaccines and those who did not. Doses that were administered before 1992 were considered to be vaccines containing
thimerosal and those doses given after 1992 were thimerosal
free vaccines. Information regarding vaccine administrations
was obtained from the Danish Board of Health and data regarding autism diagnoses was retrieved from the Danish Psychiatric
Central Register. Follow ups were done from one year of age
till the year 2000 to see if there would be possible cases of autism disorders in those children. During these years, 440 cases
of autism and 787 cases of other autistic-spectrum disorders
were diagnosed among those children (table 4).

Table 4
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We can see from the results shown in table 4, that when comparing those who received at least one dose of thimerosal-containing vaccine and those who only received thimerosal-free
vaccinations there was a rate ratio of 0.85% for autism and
1.12% for other autistic spectrum disorders. Also, there was
no association between a higher dose of thimerosal-containing vaccine and a higher rate of autism disorders. The increase
in rate ratio per 25 ug of mercury was 0.98% in autism and
1.03% in other autistic spectrum disorders. In order to rule out
the possibility that some thimerosal-containing vaccines were
administered soon after 1992, the vaccinations between June
and December of 1992 were omitted from the data and similar
results were found. This study showed no association between
thimerosal intake and increased autism rates. (Hviid, et al, 2003)
In the United Kingdom, the only thimerosal containing vaccines
that have been administered in the past few decades is DTaP
and DT. The total amount of thimerosal per dose in these vaccines is 50 ug (25 ug of ethylmercury). In the United Kingdom,
the schedule for vaccination called for 3 doses by the age of 4
months, totaling 150 ug of thimerosal at that age. Data regarding
date of birth and vaccination dates were obtained for 109,863
children who were born from 1988 to 1997. Some children
were excluded from the study including those who had certain
medical conditions before the age of 6 months and those who
had received the Hep B or flu vaccination before 6 months of
age. Hg exposure was calculated based on the number of vaccine doses the children received. A number of developmental
disorders were investigated and the number of cases diagnosed,
the mean age of diagnoses, and the percentage that was male
was assessed. When these children were linked to the dates of
their vaccination and any of the neurodevelopmental disorders
they had, no evidence of increasing neurodevelopmental disorder rate was found with an increasing dose of ethylmercury.
The only disorder that showed a possible link to thimerosal was
tics, which had a hazard rate of 1.50 in 4 months of age. The rest
of the disorders had a Hazard rate close to 1, showing no link to
thimerosal. (Andrews, et al, 2004)
Another study was done in Sweden and Denmark to compare
the prevalence of autism cases with the exposure of thimerosal-containing vaccines during the 1980s and 1990s. Data regarding vaccine coverage and autism cases were collected in
these countries. The total amount of ethylmercury exposure
was calculated by multiplying the amount of thimerosal in vaccines by the number of vaccines with thimerosal administered
during that time period. The rate of autism was calculated by dividing the total number of autism cases diagnosed in those years
by the number of person-years accumulated during those years.
As shown in figure 3a, the incidences of autism in Sweden began

Figure 3a

Figure 3b

to rise in the year 1985 to a rate of around 6 per 100,000
person-years and peaked in the year 1993 to a rate of 9.2 per
100,000 person-years. The coverage of thimerosal-containing
vaccines, however, have remained steady over most of those
years, decreasing over time and eventually being completely
removed in 1993. A similar explanation goes for Denmark,
shown in figure 3b. Thimerosal-containing vaccination coverage
remained constant throughout the years 1981-1991 and ended
in 1992, but autism rates continued to increase sharply in the
years after that. We can see from these studies that the rise of
autism needs a better explanation than the exposure of thimerosal to children.

Conclusion
From the studies that have been done so far, no evidence
has been found to show a link between vaccines and autism.
Increasing autism rates need to have another explanation. It
has been suggested that the broadening of the diagnosis, and the
greater awareness of autism and other ASDs have contributed
to more diagnoses of autism. The claim that MMR is associated
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with a regressive form of autism has been proven to be highly
unlikely. The fact that MMR vaccination withdrawal did not lead
to a decrease in autism cases indicated that there is not any correlation between the two.The concern that thimerosal-containing vaccines cause autism has also not been validated. However,
despite the shorter half-life and less damage that ethylmercury
can have in comparison to other mercury compounds like
methylmercury, the current literature does not rule out a role
for thimerosal in neurodevelopmental damage other than autism to children. Therefore, it is best that thimerosal continue
to remain excluded from vaccines.
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Abstract
Cow’s milk has been part of the human diet for at least 8,000 years and provides a rich source of proteins, lipids, vitamins, and minerals. Despite its longstanding importance in human nutrition, questions remain about how compatible
cow’s milk is with our immune system. Cow’s milk allergy (CMA) is the most common form of food allergy in infants and
children and cow’s milk has been implicated in a number of immune-mediated disorders. Reviewing current research
obtained through Google Scholar and Touro’s library database on CMA and the potential role of cow’s milk in systemic
inflammation and autoimmunity reveals a tangle of contradictory findings and competing explanations. While current
research does not indicate a significant connection between cow’s milk and systemic inflammation in healthy adults or
to Rheumatoid Arthritis, it does provide significant, if contested evidence for the role of cow’s milk in Type 1 diabetes,
multiple sclerosis, and Behcet’s disease. These evolving findings must be considered when we evaluate the current
nutritional guidelines on cow’s milk.
Introduction
Cow’s Milk in the Human Diet:
Humans are the only animals known to consume the milk
of another species, a unique behavior that arose during the
Neolithic Revolution. The end of the Younger Dryas coincided
with a transformation of human subsistence patterns around
the world. Populations of hunter-gatherers became more sedentary and experimented with the domestication of plants and
animals. The first cattle were domesticated from wild aurochs
(Bos primigenius) over 10,000 years ago, in regions that are part
of present-day Turkey and Pakistan (McTavish et al. 2013). There
is disagreement about when cattle were first exploited for milk
production. The “secondary products revolution” theory, popular during the 1980s and 1990s, held that Neolithic people
did not consume dairy products until the fourth millennium
BCE, despite much earlier advances in domestication (Sherratt,
1983: Greenfield et al., 1988). Recent evidence has pushed that
date back as far as the 9th millennium BCE, when human beings
were still “stock-keeping hunter-cultivators” (Vigne and Helmer,
2007). Residue from pottery shards suggests that milk products
were widely consumed in Southwestern Asia and Southeastern
Europe by the seventh millennium BCE (Evershed et al. 2008).
Since it was first consumed during the Neolithic period, cow’s
milk has been an essential dietary staple for numerous populations around the globe and has developed an evolving cultural
significance. On the Indian subcontinent, cows have been revered for thousands of years and their milk is used for ritual
purification as well as nutrition (Simmons, 1974). Ancient Norse
mythology tells of how the first creature, Ymir, was sustained
by milk from the sacred cow Auðumbla (Haug, Høstmark, and
Harstad 2007). In Medieval Europe, cow’s milk was venerated as
a spiritual substance, embodying the divine rhythms of nature;
during the Renaissance it was celebrated for its taste and health
giving properties, with folk remedies citing it as a cure for everything from ulcers to epilepsy (Valenze, 2011). Milk consumption was transformed by two factors in the 19th century: an
improved - transportation system, which aided in the delivery
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of fresh milk from local farms to cities, and the development
of pasteurization, which helped curb the very serious problem
of milk-borne disease (Wilson, 1943: Atkins, 1978). These two
advances made cow’s milk more safe and convenient than ever
before and guaranteed its central place in the Western diet.
Today cow’s milk and dairy products are an almost ubiquitous
component of human nutrition, accounting for 14% of the caloric intake in developed countries (Bordoni et al., 2015). Global
milk production amounted to an estimated 784 million tons
in 2013, or 100 L of milk per year per person (Bordoni et al.,
2015). This massive consumption occurs despite the fact that a
substantial majority of the world’s adult population is deficient
in the lactase enzyme and may experience digestion issues with
dairy (Lomer et al. 2008).

The Economics of cow’s milk in the United
States:
Cow’s milk is a major economic commodity in the United
States.A 2002 survey estimated that the dairy industry accounts
for $140 billion in economic output, $29 billion in household
earnings, and more than 900,000 jobs (Cryan, 2004). The U.S.
Department of Agriculture estimates that domestic cow’s milk
production will reach a record 208.7 billion pounds in 2015
(“Dairy Farmers at the Barricades,” 2015).

Chemistry and Nutrition of Cow’s Milk:
Cow’s milk is complex mixture of lipids, proteins, bioactive peptides (e.g. immunoglobulin, cytokines, and enzymes), amino acids,
vitamins and minerals. The sugars (primarily lactose) and most
minerals are dissolved in solution, the lipids are emulsified in
globules, and the proteins are suspended in colloidal dispersions
(Huag et al. 2007). About 80% of the proteins in cow’s milk
are caseins, which form complexes with calcium and phosphate
(Huag et al. 2007). Although the composition of cow’s milk can
vary with the age, breed, nutrition, and stage of lactation of the
cow, on average, a cup of milk (244 grams) provides 146 calories,
7.9 grams of fat (4.6 saturated), 7.9 grams of protein, 276 milligrams of calcium, 349 milligrams of potassium, 222 milligrams
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of phosphorous, 249 IU of Vitamin A, and 97.6 IU of Vitamin D
(USDA, 2015). cow’s milk is an important dietary source of the
cis9, trans 11 isomer of conjugated linoleic acid and glutathione
(Huag et al., 2012).

Allergy, Autoimmunity, and the Hypothetical
Role of “Leaky Gut”
The human immune system is an enormously complex collection of structures and processes that protects the body against
harm by pathogens. Immunity operates at a number of levels.
The skin and mucosal membranes are the first line of protection, acting as a physical and chemical barrier to invaders. The
second level of defense is the innate immune system, in which
macrophages and neutrophils of the innate immune system
provide a robust, but non-specific defense against pathogens,
including the cytokine-mediated inflammatory response. Finally,
the adaptive immune system provides a targeted response to
specific pathogens. It is divided into humoral immunity, mediated
by B lymphocytes and their antibodies, and cell-mediated immunity, mediated by T lymphocytes. (Hall, 2016)
Allergy refers to an inappropriate immune response to a harmless substance. Most allergies are mediated by the IgE antibody,
which is secreted by B-cells in response to antigens binding
mast cells and basophils until a second exposure. Autoimmunity
refers to an immune response against the body’s own cells and
tissues. There are two classical models for the pathogenesis of
autoimmune disorders (Fasano, 2012). According to the “molecular mimicry” model, certain microbial antigens resemble
self-antigens to a degree that the immune system cross-reacts
with the latter and targets them for destruction. In the “bystander effect” model, microbes directly damage tissues, leading to
the exposure of internal self-antigens that the immune system
interprets as foreign. These two models are continuously being
expanded and revised with ongoing research and may represent
complementary descriptions of the multifaceted phenomenon
of autoimmunity. A third, more tentative hypothesis involving
the gut is presented below.
The role of the gut in immune disorders is a fascinating new
area of research. While we often think of the skin as great primary barrier of our immune system, the intestines are actually
the largest surface in the body, amounting to an area more than
200 times greater than the skin (Hollander 1999). Maintaining a
proper balance between immune tolerance and sensitivity over
this vast surface area is an exceedingly complicated task, and the
failure of such regulation is associated with allergy and various
forms of autoimmunity (Dejaco et al. 2006: Vitaliti et al. 2012).
cow’s milk is often the first foreign substance that an infant’s
gut will encounter and the first serious challenge to immune
homeostasis in the intestines. Some researchers have suggested

that there is a group of individuals who are especially prone
to immune complications from food antigens, due to excessive
permeability of the intestines and abnormal microbiota (Perrier,
C and Corthésy, 2010: Fasano 2012). These individuals, the theory goes, are not only at a greater risk for conventional food
allergies but may also find that various foods which are well
tolerated by the general populations contribute to immune dysfunction. While some promising research has been conducted
into the contributions of intestinal barrier dysfunction to immune-mediated disorders (De Kort, et al. 2011), and excessive
intestinal permeability is particularly well attested in the pathogenesis of celiac disease (Hollander, 1999), the general role of
“leaky gut” in autoimmunity remains ill-defined and controversial. While this paper does not intend to assess the validity of
this hypothesis, a growing body of research on diet, allergy, and
immune disorders suggests the need for an evolving paradigm
of the role of the gut in autoimmunity.

Purpose:
This paper will review current research on cow’s milk and the
human immune system. It will begin by exploring the prevalence, natural history, and immunopathogenesis of cow milk
allergies (CMA). It will then examine research on the possible
contributions of cow’s milk to systemic inflammation in people
without clinically defined CMA. Finally, it will assess the possible
link between the consumption of cow’s milk and a number of
immune-mediated disorders. All research into the role of cow’s
milk in non-immune-mediated disorders, including lactose intolerance, has been excluded. The discussion will examine the factors affecting research into the health of cow’s milk and assess
nutritional guidelines in light of current findings.

Methods
All research articles for this paper were obtained by searching
Google Scholar and Touro’s Library Database.

Literature Review
Definition, Prevalence, and Natural History of
Cow’s Milk Allergy (CMA):
Cow’s milk allergy (CMA) is an adverse immune reaction to one
or more components of cow’s milk. CMA is the most common
food allergy in infancy and childhood, occurring in in 2%-3%
of children in the developed world, (Ahrens et al., 2012). It is
typically classified into IgE-mediated allergies and non-IgE-mediated allergies; the former are more common and almost always
resolve during childhood and the latter persist in a small percentage of adults (Crittenden and Bennett, 2005). One study of
over 4,000 children with IgE-mediated CMA found total resolution to be 19% by age 4 years, 42% by age 8 years, 64% by
age 12 years, and 79% by 16 years (Skripak, et al., 2007). CMA
can cause a range of reactions, including diarrhea and vomiting,
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loss of blood into the intestines, respiratory tract infection, and
anaphylaxis (Freier and Kletter, 1970). A study of food allergies
in Britain during the 1990s found that CMA accounted for
greatest number of fatalities (Macdougall et al., 2002). Some of
the symptoms of CMA may initially be confused with lactose
intolerance or Hirschsprung’s disease (Kubota et al. 2006). In
order to make the diagnose a physician must observe “a definite
disappearance of symptoms after elimination of cow’s milk from
the diet, recurrence of identical symptoms after one cow’s milk
challenge, disappearance of symptoms after re-elimination of
cow’s milk, and exclusion of lactose intolerance and coincidental infections” (Sprikkelman et al. 2000).

Immunopathogenesis of CMA:
Research into the immunopathogenesis of CMA is ongoing and
its mechanisms are not fully understood. The major allergic
components of milk have been identified as four proteins in
the casein fraction (as1-, as2-, b-and k-casein) and two proteins in the whey family, although there is great heterogeneity
among the allergenic epitopes of these proteins (Ahrens et al.,
2012). The mechanisms of CMA are typically classified into IgEmediated and non-IgE-mediated.

already been implicated in Type-1 Diabetes (Lee et al., 2010: Zhu
and Paul, 2008). Another theory points to interactions between
T lymphocytes, mast cells, and neurons (Lee et al. 2010). Some
individuals with CMA demonstrate both IgE-mediated and
non-IgE-mediated reactions.
Research has implicated the dysfunction of Tregs, a subpopulation of T cells that modulate the immune system and maintain
tolerance to self-antigens in both IgE-mediated and non-IgE-mediated reactions. The body must maintain a delicate balance
between mucosal tolerance and hypersensitivity: too great a
tolerance will allow dangerous antigens to accumulate in the
body and too great a sensitivity will lead to indiscriminate
immunization against harmless foreign particles. Tregs help to
regulate this balance by secreting “tolerogenic cytokines” such
as TGF-beta 1 and IL-10. The resolution of CMA in children has
been associated with the development of Treg cells. For example, Karlsson et al. (2004) gave milk to 21 children who had been
following an elimination diet for at least two months and found
that those who had outgrown the allergy had higher levels of
circulating CD4(+)CD25(+) T cells.

Looking Beyond CMA:
IgE-mediated CMA occurs in two stages (Vitaliti et al. 2012:
Brandtzaeg 2001: Beyer et al. 2002). When an allergic child first
consumes cow’s milk, the immune system undergoes a process
of “sensibilization.” First, antigen-presenting cells (APCs) consume milk particles and display allergenic fragments on their
surfaces. Then 2 T helper (Th2) cells, which are insufficiently
regulated by the immune system in CMA, come into contact
with the allergen fragments and become activated.The Th2 cells
in turn activate B cells, which produce large amounts of antigen-specific IgE. IgE antibodies against cow’s milk proteins are
then secreted and bind to the surface of mast cells and basophiles. After this immune arsenal has been built up and the child
again consumes cow’s milk, the allergy moves to its “activation”
phase. IgE associated with mast cells bind allergenic epitopes on
milk proteins, triggering an intracellular cascade that culminates
in the release of histamine, platelet activating factor, and other
inflammatory mediators. Chatchatee et al. (2001) found that the
presence or absence of two binding regions IgE (AA 69-78 and
AA 173-194) can be used to predict whether an allergy will
resolve in early childhood or persist.
Although many cases of CMA involve an IgE-mediated mechanism there are also many cases that do not present circulating
IgE specific for cow’s milk proteins. The immunopathogenesis
of non-IgE- mediated CMA is more obscure and a number of
mechanisms have been proposed. One theory suggests the reaction is mediated by Th1 cells, host immunity effectors that
typically act against intracellular bacteria and protozoa and have
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The prevalence of CMA is well established and research has
increasingly shed light on its mechanisms, but what about the
impact of cow’s milk on the immune systems of people without
clinically defined CMA? In some quarters dairy has been accused of having “pro-inflammatory” properties and implicated
as a cause or aggravating factor in a number of immune-mediated conditions. Some health resources have advised that people
cut out dairy entirely. The rest of this paper will examine some
of the research on these claims about cow’s milk and the immune system.

Cow’s milk and Systemic Inflammation:
Systemic inflammation is caused by the release of pro-inflammatory cytokines from immune-related cells and the chronic
activation of the innate immune system. It is a risk factor for
atherosclerosis, metabolic syndrome, type 2 diabetes, cardiovascular diseases, and other conditions (Labonte et al. 2013).
The causes of systemic inflammation are notoriously difficult to
isolate, and there has been disagreement over whether cow’s
milk-based dairy can contribute to systemic inflammation in
healthy adults.
Although some epidemiological studies have found a correlation
between dairy consumption and biomarkers of inflammation,
the overwhelming majority of controlled studies have found a
neutral or anti-inflammatory effect (Bordoni et al. 2015). Nestel
et al. (2012) looked at four different full-fat dairy foods and
found that they did not increase eight circulating biomarkers

How Compatible is Cow’s Milk with the Human Immune System?

related to inflammation. Schmid et al. (2015) found no significant difference in inflammatory markers after subjects ate a
high-fat dairy and high-fat non-dairy meal. Several studies have
even reported an inverse correlation between dairy consumption and inflammation. Panagiotakos et al. (2010) looked at
the concentrations of the inflammatory factors CRP, IL-6, and
TNF-α in individuals consuming more than 14 servings of dairy
products a week and found them to be 29%, 9%, and 20% lower
than those in individuals consuming less than 8 servings a week.
Esmaillzadeh and Azadbakht (2010) studied 486 healthy women
aged 40-60 years found that subjects on a low-fat dairy diet had
lower circulating levels of IL-6 and sVCAM-1 than the control.
Labonte, et al. (2013) conducted a meta-analysis of 9 studies and
found no significant relationship between dairy consumption
and systemic inflammation. Finally, Bordoni et al. (2015) conducted the largest meta-study to date (52 human studies) and
found that the consumption of dairy products is generally associated with anti-inflammatory effects in humans. Of particular
note was that none of the studies using low-fat dairy products
indicated a pro-inflammatory response. Taken together, these
findings suggest that the association between cow’s milk and
systemic inflammation in healthy adults is largely unfounded.

(2010) reported on the Trial to Reduce IDDM in the Genetically
at Risk (TRIGR), in which Finnish researchers assigned 230 infants to drink either conventional cow’s milk-based formula or a
dairy-free alternative. Ten years later, children who were fed the
non-dairy alternative exhibited 50-60% fewer markers of β-cell
autoimmunity.Villagrán-García et al. (2015) studied 150 children
and found that those who began drinking cow’s milk in early
childhood were four times more likely to have T1D, one of the
most dramatic results yet reported.
Several mechanisms have been proposed for a possible link between a child’s early exposure to cow’s milk and T1D. One theory suggests that cow’s milk proteins may mimic autoantigens of
the pancreas beta cells, leading to the autoimmune destruction
of these cells (Kolb & Pozzilli, 1999). Another suggests that early
exposure to cow’s milk leads to elevated antibodies against
bovine insulin and subsequent immunization against human
insulin (Vaarala et al., 1999). A more recent proposal involves
beta-lactoglobulin, a whey protein found in cow’s milk but not
in human milk, and glycodelin, a near-homologue that regulates
T-cells. According to this theory, some infants produce antibodies against beta-lactoglobulin, which cross-react with glycodelin
and allow autoreactive T-cells to proliferate (Goldfarb, 2008).

Cow’s milk and Immune-Mediated Diabetes:
Diabetes mellitus type 1 (T1D) is a form of diabetes mellitus
that results when T-cell-mediated autoimmunity destroys the
insulin-producing beta cells of the pancreas. Although this form
of diabetes has a strong genetic basis, it is also influenced by
environment. The precise environmental triggers of T1D are a
matter of ongoing research and debate, with some suggesting
the role of particular antigens (Knip and Simell, 2012). The literature appears to be split on the question of whether cow’s milk
has a role in the pathogenesis of T1D.
The controversy began in 1984, when Borch-Johnsen et al. suggested there was an inverse-correlation between T1D and the
duration of breast-feeding. Although some subsequent studies
cast doubt on this link, researchers began to explore early exposure to cow’s milk (as opposed to discontinued feeding by
human milk) as a possible cause. Following this hypothesis, Scott
(1990) looked at consumption of milk per-capita and found a
significant positive correlation between consumption of unfermented milk protein and incidence of T1D in data from various
countries. More precise epidemiological studies soon followed,
such as a study of 690 T1D children in Finland, which found
that children were 1.5 times more likely to develop T1D if they
were exposed cow’s milk early in life (Virtanen et al. 1993). The
first meta-analyses showed a modest, but significant increase of
diabetes in children who were exposed to cow’s milk before the
age of 3 months (Gerstein, 1994; Norris & Scott, 1996). Some
recent studies have expanded on these findings. Kinip et al.

Although some epidemiological studies have supported a link
between cow’s milk and T1D, and a number of plausible mechanisms have been proposed, there is also conflicting evidence.
For example, Savilahti and Saarinen (2009) found that infants
who were exposed to cow’s milk very early in life were actually
slightly less likely to develop T1D before age 8 (although the discrepancy disappeared by age 11.5). Karlsson et al. (2001) studied
30 children with T1D and 18 healthy, age-matched children and
found no difference in their Th1- and Th2-like immune response
to cow’s milk proteins, suggesting that cow’s milk antigens do
not have a significant role pathogenesis. Some researchers have
argued that the existence of populations in which there is a high
level of dairy consumption and a low rate of T1D disproves any
connection (e.g. Iceland and Zealand), although these discrepancies have also been explained by the fact that protein content
can vary by region (Thorsdottir, 2000). Some have suggested
that only cow’s milk with A1-type casein is contributing factor
to T1D (Laugensen and Elliot, 2003), while others argue that
the apparent differences between A1-type and A2-type milk are
really due to differences in sun-exposure and vitamin D production (Merriman, 2009). Ultimately, the relationship of cow’s milk
and T1D remains a matter of debate, despite some epidemiological evidence supporting a causal link and the elaboration of
a number of plausible mechanisms.

Cow’s milk and Multiple Sclerosis:
Multiple sclerosis (MS) is a chronic inflammatory disease in
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which the myelin sheaths that insulate the central nervous
system are damaged. A connection between cow’s milk and
multiple sclerosis (MS) has long been debated. One of the first
large scale studies on the question was Malosse et al. (1992),
which examined the relationship between MS prevalence and
dairy product consumption in 27 countries and 29 populations
all over the world.The study found there was strong correlation
between MS prevalence and the consumption of liquid cow’s
milk, but not between MS and more processed forms of dairy,
like cheese. Some researchers have proposed that molecular
mimicry between CNS myelin antigens and cow’s milk proteins
could explain the relationship. According to this theory, the IgE
targeted to the cow’s milk proteins cross-react with the myelin
and lead to damage of the nerve cells (Ahrens et al., 2012). It has
been suggested that the failure of T cells to regulate auto-reactive CD4+ and CD8+ cells has a role in the disease (Viglietta
et al., 2004). Given the possible role of autoreactive T cells in
MS, the mechanism proposed by Goldfarb (2008) for T1D may
also be plausible here. Particularly interesting in this respect are
studies linking the autoimmunity of T1D and MS (Winer et al.,
2001).
Some studies have questioned the link between cow’s milk and
MS. Ramagopalan et al. (2010) examined 6638 cases of MS in
Canada and found no significant difference in the percentage
who reported childhood CMA, an odd finding if there is a significant cross-reaction between cow’s milk proteins and myelin.
Ashtari et al. (2012) examined 48 healthy subjects and 48 subjects with MS and found no difference in the detection of cow’s
milk-specific IgE. Given these contradictory results, the role of
cow’s milk in MS remains uncertain.

Cow’s milk and Betcet’s Disease:
Betcet’s disease (BD) is characterized by chronic, immune-mediated inflammation of the blood vessels, leading to skin rashes
and lesions, optic atrophy, and ulcers of the mouth and genitals.
Although the etiology of the disease is not fully known, there is
strong evidence for the role of Th17 cells, adaptive immune cells
that are also associated with MS and RA (Hatemi et al. 2012).
Research on cow’s milk as a factor in Betcet’s disease is currently very limited. Triolo et al. (2002) cited promising research
on the relationship between cow’s milk and immune-mediated
conditions like T1D and MS as a basis for examining the role of
cow’s milk in BD. First, the study cultured lymphocytes from 16
patients with BD and eight normal controls in the presence of
ß-casein, ß-lactoglobulin, and a number of controls. ELISA revealed that when cultured with milk proteins lymphocytes from
BD subjects produced significantly more IFNγ, a cytokine associated with auto-inflammation, than lymphocytes from the controls. Then the study used ELISA to analyze the serum antibody
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levels of 46 patients with BD and 37 healthy controls and found
significantly higher levels of anti-ß-casein and anti-ß-lactoglobulin antibodies in the subjects with BD.
These results suggest some correlation between BD and sensitivity to milk proteins, but do not define a causal order. The authors suggest that milk proteins may damage the gut and lead to
immune dysfunction and offer two possible mechanisms. First,
the caseins in cow’s milk may give rise to peptides that mimic
opiates and bind T cells and macrophages, disrupting their function. Second, molecular mimicry between cow’s milk proteins
and self-proteins may lead to damaging cross-reactivity. These
mechanisms are only speculative however, and there has been
little research on the relationship between cow’s milk and BD.
The rarity of BD (approximately 0.1-7.5 /100,000 in Europe and
the USA ) makes epidemiological studies difficult to conduct
(Zouboulis, 1999).

Cow’s milk and Rheumatoid Arthritis:
Rheumatoid arthritis (RA) is a chronic inflammatory disorder
that primarily affects the small joints in the hands and feet, leading to swelling, pain, and loss of mobility. cow’s milk has sometimes been cited as a contributing factor to RA. Although dairy
has been identified as an aggravating factor in individual cases of
RA (Panush et al. 1986: Panush, 1990), larger studies have failed
to find a connection between the disease and the consumption of cow’s milk. Panush et al. (1983), for example, studied 11
subjects on a dairy-free diet and 15 subjects on a placebo diet
and found no significant differences in rheumatologic or immunologic findings. The literature on diet-therapy for RA is not
extensive and tends to dispute any connection between cow’s
milk and RA; however, there are indications that dairy may be an
aggravating factor in a small percentage of cases.

Discussion
The Challenges of Studying cow’s milk:

Determining the impact of cow’s milk on the immune system is
complicated by a number of factors. Allergic and autoimmune
reactions are multifaceted and reflect a confluence of individual biochemistry, genetics, and environmental influences that
is not fully understood. Milk itself is a complex mixture with
numerous bioactive components, and its composition can vary
by region. Moreover, the consumption of cow’s milk is always
part of a large, multivariable diet, making it hard to rule out
confounding factors. Any interpretation of the evidence must
be cautious given the enormous complexity of the variables.

Current Nutritional Guidelines for cow’s milk:
The 2010 dietary guidelines authored jointly by the Department
of Agriculture and the U.S. Department of Health and Human
Services stress the importance of cow’s milk and cow’s milk-products as part of a healthy diet. The guidelines recommend 3 cups
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per day of fat-free or low-fat milk and milk products for adults
and children over 9, 2.5 cups per day for children ages 4-8, and
2 cups for children ages 2 -3.

Assessment of Results:
Cow’s milk is a vital staple of American nutrition, economy, and
culture. This does not diminish the importance of continued
research into the effects of cow’s milk on human health. CMA
is the most common form of allergy in childhood and can lead
to serious complications. Beyond clinical CMA, cow’s milk may
impact the immune system in subtle, unexpected ways. Upon
reviewing the evidence, there is no strong indication that cow’s
milk is a contributing factor to systemic inflammation in healthy
adults or to RA. However, there is some significant, but contested evidence that it plays a role in the pathogenesis of T1D,
MS, and Behcet disease. Currently, there is much we do not
know. One theme emerging from the literature is the difficulty of drawing conclusions from epidemiological studies. Some
epidemiological studies reveal a striking correlation between
cow’s milk and various immune disorders while others yield
conflicting results. While prospective cohort studies offer obvious advantages over retrospective studies, they can still yield
opposing findings, as evidenced by the large disagreement between Savilahti and Saarinen (2009) and Knip et al. (2010) over
whether cow’s milk is a risk factor for T1D. Such discrepancies
suggest the need for further research and meta-analysis.

Additional Considerations and Conclusions:
The results are too messy and speculative to write off cow’s
milk as a “dangerous” food or to clear it of all suspicion.They do
underscore the fact that we do not yet know enough about the
bioactivity of cow’s milk to rule out the possibility of detrimental effects on immune function. This uncertainty is compounded
by recent findings that link cow’s milk to prostate cancer and
Parkinson’s (Chen et al., 2007: Mandair et al., 2014). Numerous
studies have questioned the traditional belief that consuming
cow’s milk improves bone health and some have even found
that it increases risk of fracture (Michaëlsson K. et. al. 2014:
Feskanich et al. 2014). Although many of these findings are still
questionable, taken together they may warrant a reconsideration of current guidelines, especially when people in developed
nations generally can obtain calcium and other vital nutrients
from alternative sources. Given the important place that cow’s
milk has held in human nutrition and culture for thousands of
years, and the vital role it plays in the contemporary American
economy, any shift in thinking about dairy might be difficult to
achieve. Nevertheless, it is important to evaluate the evolving
body of evidence without cultural or economic bias and arrive
at nutritional guidelines on the basis of sound science alone.
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Abstract
Placebo effect is an alternative medical approach that doctors utilize in treating health issues. For years, people thought
that placebo pills were inert drugs or medically illegitimate measures that have psychological effects on the patient,
therefore alleviating the patient’s pain. However, in recent years, with the advent of technology, more studies are involving neurological aspects to the already-proven psychological aspects of the placebo effect. Yet there is still some
opposition and much to be proven better on this topic. What is very important is that although there is opposition,
there is growing recognition that the placebo effect may actually involve changes in brain chemistry, and that the placebo effect might be a fundamental part of good medical care that will one day be universally embraced by doctors and
patients as well.
Acronyms:
CBP		

Chronic Back Pain

CCK 		

Cholecystokinin

CR 		

Conditioned Response

CS 		

Conditioned Stimulus/Stimuli

NSAID 		

Nonsteroidal Anti-Inflammatory Drug

PAG		

Periaqueductal Gray

UCR		

Unconditioned Response

UCS 		

Unconditioned Stimulus/Stimuli

Introduction
Since the 18th century, people have believed that placebo pills
were inert drugs or medically unqualified measures that have
psychological effects on the patient, therefore easing the patient’s pain (Beecher 1955). Hence, the term placebo is a Latin
derivative for “I shall please” (Moerman 2002). Furthermore, in
recent years, many studies are associating neurological aspects
to the psychological effects of the placebo effect.
Today there is a range of treatment that people categorize as
placebo - as basic as administering a Band-Aid on a wound to
inserting needles into a patient receiving acupuncture. Because
such procedures do not contain much medical efficiency, their
pain-reducing results are termed ‘placebo effect.’ If these practices do not involve elements or substances that are responsible for altering a health condition then what is it about these
techniques that can make one pain free? Because placebo analgesia has proven to be one of the most successful models in
the research of the placebo effect, this review will explain the
long-known psychological influences of the placebo analgesia, as
well as the newer and unconcluded neurological influences of
the placebo analgesia.

Several psychological mechanisms contribute to the appearance, enhancement or duration of the placebo effects. Firstly,
Pavlov’s classical conditioning is a major contributor towards
the placebo effect, whereby a patient is trained to respond positively towards a placebo stimulus. Expectations also play a big
role - the patient’s anticipation of clinical improvement is partially responsible for the onset of the placebo effect. The overall
experience that the patient experiences influences the patient’s
expectations; doctor-patient relationship, the trial site, the appearance of the pill, and the way the treatment is given are all
experience related factors that impact one’s expectations.
How can it be that just by one merely having belief one can
experience less or no pain? The neural mechanisms whereby
placebo conditioning leads to placebo analgesia remain unclear.
Scientists are attempting to find better explanations for the
placebo effect by attributing it to neurological mechanisms of
the body. Ascending pain signals travel through one’s spinal cord,
then to the thalamus, and then to the sensory- processing regions of one’s cerebral cortex. In order for one not to experience pain due do to a pain provoking stimulus, there would have
to be changes in the sensory network of the brain or in the spinal cord. Recently, researchers are associating opiate analgesics
to the placebo effect.They are attempting to prove that placebo
treatment engages opioid systems which block pain in the spinal
cord. However, studies also show that there in fact is non-opioid
related analgesia. Nonetheless, the explanations remain unclear.
From the research done, it is evident that the placebo effect has
psychological aspects and that there is a difference in brain activity due to placebo treatment which is seemingly responsible
for placebo analgesia. Nonetheless, future research is required
in order to pinpoint the definite neural activity responsible for
the pain reduction.

Methods
In an effort to answer the question asked above, many published
articles, clinical trials, and research papers have been examined.
Primarily, Touro College’s library database as well as Google
Scholar were used to search for pertinent material. Original
research papers that were referenced were also studied. An
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attempt was made to determine if the placebo effect, as a result
of the placebo treatment, is psychologically and or neurologically fact or fiction.

Discussion
Psychological Aspects: Learning and Classical
Conditioning
People who suffer from pain, like a headache, and who usually
ingest aspirin, learn to associate the color, taste, and shape of
the pill with pain-decrease. After recurring associations, if such
people are given a placebo pill, such as a sugar pill resembling aspirin, they will feel less pain. Other stimuli, such as medical personnel features, hospitals, and therapeutic equipment can also
be associated with clinical improvements and therefore act as
conditioned stimuli that impact healing effects (Benedetti, et. al.
2010). A 1960s’ experiment found that a scopolamine injection,
a medication used to treat motion sickness and other types of
nausea, affected motor changes in a rat. Furthermore, identical
motor changes also transpired after a placebo injection made
of saline solution was administered after the scopolamine injection (Herrnstein 1962). Corresponding occurrences exist in
humans too. Notably, if a placebo pill or procedure is given after
two preceding administrations of an effective painkiller or practice, the placebo analgesic response is much larger (Amanzio,
Benedetti, 1999). That effect emphasizes that the placebo effect
is definitely a learning phenomenon.
Like other profound scientific developments, classical conditioning was discovered accidentally. In the 1890s, Russian physiologist Ivan Pavlov was observing dogs salivate in response to being
fed. He then noticed that the dogs began salivating whenever
he arrived in the room they were in, while he did not always
have food with him (McLeod 2007). From this incident, Pavlov
believed that some responses are innate, they don’t need to
be learned. In example, dogs do not learn to salivate whenever
they see food as this reflex is inherent. In psychological terms,
an unconditioned stimulus leads to an unconditioned response.
Furthermore, over time the dogs began salivating as soon as they
saw anything that they associated with their food. Therefore,
they would salivate in the presence of a lab assistant even when
he did not come with food (Windholz 1995). In psychological
terms, the phenomenon is due because when an unconditioned
stimulus is paired with a neutral stimulus, the latter becomes a
conditioned stimulus that propels a conditioned response comparable to the unconditioned response. Pavlov furthered his
research by experimenting with a bell; the dog was conditioned
to salivate when a bell rang as he associated it with the food.
Numerous clinical trials attribute the positive placebo treatment effects to Pavlov’s classical conditioning. Just as a dog salivated in response to a food-associated person or object, people
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can experience a reduction in pain due to a painkiller-associated
placebo procedure or drug. Indeed, a 1970s’ experiment proves
that placebo effects are in large due to classical conditioning;
saccharin, a flavored drinking solution, was paired with cyclophosphamide, an immunosuppressive drug, and given to rats.
After, the rats were immunized with sheep red blood cells.
On the seventh day, the rats that had been again exposed to
saccharin at the time of antigenic stimulation had a lower concentration of hemagglutinating antibodies in comparison with
non-conditioned animals given saccharin, conditioned animals
that were not re-exposed to saccharin, and a placebo group.
Hence, the experiment proves that after associative learning,
simply a liquid has the ability to mimic the effects of an active
drug and thus legitimizes the placebo effect (Ader, Cohen 1975).
In response to people who argue that such conditioning is
not possible to exist amongst human beings, an analogous trial
provides substantial evidence that behavioral conditioning of
immunosuppression is in fact promising in humans. Recurrent
associations between cyclosporine A - an immunosuppressant
drug - and a flavored drink incited conditioned immunosuppression in healthy male volunteers. However, more than one
associative learning trial was necessary in order to bring about
the fascinating results (Goebel, et al 2002).

Psychological Aspects: Expectancy
While Pavlovian conditioning serves as an unconscious influence towards placebo effects, expectancy serves as a conscious
one. The expectancy theory hypothesizes that one’s expectations impact ones future experience (Kirsch 1999). Therefore, if
one expects clinical improvement, his chances of improving are
that much greater. This theory is evident in the following 2010
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double-blind clinical trial: A painful laser stimulus was delivered
individually to twenty healthy participants before and after each
was given a 0 or 4 mg/kg cup of caffeine. Some participants were
told that their drink contained a painkiller, while the others
were told their drink was a placebo solution. After measuring
the reported pain and expectancy levels, it was clear that the
information that a painkiller was given enhanced the analgesic
effect of caffeine compared to caffeine given with no drug information (Bjørkedal, Flaten 2011). Moreover, those that were in
the active placebo condition group - were told they were given
a painkiller and they received caffeine – overall reported less
pain than the subjects in the caffeine condition group – were
not told they were given painkiller and they received caffeine.
This reiterates the expectancy theory, as the first group was
given two qualities (caffeine and drug information) that made
them expect an improvement, while the latter group was only
given one (caffeine).The expectancy of pain relief modulated the

variations of spontaneous pain, at the starting time and at two
more points thereafter (6 hours and 2 weeks). As reported,
there was no noteworthy difference between the two groups
in their pain intensity and in pain related brain activity. And both
groups reported more than a 50% pain decrease. Moreover,
when compared with an untreated chronic-back-pain-group at
similar intervals, the patch treated CBP group experienced a
considerably bigger decrease in back pain (Hashmi et al, 2012).

Figure 3

Figure 2

Variation of CBP pain with treatment type and treatment duration.
Treatment duration, but not type, significantly decreased CBP pain.
(Hashmi et al).
These findings support the expectancy theory, as the patients
who experienced a more encouraging experience by being
given a patch consequently felt less pain later on (fig. 3).

Subjects reported larger reductions in pain after 4mg/kg caffeine
(caffeine, active placebo) compared to after 0mg caffeine (control,
placebo). (Bjørkedal, Flaten 2011)
decreased pain experienced by the subjects (fig. 2).
From the above trial, it is evident that verbal gestures enhance
expectancy in patients. Additionally, the overall experience
that the patient experiences influences his/her expectancy of
clinical improvement and consequently his/her clinical results.
The doctor-patient relationship, the trial site, the appearance
of the pill, and the way the treatment is given are all included in one’s experience and can enhance the placebo effect. In
another study, the effectiveness of 5% Lidocaine patches was
compared with the effectiveness of placebo patches in treating
chronic back pain. In the randomized double-blind study, 15 patients received 5% Lidocaine patches and 15 received placebo
patches. Functional MRI was used to ascertain brain activity for

Another method to reinforce one’s expectation of clinical
improvement, is to educate the individual about the so-called
painkiller one is going to ingest. A random group of fifty university students agreed to either undergo placebo treatment
under the appearance of a new analgesic painkiller capsule or
to be put in the control group which did not receive placebo
treatment. While some participants were handed educational
handouts explaining the analgesic effect, others were not. The
subjects then received electrically-induced pain at varied intensities, and those that ingested the realistic looking drug capsules
reported analgesia. Furthermore, participants who also read the
handouts regarding analgesia reported an even higher decrease
in pain (Tang, Colagiuri 2013). This experiment highlights that
the appearance of the pill and the knowledge of analgesia both
contribute towards the patients expectancy and thus towards
his or her placebo analgesia.

Psychological Aspects: Conditioning vs.
Expectancy Theory
After much research, it is evident that both the conditioning
and expectancy theories are driving forces of placebo effects.

193

Aliza Jeidel

However, can they coexist, and is one more potent than the
other? In response to the former, both psychological mechanisms can surely coincide. For example, a patient who receives
a sugar pill on its own after repetitively receiving the pill together with other analgesic drugs will imply both mechanisms; the
sugar pill has become the conditioned stimulus to invoke analgesia, and the fact that the patient received medicine prompts
him to expect a recovery.
Regarding which mechanism is more vital, Stewart-Williams
and Podd (2004) reviewed many clinical trials and concluded
similarly to what many others have suggested: each mechanism
plays a different part in the production of placebo effects.When
a doctor verbally encourages a patient, when an inert pill or
procedure resembles a legitimate pill or procedure, and when
other such characteristics mentioned previously exist when
a patient receives a placebo, he/she learns to expect an improvement, which is a conscious belief. When one’s conscious
is involved, he can experience subjective and or physiological
placebo effects. On the other hand, when placebos represent
CS, the patient can either unconsciously believe in a placebo
effect or the patient can consciously expect improvements in
his situation.The conscious expectations and the non-conscious
learning yields subjective and physiological (objective) placebo
effects. Whilst expectancy learning is always a conscious action,
conditioning can be conscious or not - depending on whether
expectancy coincides with the conditioning. Nonetheless, each
form of learning can produce subjective as well as physiological
outcomes.
Others describe the correlation between expectations and
conditioning differently. A study concluded that placebo responses are facilitated by expectation when conscious physiological processes - for example, pain - exist, notwithstanding,
a conditioning procedure may simultaneously be implemented
(Benedetti et. al, 2003). Sixty participants were divided into five
groups and induced with pain in their forearms once per day
for five days. Such ischemic pain increases over time rapidly, and
the pain becomes excruciating after approximately 13 minutes.
After the painful stimulus was implied, each participant stopped
a timer when the pain became unbearable, and thus the average
pain tolerance level for each group was recorded. As each group
was treated differently throughout the five days, the results of
each group greatly varied. Some were told analgesia suggestions
or hyperalgesia suggestion, some experienced conditioining
via ketorolac anti inflamatory analgesic, and some received a
combination. Evidently, verbally induced analgesia expectations
raised the pain tolerance; whereas, suggestions of hyperalgesia
eradicated pain tolerance. This testifies that not only are positive words empowering, negativity is impactful too. Moreover,
this highlights the detrimental effects of unencouraging words

194

in the medical scene.When analgesia suggestions and conditioning were both implemented, the tolerance level rose higher. Yet,
when conditioning and hyperalgesia suggestions coincided, the
expectations outweighed the preconditioning effects of ketorolac, as the subjects’s overall pain tolerance decreased. The study
proves that analgesic placebo responses seem to be primarily
mediated by expectations, such as verbally induced expectations.
The study of the placebo phenomenon has important implications on non-placebo procedures. The equivalent psychological
factors that mediate the placebo effect are likely to be effective
when an individual is given an active substance or undergoes
an active procedure. Accordingly, a better understanding of
the psychological mechanisms essential to the placebo effect
is relevant in order to contribute these psychological factors
to non-placebo treatments as well. For example, by increasing
patients’ positive expectancies for the effects of an active drug
or procedure, it is conceivable that the drug or procedure will
yield stronger drug effects without the use of stronger doses.
There are numerous ways that physicians can achieve this: They
can inform patients about others for whom the treatment
proved successful, and doctors should update patients on the
clinical research that portrays the treatment as worthwhile.
Additionally, physicians should make people aware of the minor
side effects related with the treatment. Then, when people
come across any such symptoms in themselves (irrespective
of whether these symptoms are a result of the active drug),
they are likely to assume that the drug is working well. This will
possibly boost their expectations for a positive effect, which will
thereafter enhance the placebo element of the active treatment.
Using these strategies, physicians can probably achieve stronger
drug results without administering alternative stronger drugs or
greater doses. This would be a safer solution for the patient, as
he or she will not be exposed to unnecessary strong medication, and this will also decrease the costs of medical care. (Podd,
Stewart-Williams 2004)

Neurological Aspects
Placebos have no innate power to elicit given results. Yet, they
can produce the effects which are anticipated or sought. Placebo
pills and procedures do not act on the brain to bring about placebo effects; however, placebos can stimulate expectations and
CR which impact pain-reducing neural systems.What is responsible for the relation between the psychological mechanisms
and placebo analgesia?

Neurological Aspects: Opioids
The neurology of placebo was discovered when researchers
found that placebo analgesia is facilitated by endogenous opioids. They were prompted to make this hypothesis after they
observed that naloxone, the opioid antagonist, can oppose the
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effects of placebo analgesia (Levine et. al, 1978). Since then, further studies have emphasized that finding. Researchers examined the mechanisms fundamental to the activation of endogenous opioids in placebo analgesia (Benedetti, Amanzio 1999).
Once a day, for five days, ischemic arm pain was induced into
229 participants. The subjects were divided into twelve groups,
each treated differently. Each group received a combination of
two or more of these
treatments throughout the five-day-experiment duration: the
opioid agonist morphine hydrochloride, the non-opioid ketorolac (nonsteroidal anti-inflammatory drug; NSAID) tromethamine, no treatment, an open injection of saline, or open or
hidden opioid antagonist naloxone. The order of each group’s
treatment was made so that the treatment can serve as drug
conditioning, expectation cues, or both. When morphine was
administered, and when saline was openly injected and was
believed to be a morphine-like (expectation and or drug conditioning), participants experienced less pain. Any participant
who received naloxone after morphine (ketorolac was not
administered), whether open or hidden and whether used as
an expectation cue or not, experienced no difference in pain.
When ketorolac was issued, there was pain relief. Moreover,
when saline was issued, it mimicked the ketorolac effects. What
was even more fascinating about the results was that when naloxone was issued after ketorolac, pain was partially diminished.
This proves that naloxone only somewhat blocks analgesic effects; therefore, there must be non-opioid factors in addition to
opioid factors influencing placebo analgesia. The results of the
experiment prove that the opioid system is surely involved in
placebo analgesia, yet there are also other aspects sometimes
involved.
There is a lack of evidence proving how non-opioid pathways
serve in placebo analgesia. However, just as ketorolac is a
NSAID, placebos that mimic ketorolac or other NSAIDs’ activity, probably behave like such drugs. They act at peripheral
and also central places in the spinal cord, hindering the cyclo-oxygenase enzyme that is essential for the transformation
of arachidonic acid into prostaglandins and thus preventing a
painful experience.
Because studies prove the anti-opioid accomplishments of the
neuropeptide cholecystokinin (CCK), further studies were done
and demonstrated that the blockade of CCK receptors makes
the placebo analgesic response possible, thus suggesting that the
CCK role in placebo analgesia is quite impeding and that the
opioid system is important in order for placebo analgesia to
occur. This finding imparts that by irritating the anti-opioid action of CCK at the time of a placebo practice, the endogenous
opioid systems can be activated. (Benedetti, Amanzio 1997) In

a more recent study, forty participants were divided into four
groups in order for the effects of CCK type-2 receptors to
be examined (Benedetti et. al, 2010). Each participant was induced with ischemic arm pain like in previously mentioned experiments, and each group was treated differently. The results
portrayed that activation of CCK type-2 receptors, which was
achieved by means of administering the agonist pentagastrin,
abolished placebo analgesia even after morphine-conditioning
(placebo treatment) occurred. Evidently, CCK resembles naloxone. Furthermore, this study suggests that the equilibrium
between CCK elements and opioids is critical in placebo treatment. So, when patients do not respond as predicted to placebo
treatments, possibly CCK type-2 receptor hyperactivity exists
in the patient’s body-makeup.
What exactly is the endogenous opioid system? In general, the
endogenous opioid system is an inborn pain-relieving method.
It consists of dispersed neurons that produce three opioids: beta-endorphin, the met- and leu-enkephalins, and the dynorphins.
These opioids behave like neurotransmitters and neuromodulators at three main categories of receptors - mu (μ), Delta (δ),
and kappa (κ). Once attached to the receptors, they send signals
which in turn block pain, slow down breathing, and have an overall calming effect; therefore, the patient experiences analgesia.
In order to more fully comprehend how opioids modulate the
conduction of pain, one needs to understand the pathway by
which pain is transmitted - beginning from its origin until its place
of interpretation and perception in the brain. There are two
types of first order neurons in which pain is transmitted along:
In terms of nociceptive pain transmission, acute pain is transmitted mainly by A-delta afferent sensory nerve fibers, while
chronic pain is transmitted mainly by unmyelinated C sensory
afferent nerve fibers until it reaches the spinal cord. Because
these nerve fibers are unmyelinated, chronic pain is transmitted
slower than acute pain. Nociceptors, free nerve endings which
are found in numerous visceral and somatic tissues all over the
body, are stimulated by different sorts of noxious (harmful)
stimuli - such as chemical, thermal, and mechanical - and once
stimulated there is a release of leukotrienes, bradykinin, histamine, prostaglandins, potassium ions, and substance P. These
substances activate the nociceptors which results in the generation of an action potential down the first order neurons and
heading towards the spinal cord. When the fibers arrive at the
dorsal gray horn of the spinal cord, they release neurotransmitters - glutamate, substance P, and calcitonin gene related peptide
- and thus synapse with second order nerve fibers.The released
neurotransmitters incite the depolarization of the second order
neuron which crosses over to the opposite side of the spinal
cord, entering the contralateral spinothalamic tract and from
there ascends up the spinal cord and ultimately into the brain.
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Here, pain is modified via descending pathways and this results
in an individual experiencing pain.
Now, how do opioids hinder the descending pathways so that
an individual does not perceive pain? Opioid agonists bind to
μ -opioid receptors within the midbrain of the brainstem, on
inhibitory interneurons. The opioid agonist action at these neurons results in a lessening in the inhibitory effects on the nerve
fibers exiting the periaqueductal gray (PAG). Hence, they lead
to disinhibition of the descending nerves from the PAG. In turn,
there is an increase in their motion and in their communication
to the raphe nuclei. Moreover, there will be a disinhibition of
neurons in the raphe nuclei. There will be a general stimulation
of the descending nerve fibers which are descending through
the lateral funiculus in the spinal cord, and they eventually reach
the dorsal horn of the spinal cord. As this is the site in which the
original pain stimulus enters the spinal cord in its ascent to the
brain, here the nerve fibers influence the activity of the initial
pain stimulus.
Opioids impede afferent sensory nerve fibers, as well, that are
ascending the spinal cord traveling towards the brain. Opioids directly attach to presynaptic mu-opioid receptors and thus cause
an inhibition of pain transmission through the first order afferent sensory nerve fibers which enter the spinal cord. This leads
to a lessening in the discharge of substance P that is required
for the stimulation of second order neurons. Furthermore, opioids can directly attach to postsynaptic mu-opioid receptors on
different ascending nerve fibers, and this adds to the diminished
communication to the ventral posterolateral nucleus and consequently to the cerebral cortex. Additionally, opioids can indirectly inhibit second order ascending neurons in the spinal cord;
they modify the ejection of substance P and serotonin from the
stimulated descending nerve fibers from the raphe nuclei which
control endorphin containing neurons inside the dorsal horn.
The outcome of the impacts of opioids on the nerves found in
the dorsal horn is the pain transmission inhibition.
As one’s body does not produce enough natural opioids to
alleviate excruciating or prolonged pain, opioid drugs are manufactured. Comparable to their endogenous complements, opioid drugs - opiates - act at the same receptor sites, producing
analgesia as well.This wonder is possible, as the drugs mimic the
endogenous opioids’ chemical makeup. For this reason, patients
who experience much pain are prescribed with painkillers –as
they are opiates which mediate analgesia. When a placebo is
administered, the goal is that the endogenous opioid system
is activated as a result of the psychological influence on the
patient’s mind – the individual is convinced he or she received
an opiate, so his body responds respectively.
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Ethics of Placebo Treatment
As the physiology caused by placebo treatment is not conclusive, the placebo effect is not universally recommended. In fact,
many view placebo treatment as immoral. According to Nikola
Biller-Andorno (2004) of University of Goettingen, Germany,
placebo treatment is only permissible when used for therapeutic reasons and when no better proven alternative exists.
Additionally, the patient cannot be deceived, rather the doctor
must acknowledge the patient’s empowerment and autonomy.
If the physician fails to abide by these standards, rather than
practicing ethically he is practicing blunderingly. Because of such
guidelines, it is difficult to practice placebo treatment on sick
patients. Therefore, researchers are forced to set up trials in
order to examine placebo effects.

Ethnic
After much research, it is noticeable that the placebo effect has
become more effective. DiSalvo elaborated about the placebo
effect in a 2015 edition of the Forbes magazine. He wrote that
after reviewing a study of 84 clinical trials which were carried
out between the years 1990 and 2013, he concluded that the
placebo effect is getting stronger. However, he adds that this is
only true of trials in the United States. Possibly because America
is more advanced than many countries, the ability to conduct
placebo treatments is more feasible. More importantly, he adds
that America is the only country aside from New Zealand
that allows drug companies to sell their products directly to
consumers. This is blatant when one watches TV and sees the
numerous drug commercials. The advertising in itself can contribute towards the placebo effect by creating expectation cues.

Conclusion
After examining the articles and experiments regarding placebo treatments and effects, it is apparent that while placebo
treatment definitely has psychological influence on patients, the
neurological influence is unclear. Many are skeptical of placebo
effect all together. They argue that possibly the percentage of
patients that report improvement would regardless have improvement – that is to say, often pain reduces over time so even
without a placebo treatment one can be somewhat relieved
from pain. However, in many trials, there are ‘natural history’
groups which are used to compare their pain tolerance to the
placebo treated group’s pain tolerance. And these studies have
proven that the placebo treated group’s pain tolerance was better than the non-placebo treated group’s tolerance. This topic
is fascinating as it proves the power of the mind over matter.
Placebo management can trigger mechanisms that are equivalent to those triggered by drugs, which points out a parallel
between psychological and pharmaceutical effects. With further
research, placebo effect may become completely acceptable and
instead of administering drugs which often have harmful side
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effects or which are sometimes rejected by patients, placebo
treatments will serve as alternatives.
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